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The  National  Institute  of  Hygiene  and  Epidemiology  (NIHE)  in  Hanoi  focuses  on  prevention  and 
control of communicable diseases and operates under the authority of the Vietnamese Ministry of 
Health. In  addition to  scientific  research  in  epidemiology, medical microbiology, immunology,  and 
molecular biology, NIHE conducts various national programmes on infectious disease surveillance 
and  control,  develops  vaccines,  and  conducts  public  health  training  and  education  at  both 
undergraduate and post-graduate levels. Founded in 1926 as the Pasteur Institute of Hanoi, NIHE 
became a national public health institute in 1997. Today it employs some 300 people, 
 
Many  major  infectious  diseases,  including  tetanus,  typhoid, mumps,  meningitis,  hepatitis,  plague, 
rabies and malaria, have been significantly reduced or eradicated (polio) in Vietnam over the past 10 
years.  However,  tuberculosis,  dengue  hemorrhagic  fever,  viral  encephalitis,  diarrhoea,  measles, 
cholera and HIV/AIDS remain major public health problems, and the country is ever a geographical 
hot spot for emerging infectious diseases such as SARS and avian influenza.  
 
Presently  NIHE’s  main  research  focus  is  emerging, and  re-emerging infectious  disease  including 
influenza, dengue, hand-foot and mouth disease, viral encephalitis, HIV/AIDS, rabies. Institute plans 
for the future are to build an International Center for Biomedical Research, which would serve as an 
epidemic intelligence center focused on early detection and rapid response for emerging diseases 
and pandemics that threaten Vietnam and other countries in the region.  
 
NIHE  is  a  member  of  the  International Association  of  National Public  Health  Institutes  (IANPHI), 
Pasteur  Institute  Network,  Asian-African  Research  Network  of  Infectious  Diseases,  Emerging 
Infectious Diseases (EID) Program of ASEAN and currently has strong partnership with 9 international 
governments, neighbouring countries, and collaborates closely with 23 institutes and universities and 
international organizations, such as WHO, Unicef, PATH, JICA, FHI, US CDC, GAVI, NHI, IVI, NIID, 
Nagasaki and Oxford University. 
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Welcome 
 
 
On behalf of the Organising and Scientific Committees we take great pleasure in welcoming you to 
Hanoi  for  the  second  isirv  Antiviral  Group  (isirv-AVG)  conference  on  Severe  Influenza:  Burden, 
Pathogenesis and Management, organised in conjunction with the National Institute of Hygiene and 
Epidemiology (NIHE).  
 
The 2009 A(H1N1) pandemic was a stark reminder of the unpredictability of influenza and the many 
gaps that remain in our understanding of the pathogenesis and management of severe influenza, 
whether  due  to  pandemic,  seasonal  or  H5N1  viruses.  This  recent  experience,  coupled  with  the 
persistent  threat  of  highly  pathogenic  avian  A(H5N1)  and  new  information  on  its  potential 
transmissibility, demands a renewed focus on the management of severe influenza. 
 
This conference therefore brings together leading experts to present their research and discuss all 
aspects of severe influenza, including its epidemiology and clinical manifestations, virus and host 
factors in SARI pathogenesis, and clinical management, including intensive care strategies and the 
role  of  antivirals  and  other  interventions  in mitigating  disease  severity  as  well  as  the  problem of 
antiviral resistance. 
 
Its location in Hanoi reflects the continuing threat of H5N1, particularly in South-East Asia where 
some two-thirds of human cases have been reported, and the divergent evolution of the viruses in this 
part of the world, as well as the burden of seasonal influenza in countries with limited use of vaccine. 
Moreover, about a fifth of the 600 or so cases of H5N1, with its high fatality, have occurred in Viet 
Nam, and the medical services in this country were in the forefront in confronting the emerging threat 
during 2004-2005, treating over 60% of the H5N1- infected patients. 
 
The  programme  incorporates  a  combination  of  symposium  sessions  to  provide  a  comprehensive 
review of the various aspects of severe influenza and its management, workshops to provide a forum 
for more  detailed  discussion  of  particular themes,  and  more  practical  demonstrations  of  selected 
topics.  
 
We  thank  all  who  have  contributed  to  making  this  conference  possible:  the  members  of  the 
Organising  and  Scientific  Committees  for  their  imaginative  contributions;  the  generous  financial 
support  of  our  sponsors,  including  provision  of  travel  grants  for  more  than  20  participants;  but 
particularly  to the  staff  of  NIHE  and  DeSouza  Associates  who  have  dealt  so  effectively  with  the 
logistics and organisational challenges to bring the conference to fruition.  
 
We  trust  that their  efforts  will  be  rewarded  by  the  success  of  the  conference  in  enhancing  your 
understanding  of  the  various  aspects  of  the  clinical  management  of  severe  influenza  and  other 
respiratory disease. In addition, we hope that you have a stimulating and productive experience which 
will engender collaboration and encourage participation in isirv and the antiviral Group.  
 
 
 
 
Alan Hay 
Chair of isirv-AVG 
Nguyen Tran Hien 
Director of NIHE 
John Watson 
Chair of isirv 
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Programme 
 
Monday 29
th October   
 
07:00 onwards 
 
Registration 
 
09:00-09:20 
 
 
09:20-09:40 
 
Welcomes by Prof Nguyen Tran Hien (NIHE), Alan Hay (Chair AVG) &  
John Watson (Chair isirv)  
 
Special Remarks:  Madam Nguyen Thi Kim Tien, Minister of Health, Viet Nam  
 
 
 
 
09:40-10:00 
 
 
10:00-10:30 
 
 
10:30-11:10 
 
Symposium Session 1:  Burden of Severe Influenza and SARI  
Chairs:  Nguyen Tran Hien, Viet Nam &  John Watson, UK 
 
·  Incidence, Severity & Impact of Seasonal and Pandemic Influenza - summary 
of key conclusions from an isirv meeting, September 2012  
John Watson, UK  
·  Keynote Lecture 
Epidemiology and Impact of Severe Influenza and SARI:  Asian Perspectives  
Takeshi Kasai, Viet Nam  
·  Overview on Influenza Vaccines 
Lance Jennings, New Zealand & Nguyen Tran Hien, Viet Nam 
 
11:10-11:30 
 
Tea/Coffee 
 
11:30-13:30 
 
Symposium Session 2:  Influenza Pathogenesis and Acute Lung Injury 
Chairs: John Nicholls, HK, SAR China & Menno de Jong, The Netherlands 
 
·  Immunopathology of Acute Lung Injury and ARDS  
Malik Peiris, HK, SAR China  
·  Observations from Avian H5N1 Patients  
Tran Tinh Hien, Viet Nam 
·  Mechanisms of Severe Pandemic 2009 H1N1 Illness   
Peter Openshaw, UK 
·  Host Genetic Factors in Susceptibility and Severity   
Peter Horby, Viet Nam 
·  Viral-Bacterial Interactions:  Therapeutic Implications  
Jane Deng, USA 
 
13:30-14:30 
 
Lunch  
 
14:30-16:00 
 
Concurrent Workshops 1  
 
a.  Influenza Antivirals – effectiveness, safety, novel agents, usage, national  
policies, guidelines 
Chairs:  Nahoko Shindo, Switzerland & Bin Cao, China 
 
Nahoko Shindo - Development of WHO Standard Guideline on Clinical 
Management of Influenza Virus Infection 
Reiko Saito – Clinical Effectiveness of Neuraminidase Inhibitors – Oseltamivir, 
Zanamivir, Laninamivir, and Peramivir – for Treatment of Influenza A(H3N2) and 
A(H1N1)pdm09 Infection 
Jean-François Rossignol - Nitazoxanide in the Treatment of Acute Uncomplicated 
Influenza 
Jaap Goudsmit – Human Monoclonal Antibodies to Prevent and Treat Influenza A 
and B, Including Infections by H5N1 Virus 
Donna Ambrosino – Design of a Broadly Neutralizing Antibody Targeting 
Influenza 
Celine Deffrasnes – Modulating the Expression of Host Molecules Decreases 
H5N1 Replication 
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  b.  Severe Influenza and SARI Epidemiology – impact, surveillance, healthcare 
utilization, vaccines 
Chairs:  Abdullah Brooks, USA & Mai Le, Viet Nam 
 
Abdullah Brooks 
Maciej Boni - Understanding Influenza Dynamics Through Serial 
Seroepidemiology 
Ji Yun Noh – Laboratory Surveillance on Influenza-like Illness at Emergency 
Department in Seven Teaching Hospitals, South Korea: 2011-2012 
Taro Kamigaki – Estimates of Severe Acute Respiratory Infections Incidence in a 
City of the Philippines, 2009-2011 
Pham Quang Thai – Effect of Climate on ILI Dynamics and Seasonality in 
Vietnam from 1991 to 2010 
Helen Green – Severe Influenza Critical Care Surveillance:  Insights into the 
Impact and Severity of the 2010/11 Influenza Season Relative to the 2009/10 
Pandemic Season in England 
 
16:00-16:30 
 
Tea/Coffee 
 
16:30-18:30 
 
 
Demonstrations 
 
·  WHO Training Materials on SARI Management  
Nahoko Shindo, Switzerland, Paula Lister, UK & Janet Diaz, USA 
·  National Surveillance Platforms in Viet Nam 
Nguyen Tran Hien, Viet Nam 
·  Neuraminidase Inhibitor Resistant and Sensitive Reference Viruses for Use in 
Susceptibility Testing 
Aeron Hurt, Australia 
·  Analysis of Antiviral Resistance Data – IC50 determination and statistical 
analysis    
Larisa Gubareva, USA & Adam Meijer, The Netherlands 
 
19:30 
 
Conference Dinner - Temple of Literature 
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Tuesday 30
th October   
 
08:45-10:45 
 
Symposium Session 3:  Advances in Clinical Management  
Chair:  Arnold Monto, USA  
 
·  New Developments in Influenza and Respiratory Pathogen Diagnostics  
Christopher Wong, Singapore  
·  Influenza Antiviral Effectiveness in Hospitalised Patients (Including 
Intravenous NAIs)  
Norio Sugaya, Japan 
·  Detection and Management of Antiviral Resistance Emergence  
Guy Boivin, Canada  
·  Adjunctive Therapies and Immunomodulatory Agents in SARI Management  
David Hui, HK, SAR China 
·  Ventilatory Strategies, Fluid Management and Supportive Care in ALI/ARDS 
Andrew Luks, USA 
 
10:45-11:15 
 
Tea/Coffee 
 
11:15-12:45 
 
 
 
Concurrent Workshops 2 
 
a.  SARI Pathogenesis and Treatment – receptors, host responses, host-
directed therapies, biologic response modifiers  
Chairs:  Nelson Lee, HK, SAR China & Tim Uyeki, USA 
 
Nelson Lee – Pathogenesis of Severe Influenza: Virus, Host, and Virus-Host 
Interactions  
Eric Bortz – Host RNA Binding Proteins Regulate Adaptation of H5N1 HPAI 
Polymerase to Human Cells 
Hassan Zaraket – The Hemagglutinin Protein Acid Stability Regulates H5N1 
Influenza Virus Pathogenicity and Host Adaptation 
Amabel Tan – Immune Stimulants as Potential Agents Against Pandemic 
Influenza and Secondary Bacterial Infection 
Annette Fox – Severe Pandemic H1N1 2009 Infection is Associated with 
Transient NK and T Deficiency and Abberant CD8 Responses 
Sarah Fardy – Analysis of Inflammasome Related Molecules in the Response to 
H5N1 Avian Influenza 
 
b.  Antiviral Resistance – surveillance/monitoring, mechanisms, assay 
development  
Chairs:  Jenny McKimm-Breschkin, Australia & Philippe Buchy, Cambodia 
 
Jenny McKimm-Breschkin – Screening Neuraminidase Inhibitor Susceptibility of 
Avian Influenza Isolates from SE Asia 2005-2008 Identifies H5N1 I222 Mutants 
with Reduced Oseltamivir Sensitivity  
Philippe Buchy – Cross-Neutralization Activity of Anti-H5N1 Specific Polyclonal 
Immunoglobulins Against Heterologous Strains of H5N1 Virus 
Angie Lackenby – Classification of Neuraminidase Inhibitor Susceptibility for 
Surveillance 
Martin Schutten – Treatment-Emergent Oseltamivir Resistance in Influenza A 
Viruses in the Influenza Resistance Information Study (IRIS) is Uncommon and 
Associated with Patient Age and Year of Enrolment 
Adam Meijer – Oseltamivir-Resistant A(H1N1)pdm09 Influenza in Travellers 
Returning from Spain 
Mika Shigematsu – What will Influenza Surveillance tell you about Antiviral Use 
and Resistance? 
 
12:45-14.00 
 
Lunch  
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14:00-16:00  Symposium Session 4:  Meeting Clinical Challenges  
Chairs:  Frederick Hayden, USA & Tim Uyeki, USA   
 
·  Antiviral Studies and Viral Fitness in Animal Models of Influenza  
Yoshihiro Kawaoka, USA   
·  Influenza Encephalopathy and Related Neuropsychiatic Syndromes 
Masashi Mizuguchi, Japan  
·  Severe Influenza in Pregnancy: Mechanisms and Management  
May Li Lim, Singapore    
·  Influenza Prevention and Treatment in Transplant Recipients and     
Immunocompromised  Hosts  
Michael Ison, USA  
·  Advances in Antivirals for Non-Influenza Respiratory Viruses   
Frederick Hayden, USA 
 
16:00-17:00 
 
isirv-AVG Annual General Meeting 
 
17:00-19:00 
 
Poster Reception 
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Wednesday 31
st October   
 
08:30-10:15 
 
Concurrent Workshops 3 
 
a.  Clinical Issues – unusual syndromes, diagnostics, ventilatory strategies,  
clinical management, healthcare worker protection  
Chairs:  David Hui, HK, SAR China, Andrew Luks, USA & Shigeru Saito, Japan  
 
Shigeru Saito – No Maternal Death Caused by Pandemic (H1N1) 2009 in Japan 
Toshihisa Ishikawa – Rapid and Sensitive Detection of Highly Pathogenic H5N1 
Influenza Virus by The SmartAmp Method      
Jiu-xin Qu – Etiological Study of Community-Acquired Pneumonia Among 
Adolescents and Adults Patients With Low or Moderate Severity 
Shu Qiao Yang – Influenza Pneumonia: A Concurrent Comparison Between 
pH1N1 and H3N2 in the Post-Pandemic Period  
Steven Rockman – Efficacy of a Single Dose of Intravenous Immunoglobulin to 
Prevent Pandemic Influenza 
Cam Binh – The Ethics of Research in Rapidly Evolving Infectious Disease 
Epidemics 
 
b.  Consequences of Antiviral Resistance Mutations, Fitness, Animal Models  
Chairs:  Jilong Chen, China & Elena Govorkova, USA 
 
Jilong Chen – Identification of Novel Host Factors Involved in Regulating 
Influenza Virus Infection and Replication 
Sylvie van der Werf – Impact of Genetic Variations of the Neuraminidase of the 
H5N1 and Pandemic H1N1pdm09 Viruses on Their Enzymatic Activity and 
Sensitivity to Neuraminidase Inhibitors    
Aeron Hurt – Using Ferrets to Assess the Fitness of the Oseltamivir-Resistant 
A(H1N1)pdm09 Viruses Responsible for a Cluster of Community Cases in 
Australia in 2011 
Erhard van der Vries – H1N1 2009 Pandemic Influenza Virus:  Resistance of the 
I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis   
Andrés Pizzorno – Evaluation of Pandemic Influenza A/H1N1 Virus Mutations 
Conferring Resistance to Zanamivir 
Tatiana Baranovich – T-705 Suppresses Influenza A Virus Infectivity Via Lethal 
Mutagenesis 
 
10:15-10:45 
 
Tea/Coffee 
 
10:45-13:00 
 
 
 
Symposium Session 5:  Future Directions 
Chairs:  Alan Hay, UK & Tran Tinh Hien, Viet Nam 
 
·  Influenza Evolution:  Can We Predict What’s Next?  
Jesse Bloom, USA  
·  Antivirals in 2009 Pandemic – lessons and implications for future strategies 
Maria Zambon, UK  
·  Antiviral Combinations and Biotherapeutics for Influenza  
Menno de Jong, The Netherlands  
·  New Research Paradigms in Response to Emerging Infectious Threats  
Jeremy Farrar, Viet Nam  
·  Panel Discussion:  Future Research Needs  
Frederick Hayden (USA), Jesse Bloom (USA), Menno de Jong (The 
Netherlands), Jeremy Farrar (Viet Nam), Malik Peiris (HK, SAR China), 
Nahoko Shindo (Switzerland), Maria Zambon (UK)  
 
13:00-13:15 
 
Conclusions and Close of Meeting 
 
13:15-14:00 
 
Lunch 
 
14:00-15:30 
 
Tour of NIHE 
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Monday 29
th October 
 
Symposium Session 1:  Burden of Severe Influenza and SARI  
Chairs:  Nguyen Tran Hien & John Watson 
 
Incidence, Severity and Impact of Seasonal and Pandemic influenza - summary 
of key conclusions from an ISIRV meeting, September 2012 
John Watson – Health Protection Agency, London, UK 
 
Despite preparation during the preceding years, the 2009 influenza pandemic posed considerable 
challenges to countries around the world to determine the appropriate responses.  Many lessons were 
learnt both during the pandemic itself and in the subsequent periods of ‘seasonal’ influenza activity.  
Particularly crucial in making decisions about the response was an understanding of how great a 
threat the new influenza virus posed: how likely was it that individuals would develop an illness as part 
of the pandemic, how likely was it that they would become seriously ill and how likely was it that they 
would die?  What ultimately would be the burden of illness in different populations and how effective 
would different approaches be to controlling the pandemic?  Central to answering these questions is 
an understanding of the true incidence of influenza in the population and the severity of the illness in 
different subgroups of the population. The ISIRV conference in September 2012 considered these 
issues  by  bringing  together many  of those  engaged  in  work  in  this  area  since  the  pandemic. In 
addition to consideration of the technical aspects of measuring incidence, assessing likely severity 
and predicting impact, the conference considered the role of communication and how the information 
collected  could  be  turned  into  effective  public  health  action.  The  conference  also  highlighted 
approaches to strengthening surveillance for influenza in the future and avenues for further research. 
 
Overview on Influenza Vaccines 
Lance Jennings – Canterbury District Health Board, Christchurch, New 
Zealand  
 
Influenza vaccination remains the most effective way to prevent influenza virus infection and the 
associated severe outcomes.  Recent global public health treats from avian influenza and pandemic 
influenza have highlighted major gaps in our knowledge base and ability to produce safe and effective 
vaccines  in  a  relevant  time  frame  and  our  ability  to  communicate  to  policy  makers,  health  care 
professionals and the public, the benefits and risks associated with their use. The seasonal influenza 
vaccines currently in use are predominantly egg-derived inactivated vaccines, which have consistently 
been  shown  to  provide  good  protection  against  influenza  infection  and  reduce  the  risk  of 
hospitalisation  and  death.  However  their  protection  is  antibody-mediated,  strain-specific  and  is 
dependent on the closeness of the match between the vaccine strain and the circulating virus, so that 
developing vaccines with broader and longer lasting protection is a high priority, and the “Universal 
Vaccine” the ultimate goal. 
 
The increased focus on pandemic preparedness planning following the 2004 avian influenza epizootic 
and the development of monovalent H5N1 vaccines, has lead to new knowledge surrounding pre-
pandemic vaccines; the need for vaccines which are cross-protective across the H5N1 clades, the 
role  of  adjuvanted  vaccines  and  cell  culture  derived  vaccines.  However,  our  response  to  the 
A(H1N1)pdm09 pandemic has highlighted the practical issues relating to novel vaccine development, 
production  and  global  supply.  Increased  capacity  and  new  technologies  are  needed  to  produce 
vaccines  against  a  novel  influenza  virus  in  sufficient  quantities  to  protect  populations  during  an 
emerging pandemic, not just the second wave. Seasonal influenza provides an ongoing threat with 
the cumulative annual burden, eclipsing that of each pandemic. The WHO has recently reviewed the 
recommendations for influenza vaccination which now identify pregnant women as the highest priority 
group ahead of health care workers, children aged 6 months to 5 years, people aged 65 or more, and 
people with pre-existing chronic illnesses. However recommendations need to be translated into a 
countries policy, and then control strategies implemented. In the Asia-Pacific region, control strategies 
vary widely - from countries with an appreciation of influenza impact, good surveillance, extensive 
vaccination  programs,  and  fairly  good  vaccine  uptake;  to  those  with  no  recommendations,  no 
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programs, little information about impact, and very little vaccine use.  A countries affluence is related 
to  vaccine  use,  however  policies  for  seasonal  influenza  control  with  effective  communication 
strategies need to be in place. 
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Monday 29
th October 
 
Symposium Session 2:  Influenza Pathogenesis and Acute Lung 
Injury 
 
Observations from Avian H5N1 Patients 
Tran Tinh Hien – Oxford University Clinical Research Unit, Ho Chi Minh City, 
Viet Nam  
 
Avian influenza A (H5N1) occurred in poultry throughout Asia has had major economic and health 
repercussions.  Infections  with  this  virus  have  been  identified  since  January  2004  and  despite 
intensive  clinical  management  the  case  fatality  is  still  unacceptably  high.  We  report  the  clinical 
findings among patients with confirmed cases of avian influenza A (H5N1) who presented to hospitals 
in Vietnam. In all cases, the diagnosis of influenza A (H5N1) was confirmed by means of viral culture 
or reverse transcriptase–polymerase chain reaction (RT-PCR). Patients presented to hospitals after a 
median duration of illness of 6 days with fever (75%) cough (89%) and dyspnea (98%). Diarrhea and 
mucosal bleeding at hospital admission were more common in fatal than in non-fatal cases. Common 
findings were bilateral pulmonary infiltrates on chest X-Ray (72%), lymphopenia (73%), and increased 
serum transaminase levels (ALT69%, ALT 61%). The most reliable predictor of a fatal outcome was 
the presence of both neutropenia and raised ALT level on admission (correctly predicted 91% of 
death  and  82%  of  survival). Treatment  of  oseltamivir  showed  benefit  but  use  of  corticosteroid is 
associated with increased risk of death. We observed low peripheral blood T-lymphocyte counts and 
high chemokine and cytokine levels in H5N1-infected individuals, particularly in those who died, and 
these correlated with pharyngeal viral loads. Our observations indicate that high viral load, and the 
resulting intense inflammatory responses, is central to influenza H5N1 pathogenesis. The focus of 
clinical management  should  be  established  with  early  diagnosis  and  effective  antiviral  treatment. 
There  is  an  urgent  need  for  more  coordination  in  clinical  and  epidemiologic  research  among 
institutions in countries with cases of influenza A (H5N1) and internationally. 
 
Mechanisms of Severe Pandemic 2009 H1N1 Illness 
Peter Openshaw – Imperial College, London, UK 
 
Pandemics  remain  a  major  threat  to  security,  health  and  wellbeing.  To  better  understand  the 
pathogenesis of influenza, we mounted a multicentre collaborative study of patients admitted with 
influenza like illness during and after the 2009 pandemic. Although illness was generally mild, there 
were over 8,000 flu-related hospitalisations in the UK. The disease was especially severe in some 
patients with asthma, in pregnant women and in children under 5 years of age, but many of those 
admitted to hospital had no known risk factor and were otherwise young and healthy.  
 
To learn more about the causes of severe influenza we established a consortium of 45 principal 
investigators to conduct an in-depth study of the factors that affect disease severity. the ‘Mechanisms 
of Severe Acute Influenza Consortium’ (MOSAIC, funded by the Wellcome Trust and MRC). We 
recruited  257  patients  with  influenza-like  illness  from  11  hospitals  (total  4800  beds),  obtaining 
sequential samples from the respiratory tract and blood throughout illness and recovery.  
 
Research teams were set up to focus on host (cellular immunology, soluble mediator responses, 
transcriptomics and genomics), pathogen (influenza virus genetic and antigenic characteristics, viral 
shedding and viral load) and co-pathogen (co-infecting or secondarily-infecting bacteria and viruses. 
MOSAIC allows a series of related research questions to be tested, linking the diverse information on 
a case-by-case basis from patients and controls.  
 
Analysis will take time to complete, but we have so far identified a gene variant in IFITM3 that causes 
defective host responses and increased disease severity. There are currently more than 15 separate 
investigations underway using the core clinical data and archived biobank.  Ultimately we hope to 
improve  our  understanding  of influenza  and  its  pathogenesis,  allowing  novel  approaches  to  both 
diagnosis and treatment of SARI.  14 
 
Host Genetic Factors in Susceptibility and Severity 
Peter Horby – Oxford University Clinical Research Unit, Hanoi, Viet Nam 
 
Data is accumulating to suggest an important role for host genetics in susceptibility to influenza in 
mice and humans.  So far only one gene (Ifitm3) has been convincingly shown to play a role in 
susceptibility to severe influenza A in humans and a large number of candidate genes remain to be 
explored. Susceptibility to H5N1 may be less complex than ‘human influenza’, since the phenotype 
appears to be more dichotomous than continuous, immunity probably plays a lesser role, co-morbidity 
seems  less  important,  and  familial  aggregation  is  more  marked.  Despite  the  challenges,  the 
importance of understanding the pathogenesis of highly pathogenic influenza and the possibility that a 
rare genetic variant with a moderate to large effect underlies H5N1 susceptibility, makes efforts to 
assemble DNA from H5N1 cases worthwhile. 
  
To identify single nucleotide polymorphisms associated with susceptibility to H5N1 we undertook a 
genome-wide, case-control discovery study in 51 H5N1 cases from Vietnam and Thailand. Five SNPs 
in two distinct genetic loci on Chromosome 2 were identified with odds ratios of 3-4 and P   5 x 10-5 
(three SNPs at Interleukin-1 gene cluster and two SNPs at TRPM8). One SNP at TRPM8 (rs7560562) 
reached  genome-wide  significance  at  P     5  x  10-8.  When  genetic  variation  at  both  loci  was 
considered simultaneously we found strong evidence of an association with susceptibility to H5N1 (P-
trend = 7.80 x 10-12), with an odds ratio of 31 (95% ci = 9.84 – 98.18) for individuals carrying three 
copies of the risk alleles compared to wild-type individuals.  
 
Viral-Bacterial Interactions:  Therapeutic Implications 
Jane Deng – University of California at Los Angeles, USA 
 
Bacterial pneumonias have been a major lethal complication of all influenza pandemics over the last 
century. Even during non-pandemic years, substantial epidemiologic evidence links respiratory viral 
infections  with  the  development  of  bacterial  pneumonia,  particularly  among  patients  who  require 
hospitalization.  Immunologically,  acute  viral  infections  change  the  immune  environment  in  the 
respiratory tract, thereby placing the host at risk for secondary bacterial infection. The pathogenesis of 
viral-bacterial  co-infections  appears  to  be  complex  -  on  the  one  hand,  involving  viral-mediated 
impairment  of  antibacterial innate immune  responses,  while  on  the  other,  creating  a  condition  of 
dysregulated  inflammation  that  leads  to  lung  injury.  At  the  present  time,  clinicians  face  several 
challenges to effective management of secondary bacterial infections following acute viral infections. 
During this talk, our current understanding of the pathogenetic mechanisms involved in viral-bacterial 
co-infections  will  be  presented,  as  well  as  strategies  that  researchers  and  clinicians  can  use  to 
combat this significant public health problem. 
 
Funding:  NIH R01 HL108949, CalTech-UCLA JCTM TAG award, Pfizer ASPIRE award to J.C.D.  
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O1 
 
Development of WHO Standard Guideline on Clinical Management of Influenza Virus 
Infection 
 
Nahoko Shindo 
 
World Health Organization, Geneva, Switzerland 
 
Background:  setting norms and standards, and promoting and monitoring their implementation is one 
of the core functions of WHO.  In response to the threat of avian  influenza A(H5N1) virus, and the 
emergence of pandemic influenza A(H1N1) 2009 virus, a series of "rapid advice" (emergency) and 
interim guidelines have been published.  Many of these are time-limited, scope-limited, or have been 
developed without full review of evidence or documented peer review. 
 
Aim & Scope:  the aim is to consolidate interim and emergency guidelines and other guidance notes 
into a comprehensive standard guideline.  In doing so, the evidence behind such guidelines will be 
more extensively reviewed, and cross referencing to other WHO guidelines better documented. 
The resulting guidelines will thus be valid over a longer time period, and will provide a strong 
reference base for any future emergency guidance in the event of new influenza outbreaks, epidemics 
or pandemic. 
 
The overall scope of the WHO guideline will be the clinical management of severe influenza disease.  
The following aspects will be included within this scope: 
 
•  Treatment of severe influenza e.g. viral pneumonia, ARDS, multiple organ failure, septic shock; 
•  Pharmacological interventions for treatment, including influenza antiviral drugs, anti-inflammatory 
drugs and adjunctive therapies; 
•  Non-pharmacological clinical interventions, such as mechanical ventilation, oxygen and fluid 
management. 
•  Preventing development of severe influenza; including treatment of patients at higher risk of 
progression to severe disease and prevention of infection in highest risk patients 
 
Formulating questions and choosing outcomes based on the PICOT framework:  
 
Population  All patients presenting with severe or deteriorating influenza illness 
All patients in groups defined as at higher risk of severe or complicated disease 
Intervention  Influenza antivirals (including investigational products) 
Adjunctive therapies, such as immunomodulators, serum or plasma products 
Other pharmacological and non-pharmacological clinical interventions 
Comparator  There are currently few established standards; comparator is generally no 
intervention or placebo 
Outcome  Prevention of infection (in higher risk individuals) 
Prevention of disease progression 
Time to resolution of severe illness 
Reduction in hospital or ICU admission or length of hospital stay 
Reduction in mortality 
Time  Short term (to resolution of illness) 
 
Process:  the Standard Guideline has been developed in accord with WHO standard for guideline 
development. The development of a standard guideline requires substantial evidence review and 
assessment.  Both the commissioning of systematic reviews, as well as GRADE assessments, are 
required.  Areas to be addressed include: 
 
•  Evidence that antivirals reduce morbidity and mortality associated with severe or complicated 
influenza  17 
 
•  Evidence supporting definition of higher risk groups for severe or complicated influenza 
•  Data on investigational and adjunctive therapies 
•  Evidence that standard of care in viral pneumonia and ARDS are relevant for influenza infections 
•  Efficacy of antivirals and vaccines in preventing infection in higher risk groups  
•  Confirmation that secondary bacterial infections (community acquired and nosocomial) are similar 
in influenza cases to other presentations in comparable settings 
 
Outcome:  the standard guideline is due publication later in 2012. 
 
O2 
 
Clinical Effectiveness Of Neuraminidase Inhibitors Oseltamivir, Zanamivir, 
Laninamivir, and Peramivir — for Treatment Of Influenza A(H3N2) And A(H1N1)pdm09 
Infection 
 
R Saito
1, Y Shobugawa
1, I Sato
2, T Kawashima
3, C Dapat
1, IC Dapat
1, K Hiroki
1, Y Suzuki
1,4, K Saito
1 
and  H Suzuki
1,5 
 
1Department  of  International  Health,  Graduate  School  of  Medical  and  Dental  Sciences,  Niigata 
University, 1-757 Asahimachi-dori, Chuo-ku, Niigata 951-8510, Japan; 
2Yoiko Pediatric Clinic, Niigata, 
Japan; 
3Kawashima  Naika  Clinic,  Gunma,  Japan; 
4Viral  Disease  and  Epidemiology  Research 
Division, National Institute of Animal Health, National Agriculture and Food Research Organization, 
Tsukuba,  Japan; 
5Faculty  of  Nursing,  Social  Welfare,  and  Psychology,  Niigata  Seiryo  University, 
Niigata, Japan 
 
The  clinical  effectiveness  of  the  newly  released  neuraminidase  inhibitors  (NAIs)  laninamivir  and 
peramivir has not been sufficiently evaluated in influenza-infected patients in clinical and practical 
settings. In this study, we analyzed the clinical data of 211 patients infected with influenza A virus 
subtype  H3N2  (A(H3N2))  and  45  patients  infected  with  influenza  A  virus  subtype  H1N1pdm 
(A(H1N1)pdm09) who received the NAIs oseltamivir, zanamivir, laninamivir, or peramivir during the 
2010-2011 influenza season. The duration of fever from the first dose of the NAI to fever alleviation to 
less  than  37.5oC  was  evaluated  as  an  indicator  of  the  clinical  effectiveness  of  the  NAIs  in  the 
influenza infected patients. For the A(H3N2)-infected patients, Kaplan–Meier analysis showed the 
peramivir treatment group had the fastest time of fever alleviation to less than 37.5 oC (median 17.0 
h, 95 % confidence interval [CI] 7.2–26.8 h) of the four treatment groups. No significant difference was 
found  in  the  time  to  fever  alleviation  among  the  other  antivirals,  oseltamivir,  zanamivir,  and 
laninamivir. Results of multivariate analysis, using a Cox proportional- hazards model (hazard ratio 
3.321) adjusted for the factors age, sex, body weight, vaccination status, time from onset to the clinic 
visit, and body temperature showed significantly faster fever alleviation in the peramivir treatment 
group compared with the oseltamivir treatment group. For the A(H1N1)pdm09-infected patients, only 
the oseltamivir and zanamivir treatment groups were compared, and no significant difference in time 
to  alleviation  of  fever  was  observed  between  the  two  groups.  Further  evaluation  of  the  clinical 
effectiveness of the newly released NAIs for influenza-infected patients, including those infected with 
A(H1N1)pdm09, is needed. 
 
Updated clinical results in the 2011-2012 season will also be presented. 
 
O3 
 
Nitazoxanide in the Treatment of Acute Uncomplicated Influenza  
 
Jean-François Rossignol 
 
Romark Laboratories, L.C., Tampa, Florida and University of Oxford Department of Biochemistry, 
Institute of Glycobiology, Oxford, United Kingdom 
 
Nitazoxanide (NTZ) and its active circulating metabolite, tizoxanide (TIZ), inhibit in vitro replication of a 
broad range of orthomyxoviridae and paramyxoviridae including currently circulating influenza strains 
(H1N1, H3N2 and B), avian A/Vietnam/1203/04(H5N1), parainfluenza viruses and RSV. This activity 
is  attributed  to  highly  selective  stimulation  of  innate  immunity  via  interferon-stimulated-genes 18 
 
pathways rather than a direct effect on the virus. Combinations of NTZ with oseltamivir are synergistic 
in inhibiting in vitro replication of influenza viruses (Combination Index = 0.47, CalcuSyn® software). 
Attempts to select for influenza virus resistant to NTZ in vitro have been unsuccessful suggesting a 
high barrier to resistance. A Phase 2b-3 randomized, double-blind, placebo-controlled, dose range-
finding clinical trial was conducted to evaluate efficacy and safety of NTZ in the treatment of acute 
uncomplicated  influenza. The  trial  was  conducted  in  74  outpatient  centers  throughout  the  United 
States during the 2010-2011 flu season. 624  subjects aged 12-65 years  with fever, at least one 
respiratory  symptom  and  one  constitutional  symptom  were  enrolled  within  48  hours  of  symptom 
onset. Subjects were randomized to receive placebo, NTZ 300 mg or NTZ 600 mg orally twice daily 
for 5 consecutive days. The primary endpoint was time from first dose to alleviation of symptoms (all 
symptoms  graded  as  mild  or  absent)  in  subjects  with  laboratory-confirmed  influenza  infection. 
Influenza strains were representative of the season with approximately 47% being influenza A 2009 
H1N1, 23% influenza A H3N2 and 30% influenza B. Subjects receiving 600 mg NTZ orally twice daily 
for 5 days experienced a statistically significant reduction in duration of symptoms compared to the 
placebo group (median time to alleviation 90 hrs vs. 117 hrs, P<0.001). Subjects in the low dose 
group  experienced  a  lesser  reduction  in  duration  of  symptoms  compared  to  the  placebo  group, 
demonstrating dose response. Dose-dependent reductions of viral titer were also observed during 
treatment with a statistically significant difference (P<0.001) observed for subjects in the 600 mg NTZ 
group compared to the placebo group. NTZ was well tolerated with only minor clinical side effects 
reported among the three groups. Because of these encouraging results, further studies of NTZ for 
influenza treatment are underway in the United States during the 2012-2013 flu season. 
 
O4 
 
Human Monoclonal Antibodies to Prevent and Treat Influenza A and B, including 
Infections by H5N1 Virus 
 
J Goudsmit 
 
Crucell  Vaccine  Institute,  Janssen  Center  of  Excellence  for  Immunoprophylaxis,  Leiden,  The 
Netherlands 
 
Recently we described a series of human monoclonal antibodies that all bind to Hemagglutinin (HA). 
We recovered these antibodies from the IgM pool in the blood of adults that were vaccinated with 
inflexal, the virosomal seasonal influenza vaccine. Antibody CR6261 (Science 324, 246, 2009) bound 
to the stalk of HA of all influenza viruses of Group 1 and was able to prevent infection as well as cure 
mice  up to 5 days after challenge with 25LD50 of H1N1 A/WSN/33. 
 
Antibody CR8020 (Science, 333, 843 ,2011) bound to the stalk of HA of all influenza viruses of Group 
2 and  was able to prevent infection as well as cure mice up to 3 days after infection with 25LD50 of 
H3N2 A/HK/68. Finally we discovered another three human monoclonal antibodies, two that bound 
exclusively to the head of HA of all influenza B viruses, CR8033 and CR8071, and were able to 
protect mice from influenza B infection and one antibody, CR9114, that protected mice not only from 
influenza B, but also from influenza A (Science, in press). Clinical trials with the antibodies, CR6261 
and CR8020 will commence in 2013. Proof of Concept Studies for therapy of severe influenza guided 
by point-of-care diagnostics will follow shortly thereafter. Simultaneously we are developing a mixture 
of two of these antibodies for prophylaxis to protect people at risk for severe influenza and prevent 
spread of infection in case of an epidemic. 
 
We will present the newest results on the breadth of neutralization of these antibodies using field 
isolates of seasonal influenza viruses and the ability of these antibodies to prevent and treat H5N1 
infection, including the recently described ferret-to-ferret transmissible viruses. 
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O5 
 
Design of a Broadly Neutralizing Antibody Targeting Influenza 
 
Donna Ambrosino, AN Zachary Shriver, AN Karthik Viswanatha 
 
Visterra Inc., Cambridge, MA, USA 
   
Background:  discovery of broadly neutralizing antibodies against viral pathogens, including influenza 
A,  HCV,  RSV,  Rabies  and  HIV,  is  a  major  goal  for  therapy,  prevention,  and  vaccine  design.  
Traditional approaches, using B-cell panning, transgenic mice, and phage libraries have been only 
partially successful, requiring development of novel approaches. 
 
Methods:  through structural analysis, we have identified a site on influenza hemagglutinin (HA) that is 
not  only  conserved  across  all  influenza  subtypes,  but  also  appears  to  be  resistant  to  mutation. 
Harnessing this analysis and using a protein engineering approach, we have designed >50 human 
antibodies that bind to and neutralize Group 1 and 2 influenza A virus strains, including an optimized 
candidate- VIS410. 
 
Results:    VIS410  targets  the  identified  conserved  region  and  demonstrates  good  physiochemical 
attributes, including solubility, stability, affinity and specificity.  In vitro, VIS410 demonstrates dose-
dependent viral inhibition with an IC50 in the low  g/ml range against both Group 1 and Group 2 virus 
strains.    Mechanistic  studies  indicate  that  VIS410  inhibits  HA  fusion  with  the  cell  membrane, 
consistent  with  the  design  criteria.    Furthermore,  VIS410  potently  and  specifically  protects  mice 
infected  with  a  lethal  dose  of  influenza  virus,  both  prophylactically  and  therapeutically.    As  a 
prophylactic,  single  doses  at  >  1-2.5  mg/kg  are  completely  protective.  Therapeutically,  100%  of 
infected mice treated with a single dose of antibody (< 10 mg/kg) at 48 hours post-infection survived a 
lethal  challenge  with  representative  Group  1  and  Group  2  viruses.  Antibodies  designed  by  this 
approach  also  demonstrate  significant  protection  in  a  mouse  viral/bacterial  co-infection  model;  a 
single dose of antibody is sufficient to mitigate viral challenge and prevent opportunistic bacterial 
infection. 
 
Conclusion:  VIS410 provides the potential for a novel therapeutic and passive immunoprophylactic 
agent against influenza and a framework for the design of a universal influenza vaccine. These results 
also demonstrate the potential of targeting HA to prevent infection or in treating established infection   
In addition, the breadth of VIS410 neutralization opens the potential for a single monoclonal antibody 
to provide protection from all influenza A strains, including potential pandemic strains. Finally, this 
engineering approach to creating human antibodies defines a novel pathway for rapid identification of 
therapeutics against other infectious agents. 
 
O6 
 
Modulating the Expression of Host Molecules Decreases H5N1 Replication 
 
C Deffrasnes
1, CR Stewart
1, A Oberendorf
1, C Rootes
1, K Birrer
1, P Monaghan
1, D Green
1, AG Bean
1 
 
1CSIRO Australian Animal Health Laboratory, Geelong, Victoria, Australia 
 
Objectives  of  the  study:    Avian  influenza  is  a  pandemic  threat  and  new  anti-virals  need  to  be 
developed. Studying  the  pathogenesis  of  H5N1  infection  and focusing  on  the vital  role  that  host 
proteins play in influenza replication will offer new therapeutic targets. Host proteins from the coat 
protein complex (COP) are involved in many cellular pathways such as endocytosis, protein transport 
between the endoplasmic reticulum and the Golgi apparatus, and protein glycosylation. COP proteins 
have been shown to play a role in the viral replication cycle and their role in H5N1 pathogenesis is of 
great interest. In this study, we aimed at modulating the expression of a COP protein and measure its 
impact on H5N1 replication in human cells. 
 
Methods used:  HeLa and Vero cell lines were used in this study and H5N1 infections were done in a 
BSL3  facility.  Viral  replication  was  measured  by  TCID50.  Short  interfering  RNAs  (siRNAs)  were 
designed against COP subunit alpha (COPA). siRNA transfection efficiency was evaluated by flow 20 
 
cytometry and siRNA-mediated gene expression knockdown was measured by quantitative real-time 
PCR  (qPCR).  Cytotoxicity  was  assessed  using  the  high  throughput  imager  CellInsight.  Golgi 
disruption  was  quantified  using  the  CellInsight  (immunofluorescence)  and  confocal  microscopy. 
Changes in cytokine production were measured by qPCR. Statistical analyses were performed using 
Prism software. 
 
Results  obtained:  we  successfully  identified  a  concentration  of  COPA  siRNA  showing  efficient 
downregulation  of  COPA  expression  without  any  associated  cytotoxicity.  We  found  that  blocking 
COPA and Golgi using siRNA or Brefeldin A results in significant Golgi disruption. Furthermore, we 
showed that COPA knockdown by siRNA or Brefeldin A treatment inhibits H5N1 replication. 
 
Conclusions:  our study demonstrates that transient downregulation of COPA protein is not cytotoxic. 
Moreover,  our  results  show  that  inhibiting  host  proteins  such  as  COPA  reduces  avian  influenza 
(H5N1)  replication  in  human  cells.  We  are  currently  investigating  the  impact  of  host  protein 
knockdown on cytokine expression following H5N1 infection. 
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O8 
 
Understanding Influenza Dynamics Through Serial Seroepidemiology  
 
Maciej F Boni  
 
Sir Henry Dale Fellow, Centre for Tropical Medicine, Oxford University Clinical Research Unit  
 
The  epidemic  dynamics  and  evolution  of  influenza  A  virus  occur  on  a  global  scale.    Influenza 
epidemics in temperate zones are  seasonal and more predictable than transmission dynamics in 
tropical and sub-tropical areas, but the dynamics of these two climatic zones are closely linked, with 
East and Southeast (E/SE) Asia likely playing a major role in driving global influenza circulation.  
Influenza evolution affects the dynamics of influenza epidemics globally, but we do not know which 
human populations or which epidemiological conditions drive antigenic evolution in influenza.  To 
answer this question would need genetic and epidemiological data from regions of the world that are 
suspected to play a large role in global influenza dynamics.  I will describe several such studies 
initiated in Vietnam -- with particular focus on a long-term serial seroepidemiology study -- that are 
aimed at understanding the circulation of human influenza viruses in Southeast Asia, as well as some 
of the new analytical methods we are developing.  Understanding Vietnam’s role in global influenza 
circulation will help us determine how important of a role E/SE Asia play in global flu dynamics, and it 
will help us identify which components of the Vietnam data would allow for similar analyses to be 
done in other Asian countries. 
 
O9 
 
Laboratory Surveillance on Influenza-like Illness at Emergency Department in Seven 
Teaching Hospitals, South Korea:  2011-2012   
 
Ji Yun Noh
1, Hee Jin Cheong
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1, Jacob Lee
2, Jin-Soo Lee
3, Seong-Heon Wie
4, Young 
Keun Kim
5, Hye Won Jeong
6 and Woo Joo Kim
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1Korea University, Seoul, Korea; 
2Hallym University, Seoul, Korea; 
3Inha University, Incheon, Korea; 
4The  Catholic  University  of  Korea,  Suwon,  Korea; 
5Yonsei  University,  Wonju,  Korea; 
6Chungbuk 
University, Cheongju, Korea; 
7Transgovernmental Enterprise for Pandemic Influenza in Korea, Seoul, 
Korea   
 
Objectives:  to evaluate the distribution and seasonality of respiratory viruses through the Hospital-
based Influenza Morbidity & Mortality Surveillance (HIMM), a surveillance scheme for influenza-like 
illness (ILI) based on the teaching hospitals in Korea. 
  
Methods:    respiratory  specimens  were  obtained  from  adult  patients  (≥18  years)  who  visited  to 
emergency department in seven teaching hospitals with ILI during week 40 starting Sep 25, 2011 and 
week 22 ending Jun 2, 2012. Multiplex PCR was performed to detect respiratory viruses: influenza 
virus, adenovirus, coronavirus, respiratory syncytial virus, rhinovirus, metapneumovirus, parainfluenza 
virus, bocavirus, and enterovirus. 
  
Results: during week 40 to week 22, 2011-2012, 1,983 patients who visited to emergency department 
with  ILI  were  enrolled  in  this  study.  Male  was  810  (40.9%)  and  mean  age  was  47.1±19.3.  The 
distribution of age groups were as follows: 461 (23.3%), 18-30 years; 672 (33.9%), 31-49 years; 390 
(19.7%),  50-64  years;  457  (23.1%),  ≥65  years.  Four  hundred  thirty  patients  (22.0%)  received 
influenza vaccination during 2011-2012 season. At least one of comorbidity was found in 495 patients 
(25.0%). Positive rate of respiratory viruses was 52.1% and total number of detected viruses was 
1,100. Influenza A virus was the dominant agent (677, 61.5%) followed by influenza B virus (169, 
15.4%), rhinovirus (86, 7.8%), metapneumovirus (61, 5.5%), coronavirus (36, 3.3%), parainfluenza 
virus (34, 3.1%), RSV (30, 2.7%) and adenovirus (7, 0.6%). Hospitalization rate was 3.5% (70/1,983) 23 
 
and  mortality  was  0.2%  (4/1,983).  The  epidemic  curve  was  correlated  strongly  with  the  national 
surveillance scheme based on primary care clinic. 
 
Conclusion:  this study is the first extensive laboratory surveillance for epidemiology of respiratory 
viruses in patients with ILI based on teaching hospitals in Korea. This surveillance scheme would be 
valuable as the first well-constructed surveillance system based on several teaching hospitals in 
Korea. 
 
O10  
 
Estimates of Severe Acute Respiratory Infections Incidence in a City of the 
Philippines, 2009-2011 
 
Taro Kamigaki
1, Veronica L Tallo
2, Portia P Alday
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2, Jenaline B 
Javier
2, Hitoshi Oshitani
1, Remigio M Olveda
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1Tohoku  University  Graduate  School  of  Medicine,  Sendai,  Japan; 
2Research  Institute  of  Tropical 
Medicine, Department of Health, Manila, Philippines 
 
Objectives:    although  public  health  significance  of  influenza  has  been  widely  recognized,  there 
remains limited information on the burden of disease of influenza in tropical countries including the 
Philippines. 
 
Methods:  we conducted the influenza surveillance study from January, 2009 to December, 2011 in 
an urbanized highland city of the Philippines. Severe acute respiratory infections (sARI) surveillance 
was  one  of  the  study  components  and  established  to  collect  data  and  specimens  from  one 
government and four private hospitals since April, 2009. Demographic data as well as epidemiological 
data was obtained from patients by using the standardized forms. Nasal and/or oropharyngeal swabs 
were  collected  and  tested  for  influenza  A,  influenza  B  and  respiratory  syncytial  virus  (RSV)  by 
performing RT-PCR test. The incidence of sARI associated with targeted viruses was estimated as 
the proportion of each virus/subtype positive cases per 10,000 populations. 
 
Results:  we obtained 2,458 specimens from 10,726 sARI cases from throughout our study period and 
calculated a mean crude sARI incidence of 12.1 per 100,000 populations (95% confidence interval 
0.5-59.4). Sixty three percent of all sARI cases were children under 5 years old. Overall influenza 
detection rate was 8.5% and there was an observed year round influenza activity with two possible 
peaks  each  year.  During  study  period,  influenza  A  (H1)  pdm09  brought  higher  sARI  incidence 
followed by influenza B. Surprisingly, there were only 14 deaths reported among sARI cases during 
our study period. 
 
Conclusions:  Influenza posed a certain disease burden on hospitalization especially with children 
less than 5 years old in an urbanized tropical city of the Philippines. It is important to continue to 
monitor the disease burden of influenza with ILI and sARI surveillance. 
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Effect of Climate on ILI Dynamics and Seasonality in Vietnam from 1991 to 2010 
    
Pham Quang Thai
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1 NIHE, Hanoi,Viet Nam; 
2Oxford University Clinical Research Unit (OUCRU),Vietnam; 
3IRD Viet Nam 
 
Background:  the respective influences of climatic and immunological factors on the epidemiological 
dynamics of influenza is an on-going debate. In this study we propose to test the effect of climatic 
factors on time series of influenza like illness (ILI) notifications that have been recorded monthly in 
each of the 64 provinces of Vietnam since 1991. With a latitude ranging from 8 to 24 degrees north 
and an altitude ranging from sea level to more than 3,000 m, Vietnam exhibits a high variety of 
climates on an medium-size surface (300,000 km2) and an important population size (~90 millions). 
All these  make  Vietnam  a  perfect  country to  empirically  test the  effect  of  climatic factors  on  the 
epidemiology of influenza. 24 
 
Data:  monthly ILI notifications have been passively recorded and aggregated by provinces (64) since 
1991 by the National Institute of Hygiene and Epidemiology and 3 other regional institute from each 
region of Viet Nam under the supervision of General Department of Preventive Medicine MOH. Yearly 
estimates of province population size and census of communes populations sizes in 1989 and 1999 
were available from GSO Viet Nam. Monthly average, minimal, and maximal temperatures, number of 
hours of sunshine, rainfall and absolute and relative humidity for 64 meteorological stations across the 
country were available from Viet Nam Institute of Meteorology Hydrology and Environment. 
 
Methods:  we used empirical mode decomposition on ILI time series for each province. Pairwise 
correlations between the dominant components of each pair of provinces were related to distances 
and population products in order to detect gravity coupling signatures such as traveling waves. The 
effect of climatic variables on the components of the decomposed ILI time series were tested in a 
Poisson  regression,  accounting  for  spatial  and  temporal  auto-correlation,  different  periodicity  by 
latitude; the presence of an influenza travelling wave; correlation between hours of sunshine and ILI 
also be tested.  
 
Results:  during the study period, 26,023,574 cases of ILI were reported. ILI reporting incidence for 
the whole country show a larger peak from September to November, and a smaller one from February 
to April. Other results under calculation and will be available at the time of the conference. 
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Severe Influenza and Critical Care Surveillance: Insights into the Impact of the 2010/11 
Influenza Season Relative to the 2009/10 Pandemic Season in England 
    
HK Green
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1, M Galiano
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1Health Protection Agency, London, UK 
 
Background:  in December 2010/11, despite apparent widespread A(H1N1)pdm09 infection in the 
2009/10 pandemic, the first post-pandemic influenza season in England was marked by   reports of a 
rapid increase in ICU admissions due to A(H1N1)pdm09 influenza. The impact on these services over 
the winter was greater than seen during the 2009 pandemic across all regions in England. To interpret 
this unexpected observation, surveillance data on suspected influenza critical care admissions, winter 
circulating respiratory viruses and influenza vaccine uptake in 2009/10 and 2010/11 were examined. 
 
Methods:  data on the total daily number of patients in critical care with suspected influenza from 
week 51 2010 to 7 2011 and from week 29 2009 to 8 2010 across England were collected by age 
group (<5yrs, 5-15yrs, 16-64yrs and 65+yrs). The cumulative number of critical care influenza bed 
days were calculated for 2010/11 and 2009/10. To validate the likely cause, a regression analysis 
including weekly positivity of influenza and RSV investigated samples was undertaken. Additional 
data  on  respiratory  bacterial  laboratory  reports,  temperature  and  vaccine  uptake  of  monovalent 
pandemic  influenza  vaccine  in  2009/10  and  trivalent  seasonal  influenza  vaccine  in  2010/11  was 
examined. 
 
Results:  there was a notable age shift in critical care admissions of suspected influenza from children 
(<15yrs) to young adults (16-64yrs) in 2010/11 compared to 2009/10. The peaks in critical care cases 
in both seasons coincided with peaks in A(H1N1)pdm09 activity, and additionally in 2010/11 with 
influenza B, notably cold weather and increased reports of bacterial coinfection. Regression analysis 
attributed  the  majority  of  suspected  admissions  to  A(H1N1)pdm09  in  both  seasons  with  little 
contribution  from  infections  due  to  RSV.  Overall  vaccine  uptake  in  target  groups  with  an 
A(H1N1)pdm09-containing  vaccine  was  much  higher  at  the  peak  level  of  critical  care  activity  in 
2010/11 compared with 2009/10.  
 
Conclusions:  the majority of suspected critical care admissions in 2010/11 are likely to have resulted 
from A(H1N1)pdm09 infection. A difference in vaccine uptake between seasons is unlikely to explain 
the change in impact observed. The A(H1N1)pdm09 infection age shift coupled with low temperatures 
favouring transmission and reports of secondary bacterial infection are likely to explain the increased 
impact in critical care in 2010/11 compared to 2009. 
   25 
 
Tuesday 30
th October 
 
Symposium Session 3:  Advances in Clinical Management  
Chair:  Arnold Monto 
 
New Developments in Influenza and Respiratory Pathogen Diagnostics 
Christopher Wong – Genome Institute of Singapore, Singapore  
 
Identifying  the  microbial  and  viral  pathogens  causing  clinical  disease  is  currently  still  a  difficult 
combination of clinical expertise and technical challenges.  In respiratory disease, typically 60% of 
cases have no agent identified and even after 2 weeks, 10% of all patients hospitalized for infectious 
causes do not have the agent identified.  Despite the rapid growth of products offering panels of 
molecular diagnostics, this problem has remained as the current generation of molecular diagnostics 
suffers  from  technical  problems  that  prevent  them  from  detecting:  pathogens  that  have  mutated 
through evolution or are novel strain type variants.  With the high possibility of missing a pathogen, 
doctors and researchers are reluctant to order diagnostic tests;  while companies are reluctant to 
develop new drugs to pathogens of unknown importance.  
   
I will describe an overview of some of the newer multi-plexed molecular diagnostics tests which are 
available either as lab-developed assays or recently approved by the FDA.  I will also describe the 
PathGEN® PathChip system developed at the Genome Institute of Singapore, which is a nucleic acid 
chip-based  molecular  method  that  can  amplify  all  viruses  and  bacteria  (whatever  their  genomic 
diversity) from clinical samples; and automatically detect and annotate the presence of any of more 
than 70,000 virus and bacteria genomes in a single test, that can additionally detect any co-infecting 
pathogens and simultaneously strain type them all. 
 
In a recent trial at a university hospital in Denver, US on >250 samples, the chip achieved average 
specificity  of  98%  ±  2%  and  average  sensitivity  of  83%  ±  14%  across  11  groups  of  viruses.  
Significantly, the chip had an average negative predictive value of 98% ± 2%.  We describe the 
performance  of  this  chip,  comparison  with  other  multiplex  respiratory  diagnosis  platforms,  and 
highlight applications for molecular epidemiology and novel virus discovery. 
 
Disclosures:  The  work  on  the  PathChip  is  funded  by  grants  from  Exploit  Technologies  Pte  Ltd, 
A*STAR and SPRING Singapore.  CW is founder of PathGEN Dx Pte Ltd which has licensed the 
technology from A*STAR. 
 
Influenza Antiviral Effectiveness in Hospitalised Patients (including 
Intravenous NAIs)   
Norio Sugaya – Keiyu Hospital, Yokahama City, Japan 
 
A  meta-analysis  showed  that  neuraminidase  inhibitors  (NAIs)  have  modest  effectiveness  against 
influenza illness in otherwise healthy adults and children and that there is insufficient evidence in 
regard to reducing complications of influenza. However, after the pandemic caused by H1N1/09, early 
treatment with NAIs has been reported to be effective in reducing serious cases and deaths in many 
countries.  
 
Since the approval of zanamivir and oseltamivir for use in influenza virus infection in Japan in 2000, 
rapid diagnostic tests have been routinely performed by clinicians in patients who exhibit an influenza-
like illness, and patients with positive test results, including otherwise healthy adults and children 
without any underlying illness, have usually been treated with NAIs. Even though 20.7 million cases of 
pandemic H1N1/09 infection were reported in Japan during the 2009-2010 season, only 198 deaths 
were reported nationwide. Japan may have had the lowest case fatality rate for symptomatic illness 
(<0.001%; 198/20.7 million) among the countries where a widespread epidemic was reported. The 
very low mortality rate that resulted from the H1N1/09 epidemic in Japan was mainly attributable to 
the universal implementation of early treatment with NAIs since the year 2000.  
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In  addition  to  oseltamivir  and  zanamivir, the  newly  approved  inhaled  drug  laninamivir  and  newly 
approved intravenous drug peramivir were used in Japan during the 2010-2011 season, bringing to 
four, the total number of NAIs currently being used in hospitals and clinics nationwide. The Japanese 
Association for Infectious Diseases recommends that influenza patients who have been hospitalized, 
especially patients with pneumonia, be treated with oseltamivir or peramivir. We compared the clinical 
effectiveness of the four NAIs currently being used in Japan on the basis of the duration of fever after 
the start of treatment. The results showed that peramivir was the most effective of the four NAIs 
against influenza A/H1N1/09 and A/H3N2, but that all four NAIs were much less effective against 
influenza B than against influenza A.  
 
Assessment on the basis of their clinical effectiveness and viral shedding pattern showed that the 
NAIs were probably highly efficacious against serious illness caused by pandemic H1N1/09. Because 
of their lower clinical effectiveness and the longer viral shedding period, NAIs may not be effective in 
protecting against severe illness caused by influenza B virus infection. Intravenous peramivir may be 
the best option for the treatment of severe influenza virus infection. 
 
Detection and Management of Antiviral Resistance Emergence  
Guy Boivin – Laval University, Quebec, Canada  
 
Influenza viruses are major human pathogens with a global distribution, accounting for more than 500 
000 annual deaths worldwide and with considerable impact on the quality of life and productivity of the 
society.  Due  to  the  limited  efficacy  of  vaccination,  antiviral  drugs  constitute  a  complementary 
approach in the control and prevention of influenza infections and thus play an important role in the 
management  of  influenza  outbreaks  and  pandemics.  Currently,  adamantanes  and  neuraminidase 
inhibitors (NAIs) are the only two classes of anti-influenza agents approved for clinical use. However, 
the  worldwide  emergence  and  high  prevalence  of  adamantane-resistant  virus  variants  has 
discouraged the use of the former drugs. NAIs have proved to be very effective against influenza A 
and B viruses. Nevertheless, oseltamivir-resistant strains have also been reported quite frequently, as 
in  the  case  of  seasonal  A/H1N1  viruses  that  circulated  between  2007  and  2009.  The  recent 
identification of permissive mutations in the neuraminidase gene has helped our understanding of the 
fitness and transmissibility of some drug-resistant influenza A mutants. Furthermore, new sensitive 
methods such as deep sequencing have shown that drug-resistant mutants could be present at low 
levels  in  infected  individuals  even  in  the  absence  of  antiviral  therapy  and  then  be  successfully 
transmitted. The emerging problem of NAI resistance highlights the need for continuous monitoring of 
drug resistance markers, as well as the development of new anti-influenza drugs and combination 
therapies.   
 
Adjunctive Therapies and Immunomodulatory Agents in SARI Management  
David Hui – The Chinese University of Hong Kong, Hong Kong, SAR China 
 
Cytokine dysregulation has been reported in severe viral infections such as SARS, H5N1 influenza, 
and pandemic 2009 H1H1 influenza.1-3 During the major outbreak of SARS in 2003, systemic steroid 
was widely used in Asia based on CT scan and histopathological evidence of bronchiolitis obliterans 
organizing pneumonia,4,5 but high dose of systemic steroid was associated with increased risks of 
nosocomial infections (including fatal disseminated fungal infection), and avascular osteonecrosis.6-8 
The use of systemic steroids was also associated with increased risk of nosocomial infections and 
higher mortality in patients hospitalized with severe pandemic 2009 H1N1 influenza esp with late or 
no administration of neuraminidase inhibitors.9-12 Use of systemic steroid for SARS or seasonal 
influenza may delay viral clearance.13,14 Passive immunotherapy in the form of convalescent plasma 
appeared  useful  as  rescue  therapy  in  SARS,15  H5N1,16  and  pandemic  H1N1  2009  influenza17 
although such treatment would be limited by the supply from suitable donors who have fully recovered 
from the infections. There are conflicting data whether chronic users of statins are protected from 
developing more severe influenza and there is a lack of data on the role of acute use of statins in 
severe  viral  infections.18-20  More  data  are  needed  to  explore  the  potential  role  of  intravenous 
gammaglobulin,  and  other  drugs  with  immuno-modulating  properties  such  as  gemfibrozil, 
pioglitazone, N-acetyl-cysteine, clarithromycin, celecoxib and mesalazine.21 Other modalities such as 
therapeutic  plasma  exchange,  and  polymyxin  B-immobilized  fiber  column  hemoperfusion  were 27 
 
reported  as  useful  for  severe  pandemic  2009  H1N1  infection  and  these  would  require  further 
investigation. 
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Ventilatory Strategies, Fluid Management, and Supportive Care in ALI/ARDS  
Andrew Luks – Harborview Medical Center, Seattle, USA 
 
Patients who develop the Acute Respiratory Distress Syndrome (ARDS) in the setting of influenza 
infection  are  at increased  risk for morbidity  and mortality. While  antiviral  therapy  is  an  important 
component of care for these patients, it is by no means sufficient to ensure a good outcome and 
additional measures are necessary. Patients who develop ARDS require high levels of supplemental 
oxygen  to  counteract  the  hypoxemia  that  results from  extensive  shunt  physiology. Many  patients 
require invasive mechanical ventilation for support of oxygenation, but in resource-limited settings 
supplemental oxygen via face mask may be the only available intervention. The use of non-invasive 
positive pressure ventilation in cases of severe hypoxemia remains without support in the literature. 
Patients  deemed  to  have  ARDS  who  receive  mechanical  ventilation  should  be  placed  on  lung 
protective ventilation, whereby the tidal volume is decreased to 6 mL/kg of their ideal body weight and 
distending  pressures  are  maintained  below  30  cm  H2O.  Patients  will  require  increased  inspired 
oxygen concentrations and increased levels of positive end-expiratory pressure (PEEP) to support 
oxygenation  and  counteract  atelectasis,  although  there  is  no  clear  evidence  to  support  particular 
PEEP strategies. While high inspired oxygen concentrations and increased PEEP are sufficient in 
most patients to maintain adequate oxygenation, a minority of patients develop refractory hypoxemia 
and  require  one  of  several  additional  therapies, including  prone  positioning,  inhaled vasodilators, 
infusion of paralytic medications or extracorporeal membrane oxygenation (ECMO). Application of 
these “rescue strategies” is complicated, however, by the lack of clear guidance in the literature as to 
what level of oxygenation problems constitutes “critical hypoxemia” and, therefore, necessitates use 
of  these  strategies,  and  the  proper  approach  to  selecting  between  these  options.  While  much 
attention was devoted to these strategies in the recent H1N1 epidemic, clinicians must not lose sight 
of simple measures that also make a difference in patient outcomes by decreasing complications that 
lead to increased morbidity and mortality, including elevating the head of the patient’s bed, ensuring 
adequate  prophylaxis  against  venous  thromboembolism  and  gastrointestinal  bleeding  and 
conservative fluid management in the post-resuscitative phase of the patient’s illness.  Attention to 
details such as these, along with appropriate implementation of lung protective ventilation, go a long 
way toward improving patient outcomes in patients with severe lung injury.    28 
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Pathogenesis of Severe Influenza: Virus, Host, and Virus-Host Interactions 
 
Nelson Lee 
 
The Chinese University of Hong Kong, SAR China 
 
For  ‘seasonal’  influenza  severe  and  fatal  infections  occur  predominantly  in  the  elderly  and 
compromised individuals. For ‘pandemic’ influenza (e.g. H1N1pdm09), an increased proportion of 
younger (35 65 years), previously healthy adults are observed to develop severe diseases. Besides 
persons with conventional risk factors, pregnant women and obese individuals are found to be at 
increased risks. For ‘avian’ influenza (e.g. H5N1), persons with all ages are affected. A fulminant 
course of illness occurs in most patients, except perhaps in some younger children, such as those 
less than 5 years of age. Certain symptoms like sore throat and runny nose seem to indicate the 
predominant site of infection. However what factors determine these different manifestations are not 
entirely clear. Emerging data suggest that a combination of virus factors (e.g. genetic constellation, 
virulence, receptor affinity or tropism), host factors (e.g. underlying immunosuppression; pre-existing 
or  cross  immunity)  and  virus-host  interactions  (e.g.  innate TLRs,  RLRs,  NLRs,  inflammasomes, 
DAMPS, Type-I interferons, pro-inflammatory cytokines; adaptive Th1, Th17, B-cell responses) are 
likely involved.  Proposed disease models include lack of pre-existing/cross immunity to the invading 
virus, inefficient viral clearance by host, continuous excitation of pro-inflammatory cytokines (e.g. IL-6, 
CXCL8/IL-8,  CCL2/MCP-1,  TNF-α),  and  aberrant,  dysregulated  adaptive  immune  responses  (e.g. 
depressed  Th1/Th17  immunity,  pathogenic  immune-complexes  formation).  Further 
immunosuppression such as corticosteroid administration and bacterial superinfection consequent to 
enhanced viral-bacterial interactions in influenza may also affect the disease course. In this workshop, 
investigators will present their research on the pathogenicity of viral HA proteins, the roles of host 
TLRs,  inflammasomes,  and  RNA-binding  proteins  in  controlling  influenza,  and  cellular  response 
dysregulation in severe infections. Better understanding of pathogenesis  of severe influenza may 
allow hypothesis generation on new therapeutic (e.g. anti-viral, anti-inflammatory) and preventive (e.g. 
pre/post-exposure prophylaxis, vaccination) approaches. 
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H5N1 highly pathogenic avian influenza A (HPAI) viruses are capable of crossing the species barrier 
from  avian  hosts  into  humans,  causing  a  severe  pulmonary  disease  often  characterized  by 
pneumonia and uncontrolled inflammatory responses.  The influenza viral polymerase complex (PB1, 
PB2, PA, NP, viral RNA) associates with a network of more than 300 human host proteins.  Taking a 
functional genomics (RNAi) approach, we have sought uncover mechanisms by which these host 
factors regulate HPAI virus RNA synthesis, induction of innate immune responses, and adaptation to 
human cells.  In a subnetwork enriched in RNA binding proteins, 18/31 (58%) were required for both 
H1N1 and H5N1 polymerase function.  One protein, DEAD-box RNA helicase 17 (DDX17), regulated 
H5N1 polymerase's synthesis of viral mRNA and vRNA in human cells.  Remarkably, RNA binding 
proteins  including  DDX17  also  governed  H5N1  HPAI  polymerase’s  adaptability  to  human  cells 
according  to  genotype  at the mammalian-adaptive  PB2  residue  627.    Thus,  this  network  of viral 
polymerase-host interactions in part controls adaptation, replication and pathogenicity of H5N1 HPAI 
viruses in humans.  Functional genomics can provide a molecular profile for assessing the replicative 
and pathogenic potential of emerging H5N1 viruses in human cells. 
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The Hemagglutinin Protein Acid Stability Regulates H5N1 Influenza Virus 
Pathogenicity and Host Adaptation  
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Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis TN 38105, USA. 
 
Highly pathogenic avian influenza H5N1 has become endemic in several countries and continues to cause 
sporadic infections in humans. The hemagglutinin (HA) protein mediates receptor binding and fusion to 
endosomes by changing confirmation under acidic environment of the endosomes. We have previously 
shown that the activation pH of the HA protein is a determinant for H5N1 influenza virus virulence in ducks 
and chickens. To determine the effect of HA protein acid stability on virulence in mammalian species, we 
generated mutant H5N1 viruses with pH altering mutations in the HA protein stalk domain and compared 
their replication to the wild-type (WT) virus in vivo. The WT virus was found to be activated for fusion at pH 
5.9 and replicate efficiently in the lungs of mice, causing significant morbidity and mortality. An Y231H 
mutation destabilized the HA protein (pH of activation  = 6.3) and attenuated  virus replication in mice, 
resulting in less weight loss and delayed mortality compared to WT. Stabilizing the HA protein by a K582I 
mutation,  which  lowered  the  activation  pH  of  the  WT  virus  by  0.5  pH  units,  resulted  in  greater  virus 
replication  in  the  lungs  of  mice  and  increased  weight  loss  and  mortality.  Moreover,  the  K582I  virus 
displayed enhanced replication in the upper respiratory tract of infected mice compared to the WT virus. 
Stabilizing the HA protein also enhanced H5N1 virus replication in the ferret upper respiratory tract early 
during infection. However, the virus replicated poorly in the lungs of infected ferrets and caused less weight 
loss than the WT virus. We have previously shown that increasing the acid stability of the HA protein 
significantly diminishes H5N1 virus shedding and virulence in Mallard ducks. Overall, we conclude that 
mammalian species may support a broad range of HA protein activation pH and that stabilization of the HA 
protein enhances H5N1 influenza virus replication in the upper respiratory tract of mammalian species. This 
could be particularly useful in optimizing live attenuated vaccines for better replication and thus immunity in 
the nasal cavity. The data also suggest that molecules that alter the acid stability of the HA protein may be 
attractive as antiviral drugs by either inactivating or preventing activation of the HA protein. 
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Immune Stimulants as Potential Agents against Pandemic Influenza and Secondary 
Bacterial Infection 
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The pandemic of 1918 and the recent 2009 pandemic has highlighted the need to continue our search 
for agents against Influenza A virus. It is important to consider that the acquisition of a secondary 
bacterial infections such as Streptococcus pneumonia has been causally associated with the mortality 
and disease severity that occurs during influenza pandemics. Therefore, targeting both IAV infection 
as well as secondary bacterial infection could be an effective treatment strategy to reduce the severity 
impact of pandemic influenza. 
 
The innate immune system plays a key role in control of early influenza infection, and disruption of 
compartments of the innate immune response has a significant impact on the severity and outcome of 
disease in mouse models of infection. The objective of this study was to investigate whether activation 
of the innate immune response could provide a generic antiviral or antibacterial “environment” that 
would  be  effective  against  respiratory  infection.  To  test  this  theory,  we  administered  synthetic 
compounds containing the TLR-2 agonist, Pam2Cys via the intranasal route to anesthetized mice 
enabling their deposition into the lung.  We demonstrate that Pam2Cys administration induces an 
immune-enhanced  environment  in  the  lung,  characterized  by  the  induction  of  neutrophils, 
macrophages, NK cells and lymphocytes and Th1 and inflammatory cytokines (but not IFN-alpha) and 
this occurs in a TLR-2-dependent manner. Furthermore, Pam2Cys prophylaxis protected mice against 
weight loss and death associated with virulent PR8 H1N1 influenza A virus and reduced viral burden 
following challenge with H3N2 and H3N1 strains of influenza A virus as well as respiratory syncytial 
virus.  We  have  recently  developed  a  mouse  model  of  influenza  and  secondary  S.  pneumoniae 
bacterial infection and shown that prophylaxis with Pam2Cys can prevent the lethality associated with 
secondary bacterial infection. 
 
This study has demonstrated the potential for such agents to offer a broad nature of anti-viral activity, 
and our findings in a model of influenza- bacterial co-infection further support the development of 
such agents against pandemic influenza.  
 
O17 
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Background: it is unclear why the severity of influenza varies in healthy adults or why the burden of 
severe influenza shifts to young adults when pandemic strains emerge.  One possibility is that cross-
protective T cell responses wane in this age group in the absence of recent infection. We therefore 
compared the acute cellular immune response in previously healthy adults with severe versus mild 
pandemic H1N1 infection. 
 
Methods  and  findings:  49  previously  healthy  adults  admitted  to  the  National  Hospital  of  Tropical 
Diseases, Viet Nam with RT-PCR-confirmed 2009 H1N1 infection were prospectively enrolled. 39 
recovered  quickly  whereas  10  developed  severe  symptoms  requiring  supplemental  oxygen  and 
prolonged hospitalization. Peripheral blood lymphocyte subset counts and activation (HLADR, CD38) 32 
 
and differentiation (CD27, CD28) marker expression were determined on days 0, 2, 5, 10, 14 and 28 
by flow cytometry. NK, CD4 and CD8 lymphopenia developed in 100%, 90% and 60% of severe 
cases versus 13% (p < 0.001), 28%, (p = 0.001) and 18% (p = 0.014) of mild cases. CD4 and NK 
counts normalized following recovery. B cells counts were not significantly associated with severity. 
CD8 activation peaked 6-8 days after mild influenza onset, when 13% (6-22%) were HLADR+CD38+, 
and was accompanied by a significant loss of resting/CD27+CD28+ cells without accumulation of 
CD27+CD28- or CD27-CD28- cells. In severe influenza CD8 activation peaked more than 9 days 
post-onset,  and/or  was  excessive  (30-90%  HLADR+CD38+)  in  association  with  accumulation  of 
CD27+CD28- cells and maintenance of CD8 counts. 
 
Conclusion: severe influenza is associated with transient T and NK cell deficiency. CD8 phenotype 
changes during mild influenza are consistent with a rapidly resolving memory response whereas in 
severe influenza activation is either delayed or excessive, and partially differentiated cells accumulate 
within blood indicating that recruitment of effectors cells to the lung could be impaired. 
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Analysis of Inflammasome Related Molecules in the Response to H5N1 Avian 
Influenza 
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Highly pathogenic avian influenza (HPAI) infection is extremely acute and associated with severe 
mortality in both humans and poultry. The rapid onset of disease suggests that virus-host interactions, 
such as the immune response to virus, might contribute to the severity. With this in mind, it is critical 
to  understand  the  host-pathogen  interactions  in  order  to  develop  novel  approaches  to  managing 
infection. Pro-inflammatory cytokines, such as interleukin (IL)-1β and IL18, are crucial to an anti-viral 
response, however, the control of the expression of these molecules is vital, as exacerbated levels 
can  lead  to  deleterious  outcomes.  In  mammals  these  cytokines  are  regulated  by  a  complex 
cytoplasmic protein scaffold known as the Nalp3 inflammasome. Currently, the mechanisms for Nalp3 
activation  are  largely  unknown,  however,  it  appears  Nalp3  and  the  associated  cleavage  enzyme 
caspase 1 (ICE) are important regulators. To elucidate the role of the inflammasome in the chicken 
response to H5N1 HPAI, we identified and characterized chicken Nalp3, ICE, IL1β and IL18 and 
investigated  their  role  during  infection.  Through  qRT-PCR,  siRNA  gene  knockdown  and  ELISA 
analysis, the chicken Nalp3 inflammasome has been identified and its role in the response to H5N1 
HPAI analysed. All 4 genes are greatly upregulated, particularly Nalp3 and ICE. In tandem with this 
was  increased  IL1β  and  IL18  protein  secretion, measured  in  chicken  sera.  Together,  these  data 
indicate a strong Nalp3 inflammasome response, following HPAI infection in the chicken. This work 
provides an insight into strategies that target the immune system for improving resistance to avian 
influenza.   33 
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Screening Neuraminidase Inhibitor Susceptibility of Avian Influenza Isolates from SE 
Asia 2005-2008 Identifies H5N1 I222 Mutants with Reduced Oseltamivir Sensitivity 
    
Jennifer McKimm-Breschkin
1,2, Susan Barrett
1,2, Pak Pudjiatmoko
3, Muhammad Azhar
3, Peter Mohr
1, 
Frank Wong
1, Paul Selleck
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1, Mia Kim
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Engineering, Parkville, Australia; 
3Directorate of Animal Health, Directorate General of Livestock and 
Animal  Health  Services,  Ministry  of  Agriculture,  Jakarta,  Indonesia; 
4Food  and  Agriculture 
Organization of the United Nations, Animal Health Service (FAO-AGAH); 
5OIE-FAO Global Network of 
Expertise on Animal Influenzas (OFFLU) 
 
Objectives:  H5N1 viruses continue to spread and evolve, and surveillance is of critical importance to 
know both the antigenic variation for vaccine preparation, as well as their antiviral susceptibility. We 
previously  reported  that  clade  2  H5N1  isolates  from  Indonesia  have  reduced  susceptibility  to 
oseltamivir  compared  to  clade  1  isolates.  We  also  identified  isolates  from  Cambodia  which  had 
reduced oseltamivir sensitivity. In collaboration with the Indonesian Ministry of Agriculture CSIRO has 
been  involved  with  an  FAO-implemented  OFFLU  project  monitoring  hemagglutinin  genetic  and 
antigenic changes in Indonesian H5N1 isolates. These isolates also provided a rare and valuable 
source  for  screening  for  susceptibility  to  the  neuraminidase  inhibitors,  oseltamivir  and  zanamivir, 
which form part of many countries’ pandemic stockpiles. 
  
Methods:  samples were screened in the MUNANA based enzyme inhibition assay for sensitivity to  
zanamivir and oseltamivir. Isolates showing reduced susceptibility were screened in the IC50 kinetics 
assay against zanamivir, oseltamivir and peramivir to determine if mutations led to changes in the 
rates of inhibitor binding. Sequences were analyzed to identify mutations associated with reduced 
susceptibility. 
 
Results:  we have screened more than 160 H5N1 isolates from Indonesia, Cambodia and Thailand 
and found no virus with an IC50 > 5 nM for zanamivir. In contrast the median IC50 for oseltamivir for 
the Indonesian isolates was~25 nM, around 30-fold higher than for the clade 1 viruses. We found that 
an S246G mutation correlated with reduced oseltamivir sensitivity in some Cambodian isolates. Of 
more concern is that we identified 8 clade 2 isolates from Indonesia which were mild or extreme 
outliers to oseltamivir with I222T/V/M mutations. IC50s for oseltamivir for I222T/V mutants ranged 
from  43-63  nM  and  for  I222M  mutants  were  >250  nM.  Outliers  were  from  different  geographic 
locations in Indonesia. Mutations at I222 led to loss of slow binding of oseltamivir, but had minimal 
effect on peramivir or zanamivir binding. We also detected another 4 Indonesian isolates with IC50s 
around 30 nM also demonstrating loss of slow binding, including one with an I117V mutation.  
Conclusions: As H5N1 still remains a pandemic threat the incidence of mutations conferring reduced 
oseltamivir sensitivity is a concern and emphasizes the need for greater surveillance.   
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Cross-Neutralization Activity of Anti-H5N1 Specific Polyclonal Immunoglobulins 
against Heterologous Strains of H5N1 Virus 
 
Philippe Buchy
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Objectives:  highly pathogenic avian influenza virus (H5N1) remains a major global health concern. 
Since 2003, the regular emergence of new outbreaks is observed in Southeast Asia and over 600 
human cases (with almost 60% of deaths) were recorded. Polyclonal immunoglobulins are known for 
their  ability  to  present  cross-reactivity  capacities.  The  objective  of  this  study  is  to  confirm  the 35 
 
neutralization activity of anti-H5N1 specific polyclonal immunoglobulins on heterologous H5N1 viral 
strains representative of virus evolution since 2004 in Cambodia. 
 
Methods:  we used classical sero-neutralization in vitro assay to investigate the neutralization activity 
of  anti-H5N1  immunoglobulins  derived  from  horse  plasma  immunized  with  inactivated  H5N1 
A/Vietnam/1194/04 strain. 100 TCID50 of 10 different clade 1 H5N1 strains belonging to 6 distinct 
lineages were incubated with a range of dilution of immunoglobulins and then transferred to MDCK 
cells  for  neutralization  analysis.  Results  obtained  were  confirmed  by  using  a  hemagglutination 
inhibition assay (HIA). 
 
Results:    incubation  of  specific  anti-H5N1  immunoglobulins  developed  on  A/Vietnam/1194/04 
inactivated strain with various H5N1 strains isolated in Cambodia between 2004 and 2011 provided in 
vitro neutralization with similar titer comprised between 1:2000 to 1:4000 for all tested strains. Results 
were confirmed by HIA. 
  
Conclusion:    these  data  underpin  the  excellent  cross-reactivity  of  these  specific  polyclonal 
immunoglobulins  on  various  H5N1  strains  isolated  in  Cambodia  and  representative  of  different 
lineages  of clade 1 H5N1 virus circulating strains in Southeast Asia. 
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Classification of Neuraminidase Inhibitor Susceptibility for Surveillance  
 
A Lackenby, R Daniels, L Gubareva, A Hurt, J Lo, A Meijer, H Rebelo de Andrade, M Siqueira, E 
Takashita, M Tashiro, D Wang  
 
WHO  Expert  Working  Group  on  Surveillance  of  Antiviral  Susceptibility  for  the  Global  Influenza 
Surveillance and Response System 
 
Influenza neuraminidase inhibitor (NI) resistance is caused by numerous neuraminidase (NA) amino 
acid substitutions but only H275Y in N1-NA is consistently associated with treatment failure. As such, 
except  for  H275Y  detection,  genotypic  assays  are  of  limited  use.  Increasingly,  laboratories  are 
performing NA inhibition assays for in vitro surveillance of NI phenotypic susceptibility. Lack of a clear 
definition of reduced susceptibility has resulted in varied interpretations lab-to-lab. We propose criteria 
and terminology to define reductions in susceptibility, to provide consistency in reporting. 
 
These criteria must be flexible enough to apply across expected lab-to-lab variations and identify but 
not overstate minor variations. A definition based on fold change, calculated from either the IC50 
value of a validated sensitive control virus or the mean/median IC50 value for type/subtype-matched 
sensitive viruses in circulation was considered most applicable.  
 
Using data from several sources (CDC USA, NIID Japan, the European CNRL, and European EQA 
panel),  fold-criteria  were  set  for  normal  (<10-fold  increase),  reduced  (10-100-fold  increase)  and 
highly-reduced (>100-fold increase) inhibition for influenza A. For influenza B the same criteria were 
set  at  <5-fold,  5-50-fold  and  >50-fold  increases  respectively.  Interpretation  of  an  IC50  indicating 
reduced  or  highly  reduced  inhibition  was  consistent  whether  the  fold-change  was  calculated  on 
sensitive control virus, seasonal/subtype mean without outliers or seasonal/subtype median including 
outliers. Peramivir sensitivity for a minority of viruses was an exception.  
 
These NI susceptibility criteria are for reporting surveillance data. The NA inhibition assay provides an 
in vitro measure of drug inhibition. While several NA substitutions causing IC50 changes in vitro have 
been  identified,  the  impact  of  host  (underlying  conditions/immunocompromise)  and  other  viral 
(replication capacity) factors on clinical outcome is unclear, as is the clinical significance of mixed 
virus populations.  As clinical data have demonstrated the reduced effectiveness of oseltamivir when 
treating H275Y-N1 viruses, this variant is classified as resistant (>100-fold increase) to oseltamivir. 
Currently there is insufficient clinical data to indicate the effectiveness of NI treatment of viruses with 
other mutations associated with IC50 changes. As natural susceptibility of influenza viruses varies, 
these criteria will be reviewed to ensure that they remain applicable. 
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Background:    a  global  observational  trial,  the  Influenza  Resistance  Information  Study  (IRIS; 
NCT00884117), was initiated in 2008 to study neuraminidase inhibitor (NAI) resistance and influenza 
disease course.  
 
Methods:  patients with influenza-like illness and/or positive rapid test result had throat/nose swabs 
collected on Days 1, 3, 6 and 10 for real-time RT-PCR analyses of influenza type, subtype and NAI 
resistance. Positive samples were cultured, sequenced (HA, NA and M2) and phenotypically tested 
for NAI resistance. Patients recorded influenza symptom scores (scale, 0 [absent] to 3 [severe]) on 
diary cards (Days 1–12).  
 
Results:  of 1855 RT-PCR-positive patients infected with single influenza strains in years 1 to 3 (925 
aged 1–12 years), 1310 had influenza A, of whom 700 received oseltamivir monotherapy within 2 
days  of  symptom  onset  (seasonal  H1,  9/47  [19%];  H3N2,  222/335  [66%];  H1N1pdm09,  469/928 
[51%]).  Genotypic  resistance  (post-Day  1)  was  detected  by  mutation-specific  RT-PCR  in  19 
oseltamivir-treated influenza A patients (H275Y in H1N1pdm09, 17; R292K in H3N2, 2). Fourteen 
were  aged  1–5  years,  one  6–12  and  four  ≥13.  Seventeen  were  enrolled  in  Year  3  (2010–11). 
Genotypic resistance in H1N1pdm09 cases was associated with later enrolment year and lower age 
(logistic regression). In H1N1pdm09 patients treated with oseltamivir monotherapy within 48 hours of 
illness onset, H275Y occurrence was significantly associated with the proportion of patients who shed 
virus  for  >6  days:  16/17  (94.1%)  of  H275Y  patients  and  250/417  [60%])  of  wt-strain  patients 
(p=0.004). Symptoms resolved before Day 6 (score of <1 for each symptom) in 10/17 (58.8%) H275Y 
and 240/409 (58.7%) wt-strain patients (not significant).  
 
Conclusions:    in  years  1–3  of  IRIS,  treatment-emergent  resistance  to  oseltamivir  in  influenza  A 
viruses was found mostly in 1–5-year-olds and in patients enrolled in Year 3. Slower viral clearance 
might have increased the risk of developing H275Y. The presence of H275Y did not affect symptom 
resolution. 
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Oseltamivir-Resistant A(H1N1)pdm09 Influenza in Travellers Returning from Spain 
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Background:    in  the  Netherlands,  20  H275Y  oseltamivir-resistant  A(H1N1)pdm09  influenza  cases 
were  found  during  the  2009/2010  pandemic.  Most  cases  were  linked  to  prolonged  oseltamivir 
treatment  and  were  immunocompromised.  Since  then,  year-around  influenza  surveillance  in  the 
Netherlands did not identify more oseltamivir-resistant A(H1N1)pdm09 viruses. Australia reported in 
2011 transmission of oseltamivir-resistant A(H1N1)pdm09 virus, associated with H275Y-permissive 
substitutions V241I, N369K, and N386S in the neuraminidase. 
 
Objectives:  to monitor influenza virus incidence, diversity, and virulence as well as antiviral resistance 
for public health decision-making. 37 
 
Methods: Influenza virus positive specimens from sentinel surveillance or hospitalized patients are 
routinely characterized by sequencing, SNP-detection RT-PCR, or IC50 determination. Background 
information on exposure, treatment, risk factors and symptoms is collected for patients with unusual 
strains. 
 
Results:    two  Dutch  patients,  a  woman  aged  17  (case  1)  and  a  men  aged  20  (case  2),  were 
diagnosed  with  oseltamivir-resistant  A(H1N1)pdm09  influenza  virus  without  prior  oseltamivir 
exposure. Direct sequencing showed that both viruses carry genetic clade 6 HAs, while the NA genes 
carry mutations that encode the H275Y substitution, associated with oseltamivir resistance, along with 
the permissive substitutions V241I, N369K and N386S. The viruses have identical partial sequences 
for HA, NA, M and PB2 genes. Dates of onset of influenza-like illness with high fever, cough and 
malaise were 13 and 14 August 2012 respectively, with prior mild symptoms starting around one 
week before, during holiday in Spain (Catalonia). However, holiday destinations were about 200 km 
apart, with no known links. The younger sister, who showed mild symptoms, probably infected case 1. 
Concurrently with case 1, the father and a Dutch friend showed similar mild symptoms. 
 
Conclusions:  two patients were identified infected by identical A(H1N1)pdm09 influenza viruses that 
apparently had naturally acquired oseltamivir-resistance. A common source was not found. HA clade 
6 A(H1N1)pdm09 viruses carrying H275Y-permissive substitutions pose a risk for the emergence of 
transmissible  oseltamivir-resistant  A(H1N1)pdm09  virus,  leaving  zanamivir  as  the  only  treatment 
option in most countries world-wide. Given the popularity of the holiday locations where these two 
infections most likely have been acquired, diagnostic evaluation of patients with influenza-like illness 
and  characterization  of  A(H1N1)pdm09 viruses  should  be  encouraged  for  -but  not  be  limited  to- 
patients travelling from this area, to monitor possible spread of this oseltamivir-resistant strain. 
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What will Influenza Surveillance tell you About Antiviral use and Resistance? 
 
Mika Shigematsu 
 
National Institute of Infectious Diseases, Tokyo, Japan 
 
Surveillance is the mode to capture burden and trend of diseases occurring. The design of the surveillance 
determines what may be able to learn from it. Influenza is a beautiful example of the case. Influenza affects all 
age group, all gender, all ethnics, all geographic area in different scale, and throughout the year with or without 
seasonality. Not only from global collaboration, but also from regional collaboration and data incorporation from 
the existing surveillance will enhance surveillance capability. 
 
History of the influenza-like illness surveillance goes back hundred years in Japan. Sound bases of notification 
system exist for sentinel case reporting and viral strain surveillance. As over 30% of Japanese population is aged 
above 65, interest in the influenza related death such as sever pneumonia and encephalitis cases rose and 
additional surveillance was introduced. Moreover, multiple case-surveillances and syndromic surveillances by 
different definition were introduced during a decade to prepare for expected influenza pandemic after sever acute 
respiratory syndrome global epidemic. 
 
On the other hand, pathogen surveillance to sample and observe changing trend of influenza virus has been 
carried out steadily alongside with the national notification system. With knowledge of Japan as the world’s 
largest consumer of anti-influenza medication, concern of the resistance induction arose among public health 
personnel.  Surveillance  for  antiviral  resistance  in isolated  influenza  strains  was initiated  during  2009  by the 
National Institute of Infectious Diseases and Japan Association of Prefectural and Municipal Health Institutes. 
Started from Oseltamivir and Zanamivir resistance and then included Peramivir and Laninamivir from late 2010. 
 
In order to link surveillance information and answer to the title question, one more data from clinical site is 
required. The information on usage of the flu remedy to hospitalized and outpatient influenza cases.  A hospital 
based surveillance is outside of national infectious diseases surveillance system in Japan, so we rely on study 
based survey and voluntary surveillance for this information. 
 
Introduce three types of surveillance data from Japan and discuss what is able to understand through existing 
surveillance from the perspective of impact of antiviral use to drug resistance induction. Then try to identify how 
the gap could be filled without increasing burdens to already over whelmed public health sector based on existing 
efforts taken in Japan. 
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Influenza Encephalopathy and Related Neuropsychiatic Syndromes 
Masashi Mizuguchi – University of Tokyo, Tokyo, Japan  
 
Patients  with  influenza,  in  particular  children,  occasionally  show  neuropsychiatric  symptoms, 
especially impairment of consciousness with severity and duration highly variable among cases.  
Acute encephalopathy (AE) refers to coma or stupor lasting for more than 24 hours, accompanied by 
seizures in the vast majority of cases. In Japan, the incidence of influenza-associated AE is 100-500 
cases every year. Based on clinical, radiologic and pathologic findings, AE is classified into many 
syndromes,  such  as  Reye  syndrome  (RS),  acute  necrotizing  encephalopathy  (ANE),  acute 
encephalopathy  with  biphasic  seizures  and  late  reduced  diffusion  (AESD)  and  mild 
encephalitis/encephalopathy  with  reversible  splenial  lesion  (MERS).  RS  is  caused  by  metabolic 
disorder, ANE by systemic cytokine storm, and AESD by excitotoxicity. ANE is characterized by high 
fatality, and AESD by high probability of neurologic handicaps. Japanese investigators published a 
guideline for influenza associated AE. 
 
Mild and transient alterations of consciousness are more common than AE. They consist of transient 
delirium during febrile illnesses, MERS (mild cases) and several other conditions. In Japan, where 
oseltamivir  has  been  prescribed  to  numerous  patients,  some  teenagers  jumped  from  a  high-rise 
apartment and others rushed into a highway. Causality between oseltamivir and delirium in these 
cases  remains  controversial.  Except for  rare  cases  of fatal  accidents,  these  patients  showed  full 
recovery. 
 
Severe Influenza in Pregnancy:  Mechanisms and Management  
May Li Lim – KK Women’s and Children’s Hospital, Singapore 
 
Data  from  influenza  pandemics  and  epidemics  indicate  that  pregnancy  is  a  risk  factor  for 
complications. Pandemics of 1918 and 1957 saw significant mortality in the pregnant cohort. Influenza 
epidemics have resulted in greater incidence of morbidity such as acute cardiopulmonary event and 
hospitalisation. The increased susceptibility to complications has been attributed to the immunological 
suppression associated with pregnancy. The immune suppression theory lends support to the idea 
that exacerbated viral burden is the reason behind lethality of influenza infection. There is suggestion 
however  that  the  severity  of  infection  is  related  to  immune-based  tissue  injury.  The 
immunomodulatory role of estrogen is thought to be implicated. Prompt institution of medical therapy 
is an imperative in pregnant women with influenza infection as it reduces the risk of complications. 
Education of women will help to raise awareness and reinforce the importance of early presentation 
for medical attention. Vaccination must be recommended to all pregnant women and women of child-
bearing age as this will minimise the risk of infection.  
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Influenza Prevention and Treatment in Transplant recipients and 
Immunocompromised Hosts  
Michael Ison – Northwestern University, Chicago, USA  
 
The  host  immune  response  is  critical for the  control  and  clearance  of influenza virus  after initial 
infection.  Unfortunately, key components of the adaptive response to influenza is compromised in 
solid organ and hematopoietic stem cell transplant recipients.  As a result, influenza in these key 
patient population is associated with prolonged viral shedding, more frequent complications, including 
bacterial  and fungal  superinfections  and  rejection,  and  increased  mortality.   While vaccine is  the 
critical prophylaxis strategy in other  populations, response rates are diminished, particularly early 
post-transplant,  among  immunocompromised  patients.    Prospective  data  suggests  that  antiviral 
prophylaxis represents an effective and safe alternative to vaccine in patients who would be predicted 
to  have  poor  responses  to  influenza  vaccine.    While  there  have  not  been  prospective  studies 
completed  of  antiviral  therapy  in  solid  organ  or  hematopoietic  stem  cell  patient  populations, 
retrospectively collected data clearly demonstrates that early therapy is associated with reduced rates 
of progression to lower airway involvement, morbidity and mortality.  Therapy may also be associated 
with reduced rate of chronic rejection in lung transplant patient populations.  Further studies are 
needed to define the optimal regimen (including combination therapies), dose, duration and endpoint 
to define successful treatment.  Lastly, emergence of antiviral resistance appears to be more common 
among  transplant  recipients  and  studies  are  needed  to  better  define  risk  factors,  kinetics  of 
emergence of resistant variants, and the optimal therapeutic intervention to prevent and manage 
resistant variants. 
 
Advances in Antivirals for Non-Influenza Respiratory Viruses 
Frederick Hayden – University of Virginia School of Medicine, Charlottesville, 
USA 
 
A  modest  number  of  antivirals  have  been  tested  for  treating  non-influenza  respiratory  viral  infections 
(RVIs),  and  currently  agents  of  proven  therapeutic  value  are  largely  limited  to  influenza.  Seasonal 
prophylaxis with RSV-neutralizing monoclonal antibody against the viral F protein (palivizumab) provides 
partial protection against severe RSV disease in high-risk infants (prematurity, those with a congenital heart 
disease  or  bronchopulmonary  dysplasia),  but  palivizumab  is  not  effective  for  treatment  in  hospitalized 
children and is extremely costly. Aerosolized ribavirin (AE) is approved for treating RSV infections in infants 
but is difficult to administer, costly, and of unclear effectiveness. Most data on antivirals for non-influenza 
RVIs derives from observational reports in immunocompromised hosts, particularly hematopoietic stem cell 
transplant (HSCT) and lung transplant (LTx) recipients, and in other at-risk populations 
 
Use  of  AR,  especially  when  combined  with  anti-RSV  immunoglobulins,  reduces  the  likelihood  of  RSV 
progression from upper respiratory tract (URT) illness to pneumonia and mortality in HSCT patients, but AR 
is not effective in parainfluenza virus infection (PIV). An inhaled sialidase conjugate (DAS181) under study 
for influenza is active against PIV in pre-clinical studies and has been used in treating severe PIV infection 
in HSCT and LTx recipients.  Early AR or systemic (IV or oral) ribavirin appear effective in reducing risk of 
bronchiolitis  obliterans  syndrome  (BOS)  progression  or  development  in  paramyxovirus  (RSV,  PIV,  or 
HuMPV)-infected LTx patients.  Recent phase 2 studies indicated that an inhalation treatment with a small 
inhibitory RNA directed to the N gene of RSV (ALN-RSV01) reduced the risk of BOS development in LTx 
recipients.      Intravenous  cidofovir  is  the  primary  treatment  for  severe  adenovirus  infections  in  HSCT 
recipients and other immunocompromised hosts but causes nephrotoxicity and is incompletely effective. An 
oral cidofovir derivative (CMX001) has much improved tolerability and appears to benefit HSCT patients 
failing cidofovir.  Human rhinoviruses (HRVs) are the most common cause of RVIs across all age groups 
and major cause of asthma and CODP exacerbations. Two recent controlled studies reported that early 
HRV colds treatment with an oral capsid binding HRV inhibitor (BTA798) or with inhaled interferon-beta 
reduces the risk of exacerbations in asthmatic adults. Further studies on these antivirals are anticipated. 
  
Improved  understanding of the structure and function of viral proteins and of the pathogenesis of RVI 
infections  in different clinical  syndromes and patient groups will be fundamental to achieving rationally 
designed therapeutics and antiviral drugs for RVIs.  Viral replication patterns and innate immune responses 
are thought to account for much of the symptomatology of acute RVIs, and, in some cases, contribute to 
tissue damage in key target organs. Some of the pathways involved in the host responses to RVIs are also 
those necessary for efficient viral replication. Consequently, a drug has the potential to inhibit both viral 
replication and potentially deleterious host responses. 40 
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No Maternal Death caused by Pandemic (H1N1) 2009 in Japan 
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Objectives:  it is well known that novel pandemic (H1N1) 2009 virus infection increase the hospital 
admission rate and the number of maternal mortality. However, no maternal mortality was observed 
among  pregnant  Japanese  women. We  discuss  what  factors  contributed  to  the  lack  of maternal 
mortality in Japan during this pandemic. 
 
Patients and Method:  total 53 maternal death cases in 1.10 million of total birth and 45 maternal 
death cases in 1.10 million of total birth maternal were reported in 2009 and 2010, respectively in 
Japan. National data showed no maternal mortality due to pandemic (H1N1) 2009 among pregnant 
Japanese  women  in  2009  and  2010.  The  Japan  Society  of  Obstetrics  and  Gynecology  (JSOG) 
recommended the following; (i) prompt use of antiviral drugs for treatment of pregnant women on May 
8, 2009 via website, (ii) an early visit to the general practitioner when febrile on June 16, 2009, (iii) 
active use of antiviral drugs for prophylaxis after close contact with an infected person on Aug 4, 
2009, and (iv) vaccination against the pandemic (H1N1) 2009 strain on Sept 7, 2009. The number of 
visit to the JSOG website increased to 193,705 in Oct 2009. Yamada’s paper (JOGR 2012:38:130-
136) showed that antiviral medicines for prophylaxis was performed in 40,000 – 50,000 pregnant 
women, and 60% of pregnant women were vaccinated within 1.5 months after availability of a vaccine 
against pandemic H1N1 influenza. These treatment reduced the infection rate in Japanese pregnant 
women from general infection rate in Japan; 12% to 3.5% in pregnant women. Nakai et al. (J. Infect. 
2011:62:232-233) reported the clinical data of 181 hospitalized women. Seventeen (9.4%) developed 
pneumonia, two of these required admission to an ICU, and all 181 cases recovered completely. 
These rates were quite low compared to those in other countries. 
 
Conclusions:  the information by JSOG was very effective to inform the prevention and treatment of 
H1N1 infection. High rate of vaccination to pregnant women, antiviral medicines for prophylaxis and 
antiviral medicines within 48hr after symptom onset may have contributed to the maternal mortality 
zero. 
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The possibility of human-to-human transmission of highly pathogenic avian influenza A(H5N1) viruses 
is becoming a fear for human health and society. Since the first human case emerged in 1997 in 
Hong Kong, A(H5N1) viruses have been circulating among avian species and have spread throughout 
Asia, Europe, and Africa, with sporadic transmission to humans and reports of nearly 60% mortality. 
In this context, simple, cost-effective, and highly sensitive methods should be developed to detect 
influenza A(H5N1) virus. 43 
 
To  address  the  clinical  need  for  rapid  diagnosis,  we  have  developed  the  “RT-SmartAmp”  assay 
method to rapidly detect the highly pathogenic A(H5N1) influenza virus from patient swab samples. 
The  RT-SmartAmp  assay  comprises  both  reverse  transcriptase  (RT)  and  isothermal  DNA 
amplification reactions in one  step. Thus, the RT-SmartAmp assay method requires neither RNA 
extraction nor PCR reaction. We have tested its specificity and sensitivity to A(H5N1) virus. By the 
RT-SmartAmp  method,  we  could  specifically  detect  the  HA  segment  of  A(H5N1)  virus  within  40 
minutes without cross-reacting with the seasonal A(H1N1), 2009 pdm A(H1N1), A(H3N2), or B-type 
viruses. The minimal level for detection of A(H5N1) virus was estimated to be 50 copies of viral RNA 
encoding the HA segment in the RT-SmartAmp reaction mixture.  
 
In addition, we have developed an exciton-controlled hybridization-sensitive fluorescent primer, called 
“Exciton Primer”, to specifically detect the HA segment of A(H5N1) virus. The exciton primer functions 
as  a  sequence-specific  dye.  After  hybridization  to  complementary  sequences,  the  exciton  primer 
provides  a  sequence-specific  fluorescent  signal.  Owing  to  its  high  signal/noise  ratio,  the  exciton 
primer enables visual end-point detection of the RT-SmartAmp reaction. We have designed a small-
sized visual detection device for on-site detection of the A(H5N1) influenza virus. In conclusion, the 
RT-SmartAmp assay method would provide a practical tool for rapid and sensitive detection of highly 
pathogenic A(H5N1) influenza virus. This study was supported by the J-GRID Project of Japanese 
MEXT “Detection of highly pathogenic H5N1 influenza virus by the SmartAmp method”. 
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Objective:  to describe the clinical and etiological data collected from adolescents and adults with 
radiographically  confirmed  CAP  in  whom  causative  agents  were  sought  in  respiratory  secretion 
samples during the acute phase of the disease. 
 
Patients  and  methods  In  the  study,  954  patients  with  radiographically  confirmed  CAP  had  been 
enrolled, whose respiratory secretion  samples were  tested using Seeplex RV Detection kit, urine 
antigen  tests,  PCR  method,  blood  and  sputum  culture  to  detect  15  respiratory  viruses,  atypical 
pathogens and bacteria. The distribution of the microbial etiology in relation to age and severity score 
(PSI) were analyzed. 
 
Results:  mean (SD) age of the defined population was 45.24 (19.478) years (range 14-94). A total of 
393  patients  (41.2%)  were  positive for  at least  one  pathogen:  the  most  frequently  detected  was 
Mycoplasma pneumoniae (n=168, 17.6%), followed by influenza virus A (n=94, 9.9%), bacteria (n=47, 
8.8%), human rhinovirus (n=41, 4.3%) and adenovirus (n=40, 4.2%). Co-infections were found in 75 
patients  (7.9%),  and  showed  higher  mortality  than  single  infections  (p=0.032).  The  frequency  of 
Mycoplasma  pneumoniae  and  adenovirus  decreased  according  to  the  increasing  age  groups 
(p<0.001).  Opposite  trend  was  found  in  influenza  virus  A  (p<0.001)  and  bacteria  infected  cases 
(p=0.005). The frequency of atypical pathogens decreased in moderate and high risk groups (7.1% 
and  8.9%,  respectively,  p<0.001),  whereas  that  of  main  bacteria  pathogen,  Streptococcus 
pneumoniae and Klebsiella pneumoniae, increased according to risk groups (p=0.001). Similar trend 
was found in the distribution of pandemic H1N1. 
 
Conclusions:  in the defined population of CAP, M. pneumoniae, Influenza virus A, human rhinovirus, 
adenovirus and S. pneumoniae, were the most common pathogens isolated, while co-infection was 
very frequent. CAP due to M. pneumoniae is recognized by severity scoring as a low-risk condition, 
and always found in patients younger than 45 years old. Bacteria and pandemic H1N1 are identified 
as moderate- and high- risk pathogens, usually found in patients older than 45 years old. Thus, the 
choice of empiric treatment for CAP should be made according to local epidemiologic data. 44 
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Objectives:  to investigate the differences of demographic data, clinical features and cytokine profile 
between pandemic influenza A (pH1N1) 2009 infection and seasonal influenza A (H3N2) infection in 
adult patients with community-acquired pneumonia during the post-pandemic period. 
 
Methods:  based on Beijing Network for Adult Community-Acquired Pneumonia (BNACAP), patients 
with  community-acquired  pneumonia  (CAP)  during  the  first  flu  season  after  2009  pandemic(from 
November 2011 to March 2012 ) were enrolled. Identiﬁcation of inﬂuenza types  and subtypes was  
performed. Main characteristics of demographic and clinical data, and the pattern of serum cytokine 
were compared between patients with 2009 H1N1 or seasonal H3N2 pneumonia. 
 
Results:  a total of 88 CAP patients were studied, including 58 patients with pH1N1 infection and 30 
patients with seasonal H3N2 infection. Age distribution was similar in the two groups, a shift toward 
old people was noticed in pH1N1 group compared to pandemic period. When compared with H3N2 
group, higher serum levels of aspartate aminotransferase (AST), lactate dehydrogenase (LDH) and a 
lower level of albumin (ALB) were observed in pH1N1 group (p=0.006, 0.018, <0.001, respectively). 
Hospitalization rate in pH1N1 group was also higher (81.0% vs 56.7%, p=0.023), and oseltamivir was 
more  frequently  prescribed(44.8%  vs  0%).  ARDS  had  been  found  in  two  patients,  and  were 
responsible for one death, both two were infected with pH1N1 virus. Comprehensive elevated serum 
levels of cytokines and chemokines were observed in both two groups when compared with those of 
normal controls. Serum levels of IL-10 and IL-12 were found to be significantly higher in pH1N1 group 
than H3N2 group (p=0.005, 0.001, respectively).  
 
Conclusions:  our  findings  show  a  shift  toward  older  people  in  pH1N1  infections  during  the  post-
pandemic period compared to pandemic year of 2009. CAPs caused by pH1H1 virus  seemed to be 
more serious than seasonal H3N2 virus. 
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Objective:    intravenous  immunoglobulin  (IVIG)  is  widely  used  to  treat  immune  deficiencies, 
autoimmune disease and chronic inflammatory conditions.  Sporadic reports have suggested that 
IVIG may be useful in the influenza setting.  The influenza pandemic of 2009 and global circulation of 
highly pathogenic H5N1 has  sparked interest in alternative therapies for the treatment of serious 
influenza infection. IVIG has been demonstrated to contain cross-reactive antibodies to pandemic 
influenza. Further, IVIG has properties of modulating the immune response that may influence the 
hypercytokinaemia or  “cytokine storm” which is a suspected contributing factor to mortality in the 
pandemic influenza setting.  
 
Aim:  was to investigate the efficacy of IVIG in two ferret models of pandemic influenza. 
 
Methods:  two models of pandemic influenza were analysed. The swine origin H1N1 pandemic of 
2009 and highly pathogenic H5N1 model in ferrets.  IVIG was administered as a single dose at the 45 
 
time of challenge. Ferrets were assessed for weight loss, temperature, activity and viral replication 
over a 14 day post-challenge period. 
 
Results:  IVIG harvested prior to 2009 prevented significant viral replication (number of isolates and 
viral titre) of the swine origin H1N1 virus in the lung but not the upper respiratory tract.  A single dose 
of IVIG prevented mortality and significant morbidity following challenge with a lethal dose of H5N1 
virus.  The  level  of  virus  replicating  in  the  deep  lung  response  was  related  to  the  dose  of  IVIG 
administered. The mechanism of IVIG in this setting will be discussed. 
 
Conclusion:    these  studies  suggest  that  human  IVIG  is  effective  in  preventing  serious  influenza 
infection and provides an alternative treatment option requiring clinical trials. 
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Background: the world is at risk of epidemics of novel and reemerging infectious diseases.  These 
may be national, regional or international as in the case of Nipah, African Viral Haemorrhagic Fevers, 
SARS and H1N1 respectively.  It is crucial that vital public health and clinical research is conducted in 
such epidemics.  Yet the conduct of heath research during rapidly evolving epidemics or disasters 
represents an enormous challenge. There are a number of practical challenges to undertaking such 
research  but  there  are  also  major  ethical  issues  to  consider.  However,  there  is  very  little 
understanding of these issues and very little empirical evidence of the views of patients, their families, 
society and key stakeholders.  This oral presentation will review the ethical issues and present data 
on the views of key individuals from centers directly involved in responding to epidemics. 
 
Objective:  to  collect  data  on  ethical  considerations  arising  in  the  setting  of  research  on  rapidly 
evolving epidemics posed by the urgent and unpredictable nature of epidemics.  
 
Design: The study was conducted in Oxford University Clinical Research Unit (OUCRU), Viet Nam 
and  3  other  hospitals  in  Viet  Nam  with  experience  of  epidemics.  A  modified  grounded  theory 
approach  has  been  adopted.  Data  are  primarily  collected  by  in-depth  interview  and  focus  group 
discussions. The first interview round was completed at the Hospital for Tropical Diseases (HTD) with 
people representing different constituents of the health system including research staff, IRB members, 
patients/family members and study sponsors/funders who have participated in or reviewed research 
projects  on  infectious  diseases  including  SARS,  H5N1,  H1N1,  dengue  and  Hand,  Foot,  Mouth 
disease. The interviews were audiotaped, transcribed and translated in English for analysis.  
 
Result: through the interim analysis, 7 main themes emerged. These included issues concerning 1) 
the  dividing  line  between  public  health  needs,  medical  practice  and  research,  2)  vulnerability  of 
research participants and family members, 3) research information provision and factors influencing 
decisions of research participants/family members, 4) challenges faced by IRBs and factors which 
might influence their review and oversight in the setting, 5) dynamics of research collaboration, 6) 
multiple commitments of investigators and staff due to existing and emergency workloads, and 7) the 
role of the media and wider society during such rapidly evolving epidemics.  
 
Conclusion: the issues and types of considerations and their relative importance were raised and/or 
valued  differently  between  key  stakeholder  groups  due  to  their  role  and  experience  in  research 
participation. Some of these issues which were raised relate to all health related research. However, 
some very important considerations were unique to the setting of rapidly evolving epidemics. It is 
inevitable that epidemics of emerging and reemerging infectious diseases will occur in the future and 
there is a clear need to undertake crucial research.   It is therefore imperative that we understand the 
challenges and ethical issues surrounding such research.  It is desirable that research into these 
ethical challenges takes place in the inter-epidemic period in order to better prepare for the next 
epidemic. 46 
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In an attempt to provide insights into the mechanisms by which the host cell interacts with influenza A 
virus, cDNA microarray and long non-coding RNA (lncRNA) microarray were used to determine the 
differentially expressed protein-coding and non-coding genes in A549 human alveolar epithelial cells 
in response to infection with A/WSN/33 influenza virus (H1N1). All the genes whose expressions were 
altered by at least 2-fold were clustered and displayed. The protein-coding cDNA microarray analysis 
revealed 337 up-regulated genes and 1024 down-regulated genes following the viral infection. Many 
genes are involved in innate immunity, inflammatory response and intracellular transport. The long 
non-coding  RNA microarray  analysis  revealed  that  494  lncRNAs  displayed  up-regulated  and  413 
lncRNAs  showed  down-regulated  in  A549  cells  infected  with  influenza  A  virus  compared  with 
uninfected cells. We further investigated the functional involvement of selected protein-coding and 
non-coding genes in regulating influenza virus infection and replication. Interestingly, expression of 
ARHGAP21, a Cdc42-specific GAP, was found to be greatly down-regulated by influenza A virus 
infection. We found that expression of constitutively active Cdc42 or depletion of ARHGAP21 had 
profound  effect  on  the  transport  of  neuraminidase  (NA)  to  the  plasma  membranes.  Importantly, 
silencing Cdc42 reduced influenza A virus replication, whereas silencing ARHGAP21 increased the 
virus replication. Together, our results reveal that ARHGAP21 and Cdc42-based signaling regulates 
the  NA  transport  and  thereby impacts virus  replication.  In  addition,  eukaryotic initiation factor  4B 
(eIF4B) was also down-regulated by the virus infection. Knockdown or overexpression of eIF4B in 
A549 cells significantly affected influenza virus replication. Further functional analysis demonstrated 
that eIF4B is required for efficient expression of host antiviral proteins such as ISG15, IFIT2, IFITM1 
and  Mx1.  Furthermore,  we  identified  a  differentially  expressed  lncRNA  named  as  IVDR8.  Our 
experiments demonstrated that IVDR8 plays a key role in influenza virus infection and host defense. 
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The aim of our study was to determine whether genetic variations of the neuraminidase (NA) of the 
pandemic  H1N1pdm09  (N1pdm09)  and  H5N1  (H5-N1)  viruses  could  counteract  the  deleterious 
effects of the H275Y mutation in the NA, that confers high level resistance to oseltamivir (Tamiflu®) 
and lead to better fitness and transmission of resistant viruses, as seen for seasonal influenza H1N1 
viruses. 
 
Alignment of neuraminidase sequences of seasonal H1N1, H5N1 and pandemic H1N1pdm09 viruses 
along with the available crystal structures, emphasized the importance of positions 222 and 344 for 
which the impact on the NA activity of seasonal H1N1 viruses was previously shown (Rameix-Welti et 
al.Antivir.Ther.2011;16(4):597-603).  The  sequences  of  representative  NAs  were  cloned  into  an 
expression vector  and  substitutions  at  positions  222  (N  to  K/Q/R)  and  344  (Y/N  to  Y/D/N)  were 48 
 
introduced alone or in combination with the H275Y substitution. The transiently expressed proteins 
were assayed for their enzymatic properties and sensitivities to neuraminidase inhibitors (NAIs). 
   
Substitutions at position 222 had no significant effect on the affinity for the MUNANA substrate and on 
the sensitivity to NAIs of the N1pm09 and H5-N1 for the sensitive protein. However, in the presence 
of the H275Y mutation, substitutions at position 222 increased the mutants’ affinity for the substrate 
and decreased their sensitivities to oseltamivir. In contrast, whether in the presence or absence of the 
H275Y mutation, substitutions at position 344 increased or decreased the Km of the NA depending on 
the residue and the background; sensitivity to NAIs of N1pm09 changed according to the variations of 
Km, but not that of H5-N1. Using molecular modeling on structural data, we attempt to understand the 
different behavior of NAs derived from different genetic backgrounds. 
 
These studies should help determine whether such genetic variations could lead to increased fitness 
and transmissibility of viruses resistant to NAIs. 
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Oseltamivir (Tamiflu) is the most commonly used antiviral drug for the treatment of influenza infection 
in humans. In 2007-2008, oseltamivir-resistant seasonal A(H1N1) influenza viruses  with a H275Y 
neuraminidase mutation spread globally. Prior to this event, widespread transmission of oseltamivir-
resistant viruses was thought to be unlikely as the mutations that caused resistance were also thought 
to compromise viral ‘fitness’. Studies have since shown that other compensatory mutations in the NA 
of the seasonal A(H1N1) in 2007/2008 may have enabled this virus to overcome the detrimental effect 
of  the  H275Y  resistance  mutation  and  retain  the  ability  to  spread.  Since  the  emergence  of  the 
pandemic  2009  H1N1  (A(H1N1)pdm09)  influenza  viruses,  oseltamivir-resistant  A(H1N1)pdm09 
viruses  with  the  H275Y  neuraminidase  mutation  have  been  detected  in  treated  patients  but 
transmission of these viruses has been rare. However in the Newcastle region of Australia in 2011, 
oseltamivir-resistant  H275Y  A(H1N1)pdm09  variant  viruses  caused  a  cluster  of  influenza  cases 
among patients within the community not undergoing oseltamivir treatment. We assessed the relative 
fitness of these viruses using a competitive mixtures model in ferrets. Ferrets were infected with a 
series  of  deliberately  prepared  mixtures  of  a  Newcastle  H275Y  oseltamivir-resistant  virus  and  a 
closely related Newcastle oseltamivir-sensitive A(H1N1)pdm09 virus. Additional naive ferrets were co-
housed with infected ferrets to analyse the relative contact transmissibility of each virus. The relative 
proportions of oseltamivir-resistant and -sensitive virus in each ferret were assessed over time by 
molecular analysis of daily nasal wash samples. Mathematical analysis of the results demonstrated 
that the Newcastle H275Y oseltamivir-resistant A(H1N1)pdm09 viruses had equivalent or possibly 
enhanced replication and transmissibility to naive ferrets, compared to the very similar oseltamivir-
sensitive virus. Further work is being conducted to identify the viral mutations which may permit the 
acquisition of oseltamivir resistance without compromising viral fitness. Such studies are critical to 
help determine the risk of oseltamivir-resistant H275Y A(H1N1)pdm09 viruses spreading globally. 
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Two  classes  of  antiviral  drugs,  neuraminidase  inhibitors  and  adamantanes  are  approved  for 
prophylaxis and therapy against influenza virus infections. A major concern is that antiviral resistant 
viruses  emerge  and  spread  in  the  human  population.  Recently,  a  novel  neuraminidase  I223R 
mutation was identified in this subtype. So far, the resistance mechanism of this change is unknown. 
Here,  the  enzymatic  properties  of  the  I223R  mutant,  the  most  frequently  observed  resistance 
mutation, H275Y, and the double mutant I223R/H275Y were compared and the results interpreted in 
relation  to  the  structures  of  wild  type  and  I223R  mutant  neuraminidases  determined  by  X-ray 
crystallography.  Interestingly,  in  contrast  to  a  pandemic  H1N1  neuraminidase  structure  published 
recently, the active site of the I223R mutant adopted an open conformation in the absence of an 
active site ligand. Relative to wild type, KM values for MUNANA increased only 2-fold for the single 
mutant and up to 8-fold for the double mutant. Oseltamivir inhibition constants (KI) increased 48-fold 
in the single I223R mutant and 7500- fold in the double mutant, in both cases the change was largely 
accounted for by an increased dissociation rate constant for oseltamivir. These observations were 
linked to shrinkage of a hydrophobic pocket in the active site, as a result of the I223R change and the 
interaction of R223 with S247 which adopts a different rotamer in the mutant. In the wild type, this 
hydrophobic pocket normally facilitates binding of the pentoxyl substituent of oseltamivir. In contrast, 
due to the smaller, and polar, glycerol substituent in zanamivir, resistance to this inhibitor is much 
lower.  This  should  be  taken  into  account  in  the  development  of  novel  neuraminidase  inhibitors 
targeting  the  hydrophobic  pocket.  In  addition,  the  observation  here  that  the  2009  pandemic 
neuraminidase  contains  the  “open”  150-cavity  makes  this  cavity  a  suitable  target  for  new 
neuraminidase inhibitors. 
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Background: the neuraminidase inhibitors (NAIs) oseltamivir and zanamivir play a central role in the 
control of influenza epidemics and pandemics. During the 2009 influenza pandemic (A/H1N1pdm09), 
oseltamivir-resistant variants were infrequently found but were shown to maintain their fitness and 
contact  transmissibility  in  animal  models.  The  aim  of  this  study  was  to  investigate  the  effect  of 
mutations conferring resistance to zanamivir in the A/H1N1pdm09 background.  
 
Methods:  reverse genetics was used to rescue a recombinant A/H1N1pdm09 wild-type (WT) virus as 
well  as  two  NA  mutants  (E119G  and  Q136K)  reported  to  be  resistant  to  zanamivir  in  different 
influenza A subtypes. The susceptibility profiles to NAIs and the enzymatic parameters Km and Vmax 
were determined by fluorometric-based assays. Replicative capacity was evaluated by yield assays 
on  ST6GalI-MDCK  cells.  Virulence  was  evaluated  in  BALB/c mice  and  contact  transmissibility in 
ferrets. 
 
Results:  both E119G and Q136K mutants remained susceptible to oseltamivir but showed a high 
level  of  resistance  to  zanamivir,  with  832-  and  749-fold  increases  in  IC50  values,  respectively, 
compared to the WT virus. The E119G mutation significantly reduced the affinity (9-fold increase in 50 
 
Km vs the WT) but not the relative enzymatic activity. The Q136K mutation increased the affinity (5-
fold decrease in Km vs the WT) with a reduction on relative enzymatic activity (8% Vmax ratio vs the 
WT). In vitro, viral titers of both mutant viruses were reduced in the first 36h p.i. compared to the WT 
although similar peak viral titers were attained for the three viruses at 48h p.i. In mice, the E119G and 
Q136K mutants generated significantly reduced lung viral titers on day 3 (3.4x106 and 4.1x107 vs 
8.8x107  PFU/ml)  and  5  (3.0x105  and  8.6x105  vs  5.8x107  PFU/ml)  p.i.  compared  to  the  WT, 
respectively.  All  index  and  contact  ferrets  of  the  three  groups  seroconverted  for 
A/Quebec/144147/2009. The E119G mutation rapidly reverted to the WT in index and contact ferrets. 
The Q136K mutation was conserved in ferrets yet nasal wash viral titers from the Q136K contact 
group on days 2-4 p.i. were significantly lower compared to WT. 
 
Conclusions:  our results demonstrate that zanamivir-resistance mutations compromise viral fitness 
and transmissibility in A(H1N1)pdm09 viruses. This may help to explain the very low frequency of 
these mutations, particularly in the N1 subtype. 
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T-705 Suppresses Influenza A Virus Infectivity via Lethal Mutagenesis 
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Objectives:  the nucleoside analog T-705 is a promising investigational anti-influenza agent. It has 
demonstrated in vitro and in vivo activity against influenza viruses through mechanisms which are not 
completely understood. Here,  we  studied the hypothesis that T-705 enhances the influenza virus 
mutation rate, forcing the virus beyond the tolerable mutation frequency and creating a nonviable 
virus population. This mechanism, known as lethal mutagenesis, is well documented for many RNA 
viruses but not for influenza viruses.  
 
Methods:  T-705’s antiviral activity was evaluated in MDCK cells during multiple sequential passages 
with seasonal influenza A H1N1 viruses at a low multiplicity of infection (MOI = 0.001 PFU/cell) and 
with 2009 pandemic H1N1 viruses at a high MOI (MOI = 10 PFU/cell). Antiviral activity was assessed 
in MDCK cells by measuring the reduction of virus infectivity and the inhibition of viral polymerase 
activity. Relative virus infectivity was calculated by comparing virus titers determined by performing 
plaque  assays  and  RNA  titers  determined  by  performing  quantitative  RT-PCR  assays.  Mutant 
spectrum complexity was determined by performing a Sanger sequence analysis. 
 
Results:  we demonstrated that persistent infection with influenza A H1N1 viruses during the first few 
passages in MDCK cells inoculated with low or high virus doses and then treated with T-705 led to a 
progressive decline of viral infectivity and extinction (i.e., loss of infectivity) of virus progeny in vitro. 
The results of phenotypic assays based on cell viability and polymerase activity confirmed that T-705–
resistant variants were not selected. The relative infectivity of viral RNA synthesized in the presence 
of T-705 was less than that of mock-supplemented controls. Sequence analysis of the influenza virus 
variants passaged in the presence of T-705 revealed significant increases in transversion mutations, 
indicating that drug-induced error-prone replication occurred.  
 
Conclusions:  our data support the hypothesis that lethal mutagenesis is at least one of the antiviral 
mechanisms  of  T-705’s  activity  against  influenza  A  viruses.  Thus,  T-705  could  provide  a  new 
approach to treating influenza virus infections and preventing or decreasing the development of drug 
resistance during the course of treatment. 
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Influenza Evolution:  Can We Predict What’s Next?  
Jesse Bloom – Fred Hutchinson Cancer Research Center, Seattle, USA 
 
Influenza  poses  a  constant  threat  to  public  health  efforts  in  large  part  because  the virus’s  rapid 
evolution can quickly render antiviral drugs and vaccines ineffective. I will discuss  strategies that 
might eventually be applied to better predict future influenza evolution. I will begin by describing the 
experimental deconstruction of an historical influenza evolutionary pathway. I will then discuss how 
next-generation sequencing and computational techniques can be used to understand some of the 
molecular constraints that shaped the historical viral evolution. Finally, I will discuss the prospects for 
using similar approaches to forecast future viral evolution. 
 
Antivirals in 2009 Pandemic – Lessons and Implications for Future Strategies 
Maria Zambon – UK Health Protection Agency, London, UK 
 
Antiviral policy decisions during the pandemic 2009-10 were largely guided by: 
  
1.  Identification of priority groups  
2.  The role of drug resistance  
3.  Feasibility of disease containment vs mitigation strategies  
4.  Availability of stockpiles  
 
There was significant diversity amongst the national antiviral use policies.  Factors contributing to 
diversity included the structure of national health systems and influence of antiviral use polices for 
seasonal influenza.  
 
The impact of the use of antivirals, particularly neuraminidase inhibitors (NAIs) on clinical outcomes 
during the 2009-10 pandemic has not been firmly established.  A systematic approach to evaluating 
national  polices  used  for  antiviral  distribution  during  the  pandemic  may  provide  insights  about 
optimum use of antivirals at a population level.  A review of available clinical outcome data from 
observational analyses in several different countries with an analysis  of gaps in evidence will be 
presented, to assist updating pandemic plans, and promote consideration of optimum use of antivirals 
during pandemics of influenza.  
 
New Research Paradigms in Response to Emerging Infectious Threats   
Jeremy Farrar –The Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam 
 
A key lesson from a series of recent outbreaks of emerging pathogens of potential global public health 
importance  including  SARS-CoV,  highly  pathogenic  avian  influenza  A  (H5N1)  virus,  Viral 
Hemorrhagic  Fevers,  Nipah virus  and  the  2009  H1N1 virus  pandemic  was  that  mounting  clinical 
research in response to a rapidly emerging infectious disease is extremely challenging and often 
delayed.  During these events, critical clinical management and pathogenesis insights came mostly 
from sites that were already undertaking related clinical studies including those on inter-pandemic 
influenza  or  from  established  national  or  regional  research  networks  such  as  the  Canadian  and 
Australia/New Zealand Critical Care Trials Group. Even from these groups only a very small number 
of patients were enrolled in randomized controlled trials of therapeutic interventions.  There was little 
cross-border coordination, unlike that which now exists in epidemiology, virology and genomics.  The 
clinical  research  response  was  cumbersome  and  slow  despite  years  of  global  preparations for  a 
potentially devastating influenza pandemic of avian origin or the next SARS-like outbreak. Although 
observational  registries  were  mobilized,  initiatives  to  launch  randomized  controlled  trials  or  more 
sophisticated biologic studies generally missed the initial waves of the 2009 H1N1 pandemic and in 
many  cases  failed  to  enroll  sufficient  numbers  of  patients  across  the  entire  clinical  spectrum  of 52 
 
disease  into  studies,  even  during  subsequent  waves.  During the  2009  H1N1 virus  pandemic  the 
efforts to prepare for a respiratory disease outbreak allowed a reasonably rapid and coordinated 
response  on  epidemiologic  and  diagnostic  aspects  of  disease  but  failed in  the timely  conduct  of 
clinical research aimed at improving patient management or understanding pathogenesis.  The failure 
to have coordinated, comparable data on clinical management and pathogenesis of 2009 H1N1 virus 
infection meant that we missed the opportunity to improve patient outcomes. Indeed this has been a 
problem in almost all epidemics over the last decade (Nipah, SARS, H5N1, and in outbreaks of VHF) 
with very little research aimed at improving clinical management or understanding pathogenesis.  This 
has  demonstrated  that  unless  something is  done  to  change  the  barriers faced in  2009, the  next 
influenza (or other) epidemic will result in a similar missed opportunity to save lives. There is a need 
to establish a sustainable consortium of clinical research groups  with broad geographic coverage 
(including  low  resource  settings),  cross-border  coordination,  commitment  to  open  access,  and 
capacity  to  conduct  complementary  high-quality,  hospital-based  pathogenesis  and  clinical 
management studies and the flexibility to respond immediately to rapidly emergent threats. We need 
a new paradigm for clinical research in the context of rapidly emerging public health threats and one 
appropriate to the sorts of challenges we will face in the 21st Century. 
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Post-exposure Prophylaxis for 
Influenza in Pediatric Wards: 
Oseltamivir or Zanamivir after a 
Rapid Antigen Detection  
 
M Shinjoh
1 & N Sugaya
2 
 
1 Keio University, Tokyo, Japan; 
2 Keiyu 
Hospital, Kanagawa, Japan 
 
Post-exposure prophylaxis (PEP) using 
neuraminidase inhibitors against exposure to 
influenza virus has been well studied in 
household settings but not in nosocomial 
settings in pediatric wards.  We have used 
oseltamivir or zanamivir as PEP in our 
pediatric wards. All influenza cases were 
diagnosed by the influenza rapid diagnostic 
test.  
 
Results:  between 2003 and 2011, there were 
20 nosocomial introductions of influenza (10 
were A, 9 were B, and 1 was undetermined). 
The index cases consisted of 17 inpatients, 2 
parents, and 1 medical staff member. The 17 
inpatients had been admitted to the hospital for 
reasons other than infectious disease and they 
developed influenza after hospitalization. 
Among the 81 contacts, 28 (35%) were 
exposed to influenza A, and 52 (64%) were 
exposed to influenza B. The rate of secondary 
infection among contacts not given PEP was 
29% (5/17), and the rate among contacts given 
PEP was significantly lower at 3% (2/63) (p = 
0.004). The two infected contacts who had 
been given PEP were both influenza B cases, 
and both had received oseltamivir. The 
contacts who received PEP within 24 hours 
(59), for influenza A (23), and those who 
received zanamivir (15) did not develop 
influenza. No adverse events were reported.   
 
Conclusions:  PEP using oseltamivir or 
zanamivir for unexpected occurrences of 
nosocomial influenza in pediatric wards is safe 
and effective. The influenza rapid diagnostic 
test that we used was helpful for detecting 
nosocomial influenza in children. 
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Efficacy of Laninamivir Octanoate 
(CS-8958) in Contact Transmission 
of Influenza Viruses in Guinea Pig 
 
M Yamashita, M Kakuta, M Tanaka, S 
Tobiume and S Kubo 
 
Biological Res. Labs., Daiichi Sankyo Co. Ltd. 
Japan 
 
Objectives Laninamivir octanoate (CS-8958) is 
a long acting neuraminidase (NA) inhibitor 
which completes influenza treatment by a 
single inhalation and has been commercially 
available in Japan as the brand name, Inavir®. 
Efficacy of CS-8958 has been investigated in 
mice and ferrets with a direct infection of 
influenza viruses. In this study, the efficacy of 
CS-8958 and other NA inhibitors was 
investigated in a contact transmission model of 
guinea pigs.  
 
Methods:  a guinea pig (Hartley, female) was 
infected with 500 pfu of 
A/Nagasaki/I01/2009v,(H1N1) pdm09 subtype 
(donor) and housed with an uninfected guinea 
pig (acceptor) the next day (Day 0) to cause 
contact infection from a donor to an acceptor. 
Sets of these pairs were created. The 
acceptors were treated with NA inhibitors 
under various experimental conditions. Virus 
titers in the nasal wash of the donor were 
measured on Day 1 to confirm virus infection 
and those of acceptors on Day 3, 4 and every 
other day afterwards to investigate the 
efficacy. Lower limit of detection was 101.70 
pfu/mL.  
 
Results:  1.Transmission model: In donors, the 
viruses grew to near 107pfu/mL at the peak of 
Day 1 and then quickly eliminated. In 
acceptors, the viruses grew to 106-7 pfu/mL at 
Day 3-4 and were then eliminated.  
2. Administration at contact: Acceptors were 
administered 33  g/kg of CS-8958 intranasally 
once, 33  g/kg of zanamivir intranasally once 
daily for 5 days and 100 mg/kg of oseltamivir 
orally once daily for 5 days. CS-8958 and 
zanamivir delayed virus loads and reduced 
about 1/1000 of virus loads in acceptors at the 
peak of Day 6. Oseltamivir did not delay the 
virus load and was reduced by only 1/5 at the 
peak of Days 3-4.  3. Administration before 
contact: Acceptors were treated once with 190 
 g/kg of CS-8958 8, 5 or 4 days before 
contact. Virus loads were delayed in all treated 
groups and no viruses were detected in 2 out 
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of 4 acceptors of the group of - 4 days 
administration. 
 
Conclusion:  in the contact transmission model 
of guinea pigs, a single treatment of CS-8958 
was efficacious both in administration at 
contact and before contact. 
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Preliminary Results of the 
Epidemiology of Human Cases of 
Influenza A/H5N1 Virus in Vietnam 
from 2003-2012 
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Background:  with avian influenza A/H5N1 
virus (A/H5N1) endemic in poultry in the 
country, Vietnam currently has the third 
highest number of human cases of A/H5N1 in 
the world. A/H5N1 continues to pose a serious 
threat to both public health and animal health. 
This study proposes to provide 
epidemiological, laboratory, and clinical 
characteristics of 123 confirmed A/H5N1 
cases, and to identify potential health 
implications associated with temporal gaps in 
seeking healthcare services. 
 
Methods:  this is a retrospective review of 
A/H5N1 case documents from regional official 
reports, provincial preventive medicine 
centres, and hospital medical records. All 
A/H5N1 cases were confirmed by reverse 
transcriptase polymerase chain reaction at the 
National Influenza Center in Vietnam. 
Epidemiological analysis was performed to 
describe characteristics of reported cases. 
 
Results:  from 2003-2012, Vietnam 
experienced only two years with no confirmed 
human cases of A/H5N1, 2006 and 2011. Of 
63 provinces/cities of the country, 41 reported 
cases during the other eight years. The 
median age of the 123 cases was 23 years, 
(IQR 11-35). The mortality rate was 49.6%. 
Potential exposure history included close 
contact with sick or dead poultry in 45% of 
cases, poultry flocks in 54% of case 
households, 51% of cases living in a current 
poultry outbreak area, and 54% had traveled 
to a poultry raising area. Age and delay of 
hospital admission were significantly 
associated with mortality. Cases ≤ 18 years 
old were more likely to die than cases > 18 
years, (OR 2.1; 95% CI 1.0-4.6; p=0.036). Of 
99 persons who were ill > 48 hours before 
hospitalization, 54 (54.5%) died compared with 
7 (29.2%) of 24 persons hospitalized ≤48 
hours after illness onset, (OR 2.9; 95% CI 1.1-
7.6; p=0.03). Early Tamiflu treatment during 
the first two days after illness onset date was 
associated with lower mortality compared to 
treatment of more than two days, (OR 9.1; 
95% CI 1.1-80.1; p= 0.02). 
 
Conclusions:  fifty percent mortality was found 
in confirmed human cases of influenza 
A/H5N1 virus in Vietnam from 2003-2012. A 
delay in hospital admission was associated 
with higher mortality. Tamiflu treatment during 
within the first two days from onset decreased 
mortality from A/H5N1 virus. We conclude that 
early hospital admission as well as early 
treatment by Tamiflu is life-saving for cases 
infected with influenza A/H5N1 virus. 
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New Therapeutic Agents Against 
Influenza Viruses Including the 
Oseltamivir-Resistant Strains 
 
Jim-Min Fang
1,2, Jiun-Jie Shie
2, Yih-Shyun E. 
Cheng
2 and Chi-Huey Wong
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1 National Taiwan University, Taiwan, ROC, 
2The Genomics Research Center, Taiwan, 
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The most effective therapies for the treatment 
of influenza infections involve administration of 
oseltamivir (Tamiflu) and zanamivir (Relenza). 
Both oseltamivir and zanamivir target the viral 
neuraminidases. These neuraminidase 
inhibitors are designed to have 
(oxa)cyclohexene scaffolds to mimic the 
intermediate of oxonium-like geometry in the 
enzymatic cleavage of N-acetylneuraminic 
acid (Neu5Ac, also known as sialic acid), the 
outmost saccharide on the cell surface 
glycoprotein for binding with the active site of 
viral neuraminidase. However, the oseltamivir-
resistant strains of influenza viruses have 55 
 
evolved due to the extensive use of 
oseltamivir.  Though the resistance to 
zanamivir is still rare, we may also face the 
problem in treatment of the zanamivir-resistant 
viral infection. Therefore, new anti-influenza 
agents are in urgent need, especially global 
pandemics of influenza may happen in near 
future. 
 
In the past years, we have explored the 
phosphonate congeners of oseltamivir and 
zanamivir, namely tamiphosphor and 
zanaphosphor, which are more potent against 
the neuraminidases of avian and human 
influenza viruses, including the oseltamivir-
resistant strains. The phosphonate group is 
generally used as a bioisostere of carboxylate 
in drug design. In comparison with carboxylic 
acid, the phosphonic acid has higher acidity 
and stronger electrostatic interactions with the 
guanidine group. The enhanced affinity of 
these new anti-influenza agents is attributable 
to the strong electrostatic interactions of the 
phosphonate group with the three arginine 
residues (Arg118, Arg292 and Arg371) in 
neuraminidase. In this conference, we shall 
present the biologic studies and 
pharmaceutical development of tamiphosphor, 
zanaphosphor and analogs. 
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Infection with influenza type A virus causes 
epidemic outbreaks of acute respiratory 
disease that can spread as pandemics 
affecting millions of people. Vaccines are the 
best option to control the disease. However, 
not all vaccinated individuals respond to 
vaccines and the protective vaccines are not 
always available when they are most needed. 
Passive immunization (the transfer of specific 
immunoglobulins/Abs to a previously non-
immune recipient host) could offer an 
alternative strategy to prevent and treat 
influenza, and an additional therapeutic option 
to antiviral drugs that are limited by 
widespread drug resistance among influenza 
virus strains. We have developed an approach 
using avian immunoglobulin IgY, obtained from 
egg yolk of immunized hens, for prevention 
and treatment of influenza. We found that 
intranasal administration of influenza virus-
specific IgY in mice before or after lethal 
infection with influenza virus prevents the 
disease or significantly reduces viral 
replication resulting in complete recovery from 
the disease, respectively. Importantly, 
treatment with the influenza virus specific IgY 
prevented transmission of influenza-facilitated 
pneumococcal infection that is responsible for 
excess morbidity and mortality during influenza 
outbreaks. The findings suggest an affordable 
and effective approach for control of influenza, 
and influenza-facilitated pneumococcal 
infection and transmission. 
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Background:  the burden of disease due to 
influenza viruses is not well characterized for 
hospitalized severe acute respiratory infection 
(SARI) patients in Vietnam. There is little 
recognition of the clinical and economic 
impact, only limited hospital control policies in 
place, and no strategy for seasonal influenza 
vaccination. Our study proposes to provide 
initial data on the burden of human influenza 
illness in terms of morbidity, mortality and 
socioeconomic impact at the District hospital 
level in Vietnam. 56 
 
Methods:  a modified WHO case definition of 
SARI was used. Adults and children meeting 
the definition were enrolled at three selected 
district hospitals in north, central, and south 
Vietnam. Nasal and throat swabs were 
collected for influenza virus detection by real-
time reverse transcription polymerase chain 
reaction. A survey was conducted to identify 
direct and indirect costs, and loss of work days 
or school absenteeism, were estimated to 
evaluate the burden of SARI on the patient 
and family.  
 
Results:  from March 2011 through July 2012, 
of 35,228 hospitalized patients at three district 
hospitals, 4,775 (13.5%) were identified as 
SARI. Of 1,185 SARI cases tested, 173 
(14.6%) were positive for influenza viruses, 
including A/H3N2 (44.3%), B (42.2%), 
pA/H1N1 2009 (12.7%) and A/H3N2 & B 
(0.6%). Both normal and low white blood cell 
counts were found in influenza related SARI 
patients. Of influenza related SARI patients, 
18.5% required treatment in ICU. There were 
no SARI deaths at the three district hospitals. 
The median hospital stay was five days (IQR 
3-6). Of 1,169 survey respondents, 13 (1.1%) 
reported receiving an influenza vaccination 
during the previous 12 months. Socioeconomic 
impact included direct and indirect costs per 
patient of 1,328,906 VND ($US 63), an 
average of 6 work days lost and 4 school days 
lost, and care giver 5 days lost. 
 
Conclusions:  we found no deaths due to SARI 
for any cause in this study. The most frequent 
influenza viruses identified were A/H3N2 and 
B. A low rate of influenza vaccination was 
found in the study population. The costs due to 
SARI case hospitalization are important to 
patients with limited resources (per capita 
monthly income = 1,387,000 VND ($66)), even 
for only one week of the treatment. This study 
at District-level hospitals may have under-
estimated influenza related SARI burden and 
impact in Vietnam. Patients with more severe 
illness may go directly to higher level hospitals, 
such as Provincial or National, which would 
likely increase the costs. The study indicates 
that the burden and socio-economic impact of 
influenza related SARI is present but low at 
district level hospitals in Vietnam, and 
suggests that SARI burden may be better 
identified at provincial-level hospitals or higher. 
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Background:  the first case of A/H1N1pdm/09 
in Vietnam was determined on May 31, 2009, 
and the first A/H1N1pdm/09 detected by 
influenza sentinel surveillance network on July 
9, 2009, then reported in all sentinels in 
September 2009. The pandemic H1N1 was 
predominant to other seasonal influenza 
viruses during 2009 – 2010 and continuing 
circulates up to date. In this study, the 
molecular characterization of A/H1N1pdm/09 
viruses circulated in the North and Central of 
Vietnam 2009-2010 is analyzed in order to 
monitor genetic mutation related to antigenic 
changing as well as antiviral resistance in its 
evolution.  
 
Methods:  throat swab sample was collected 
from suspected cases following the NIS 
criteria. Typing and subtyping using Onestep 
RT-PCR Qiagen kit.  Isolates from RT-PCR 
positive samples reached sufficient HA titer 
(>8) on MDCK cells were selected.  Six 
segments (PB1, PB2, HA, NA, M, NS) were 
amplified and sequenced (ABI 3130). 
Phylogenetic trees were analyzed using 
maximum likelihood methods. 
 
Results:  total 43 representatives virus strains 
were selected for three regions [Northern 
(31/43), Central (5/43) and Highland (7/43)] in 
Vietnam. During 2009-2010, the HA gen was 
diverged in to 2 groups (I & II), and genetic 
different between group II was found, it may 
introduced for 4 sub-group (IIA, IIB, IIC, 
IID).The maximum likelihood tree of HA 
showing the alternate appearance of virus 
from Vietnam and those from China, Thailand 
and Taiwan. The mutations related to 
changing in receptor binding have not been 
found. 
  
The NA gene is clustered in same group that 
corresponding with group 2 of HA gene. No 
mutation related to antiviral resistance was 
found. 57 
 
All A/H1N1pdm09 isolates showed mutation 
referred to amantadine resistance on M gene 
(S31N). Two other amino acids changed on M 
protein indicate the conservative 
characterization of M gene. 
PB1, PB2 and NS gene showing a similar 
phylogenetic tree. 
 
Conclusion:  total 43 A/H1N1pdm/09 virus 
strains circulated during 2009-2010 in the 
North, Central and Highland Vietnam was 
molecular characterized. HA gen was diverged 
in to 2 groups; NA gene is clustered in one 
group corresponding with group 2 of HA gene. 
No mutation related to changing in receptor 
binding and antiviral resistance was found. 
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Background:  clinically, ARDS associated with 
H5N1 avian influenza virus (H5N1) infection is 
so severe compared as general ARDS that we 
named it Fulminant-ARDS (FARDS) (Kawachi, 
et al. JID 2009). It is an urgent mission to 
elucidate the mechanism of FARDS and to 
develop a therapeutic strategy. 
 
Methods:  we have been co-operating the 
prospective study for FARDS with National 
Hospital of Pediatrics–Hanoi (NHP-Hanoi) 
from October 2007. The entry criteria are as 
follows; 1. The patients who admitted the 
PICU-NHP with ARDS under intra-pulmonary 
reason (pneumonia), and needed mechanical 
ventilation. 2. The patients aged over one 
month. 3. P/F ratio (PaO2/FIO2 ratio) ≤ 100 
mmHg in arterial blood gas analysis during the 
stay in the PICU. Serum, tracheal lavage fluid 
and/or nasopharyngeal aspirate samples were 
collected on admission. Viral genomes were 
examined by PCR or RT-PCR method with 
TLF/NPA samples of each patient. In 55/84 
patients we tried 2 gram /kg gamma globulin 
therapy after informed consent. All patients 
were tracheal intubated and mechanical 
respiratory support was performed basically 
according to the AECC strategy (1998). 
 
Results:  eighty-four patients were diagnosed 
as FARDS matched in the criteria of 
prospective study. In 30 patients among 84, 
the following viruses were detected; 8 cases: 
Influenza viruses: H5N1 (3), A(H1N1)pdm09 
(4), H3N2 (1) and 22 cases: Rhinovirus(11), 
Adenovirus (3), CMV (4), RSV (3), Measles 
(1). In the other 54 patients, viral genomes 
were under detection limit. . No differences 
were observed in gender, age or body weight 
between viral genome positive and negative 
groups (viral genome positive: M:F=12:18, age 
0.33 years, weight 4.50 kg; viral genome 
negative: M:F=20:34, age 0.25 years, weight 
4.65 kg. ) There are significant differences only 
in survival time (days) (viral genome positive: 
24.85 vs. viral genome negative: 42.25) and 
survival probability (p=0.079 by log-lank test, 
p=0.0129 by Wilcoxon test). 
 
Conclusions:  in Vietnam, several viral 
infections occurred severe ARDS and the 
mortality rate of ARDS associated with viral 
infection was much higher than the others 
(Viral: 67%, non-Viral 31%, p = 0.0019 by 
Mann-Whitney’s U test). These results 
reinforce the importance of further research on 
the etiology of viral infection induced FARDS, 
especially H5N1. Our study will provide the 
crucial clinical information for development of 
the strategies of future therapeutic options. 
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Objective:  since February 2011, the 
Department of Clinical Epidemiology at Tan 
Tock Seng Hospital initiated surveillance of 
patients admitted with a positive influenza test 
by reverse-transcriptase polymerase chain 
reaction (RT-PCR) as part of a nationally 
mandated programme to monitor severe 
influenza cases at all hospitals. 58 
 
Methods:  we prospectively tracked all 
influenza PCR positive patients admitted from 
1st Feb 2011 to 29th Feb 2012. Data were 
collected by case note review and all samples 
were subtyped. 
 
Results:  a total of 761 patients with influenza 
were admitted within the 13-month period, with 
467 (61.4%) positive for influenza A/H3, 220 
(28.9%) influenza B, 46 (6%) influenza 
A/H1N1-2009 and 28 (3.7%) influenza A 
subtype undetermined (A/ND) respectively. Of 
these, 53 (7%) were severely ill patients (51% 
with A/H3; 23% with B; 19% with A/H1N1; 7% 
with A/ND respectively) required Intensive 
Care and/or died. The median age of these 
severely ill patients with influenza were 74 for 
A/H3; 65 for influenza B; 57 for A/H1N1 and 66 
for A/ND (p=0.089). Of these patients, 23% 
had chronic respiratory problems. Fifty-five 
percent had more than two underlying medical 
conditions. Most common diagnoses at 
admission were respiratory problems (36%) 
followed by sepsis (32%). Twenty-nine 
patients (55%) required mechanical ventilation. 
The difference in the proportion of severely ill 
patients aged 65 years or older with A/H3 
(21/27; 78%), B (7/12; 58%), A/H1N1 (3/10; 
30%) and A/ND (2/4; 50%) was statistically 
significant (p=0.044). There were no significant 
differences between the influenza subtypes 
with regards to gender, race, co-morbidities, 
the reasons for admission, need for 
mechanical ventilation, length of stay, or 
death. Of these 53 patients, 25 died (47%). 
There were no significant differences between 
those who died or survived in terms of gender, 
race, underlying medical conditions, the 
reasons for admission, flu subtypes and length 
of stay. However, age 65 years or older was 
an independent predictor (Adjusted odds ratio, 
7.0; 95%CI, 1.9-25.8; p=0.003) of death after 
adjusting for gender, race and flu subtypes. 
 
Conclusions:  we documented co-circulation of 
the different sub-types of influenza virus in 
tropical Singapore. There were no distinct 
characteristic differences among the various 
sub-types. However, severely ill patients aged 
65 years or older was an independent 
predictor of fatality.  
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Objectives:  influenza surveillance in 
Singapore is a part of the emergency 
preparedness for SARS affected countries 
recommended by the World Health 
Organization. Being in close proximity to 
countries where the highly pathogenic avian 
influenza is endemic in poultry and human 
cases are reported sporadically, an influenza 
pandemic in Singapore is a significant threat 
and hence the need for ongoing surveillance. 
 
Methods:  data collection for all laboratory 
confirmed cases of influenza is part of a 
broader infectious diseases surveillance 
carried out by the Epidemiology Unit of the 
National University Hospital, a 1000 bed 
tertiary teaching hospital.  Data, obtained from 
the hospital information systems and 
laboratory, on inpatients with influenza 
between January 2011 and July 2012 were 
analyzed using the statistical software STATA 
12. Admission to the intensive care unit (ICU) 
was a surrogate marker of illness severity. 
Logistic regression was used for risk 
estimation of association with severe 
influenza. The variables included in the final 
multivariable logistic regression model were 
based on pre-existing literature and the Akaike 
criteria for model selection. 
 
Results:  180 inpatients were diagnosed with 
influenza during the study period. 93 (51%) 
were female and median age was 30 years 
(range: 0.2 to 82 years).  28 (16%) patients 
were admitted to ICU. They were older 
(median age 46 years versus 23 years, 
p=<0.01) and more likely to be female (20 
(71%) versus 73 (48%), p=0.02). Influenza A 
was the dominant strain in the ICU cohort (27 
(96%) versus 120 (78%), p=0.02). H1N1 2009 
influenza was equally distributed in the two 
groups (14 (50%) versus 60 (39%), p=0.20). In 
the ICU cohort, 13 (7%) patients required 
ventilatory support and 2 (7%) died. Death was 
more common amongst patients admitted to 
ICU (2 (7%) versus 0 (0%), p=0.02). On the 
multivariable regression model, age (OR: 1.02, 
95% CI 1.01-1.04, p=0.01) and female sex 
(OR: 1.16, 95% CI 1.00-6.23, p=0.05) were 59 
 
significant risk factors for severe infection 
while influenza A was not (OR: 6.65, 95% CI 
0.81-49.62, p=0.08) (H-L goodness of 
fit=0.31).  
 
Conclusions:  seasonal influenza causes 
significant morbidity and mortality particularly 
amongst the elderly and female population. 
Vaccination of high risk groups is an important 
public health intervention in the management 
of this illness.  
 
P11  
 
High Mortality Associated With 
Pandemic Influenza A(H1N1)pdm09 in 
Children in Pakistan 
 
Asad Ali
a, Fatima Aziz
a, Nida Akhtar
a, Shahida 
Qureshi
a, Kathryn Edwards
b, Anita Zaidi
a 
 
aDepartment of Paediatrics and Child Health, 
Aga Khan University, Karachi, Pakistan 
bDivision of Pediatric Infectious Diseases, 
Vanderbilt Vaccine Research Program, 
Vanderbilt University, USA 
 
Objective:  during the 2009-10 Influenza 
A(H1N1)pdm09 pandemic season, Pakistan 
reported only 262 laboratory confirmed cases 
with 29 deaths (all ages) as a result of this 
virus. This is likely an under- estimation, given 
the inadequate surveillance system and limited 
diagnostic facilities to detect this virus in both 
public and private sector facilities. In the first of 
its kind study, we sought to determine the 
frequency and case fatality rate of Influenza 
A(H1N1)pdm09 infections in children 
hospitalized with acute respiratory illness at a 
tertiary care hospital in Karachi, Pakistan.  
 
Methods:  children less than 5 years old 
admitted with acute respiratory illnesses to the 
Aga Khan University Hospital, Karachi from 
17thAugust 2009 to 16thSeptember 2011 were 
enrolled and tested for influenza 
A(H1N1)pdm09 using real-time reverse 
transcriptase polymerase chain reaction (RT–
PCR).  
 
Findings:  of the 812 children enrolled, 
A(H1N1)pdm09 virus was detected in 27 
(3.3%) children. The proportion of 
A(H1N1)pdm09  positive cases varied from 0% 
to 15% in different months. The admission 
diagnosis of children with A(H1N1)pdm09 
included pneumonia (48%), bronchiolitis 
(17%), upper respiratory infection (11%), 
asthma exacerbation (7%), and one case each 
(3%) of febrile seizure, urticaria, myocarditis, 
hemolytic uremic syndrome, and suspected 
Barter syndrome. Case fatality rate for children 
with A(H1N1)pdm09 was 15%. Children with 
A(H1N1)pdm09 were 5 times more likely to be 
admitted or transferred to the intensive care 
unit (ICU) (95% CI 1.8-13.6), 5.5 times more 
likely to be intubated (95% CI 2.0-15.0) and 
12.9 times more likely to die (95% CI 4.2-39.3) 
as compared to children testing negative for 
A(H1N1)pdm09.  
 
Conclusion:  A(H1N1)pdm09 infections were 
associated with high rates of complications, 
including death in children in Karachi, 
Pakistan. Given the high case fatality rate and 
a< 5 year old population of > 18 million in 
Pakistan, it is likely that even with the relatively 
low attack rate, A(H1N1)pdm09 led to much 
higher number of pediatric deaths than what 
has been reported. 
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Objective:  to detect and characterize influenza 
viruses circulating in Cameroon through a 
sentinel surveillance system for ILI (influenza 
like illness) and SARI (Severe Acute 
Respiratory Infection) program in five years 
since November 2007. 
 
Methods:  all ILI and SARI cases were 
considered eligible for enrolment. A 
standardized questionnaire to record patients’ 
demographic characteristics and medical 
history was used. Nasopharyngeal swabs 
were collected from all enrolled cases in 
different surveillance sentinel sites and then 
sent to the laboratory for biological 
confirmation. Detection and subtyping of 
influenza viruses were performed by real time 
RT-PCR using the CDC protocol. Patient 
information and laboratory results were 
recorded in a central database (MS Access®) 
situated at the CPC. Statistical significance 
was assessed at p<0.05 for all parameters. 
  60 
 
Results:  we collected and tested a total of 
2731 respiratory specimens from November 
2007 to June 2012. Of these, 2557 (93.6%) 
were from ILI patients, and 174 (6.4%) were 
from SARI patients which were obtained 
during a short period (October 2011 to June 
2012). Among ILI patients, 558 (21.8%) tested 
positive. Overall, influenza viruses were 
detected in 34.8%, 29.1%, 26.8%, 24.8%, 
20.7%, 3.1% ILI cases in late 2007, 2008, 
2009, 2010, 2011 and early 2012, respectively. 
Of the 174 SARI cases, only 12 (6.9%) tested 
influenza positive and the majority of patients 
were less than 5 years of age (75%). During 
the same period of surveillance, the difference 
between ILI and SARI system for influenza 
detection was significant (p < 0.05) with 
highest detection among ILI than SARI 
patients. During this period, influenza 
infections were observed mainly during rainy 
season from September to November. 
However, in 2008 influenza activity was 
observed throughout the year and in 2009-
2010, some influenza activities were observed 
out of this period due to the pandemic context. 
  
Conclusion:  we document that influenza is 
responsible for both mild and severe 
respiratory illnesses in Cameroon. We were 
able to identify severe influenza infections 
among hospitalized patients paralleling the 
same seasonality as observed within the ILI 
surveillance. To our surprise, few cases of 
influenza were detected among hospitalized 
patients with SARI. It is plausible that bacterial 
and/or other respiratory viral infections are 
involved. Further testing are on-going to clarify 
this situation.  
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Background:  The State Hygiene and Anti-
Epidemic Inspectorate, MOH, is responsible 
for infectious diseases surveillance and 
response, including outbreak investigations.  
 
Back in 2005 diagnostic facilities were limited 
at the primary level. The national laboratories 
did not have the diagnostic capability, the 
required bio-safety level facilities for influenza 
virus isolation and sub-typing, or the 
equipment to perform PCR testing.  
The protocols and guidelines for the 
surveillance and response to an influenza 
outbreak were not developed. Laboratory and 
epidemiology capacity to collect virology and 
epidemiology data for influenza, including 
appropriate samples and viral isolates were in 
need to be upgraded. 
Objectives:  development of sentinel 
surveillance system and laboratory capacity for 
influenza.  
 
Material and Methods:  a list of projects was 
implemented in cooperation of WHO, World 
Bank, USAID and CDC aiming at development 
of sentinel surveillance and introduction of 
laboratory detection of influenza. 
 
Results:  the sentinel surveillance standard 
and guidance materials were developed based 
on the WHO and CDC guidelines, including 
standards of practice, recording and reporting 
forms. 
Sentinel sites were selected in Yerevan, Lori 
and Syunik. In each site, virological laboratory 
capacity was strengthened by introducing PCR 
methodology. Laboratories were renovated, 
fully equipped with equipment and reagents, 
laboratory personnel were trained.  
In each site medical facilities were selected, 
the scheme for collecting and transporting 
samples were developed, doctors and nurses 
were identified and trained according to 
sentinel standard, including sampling 
technique. Necessary primers and probes for 
seasonal influenza viruses were provided by 
CDC US and WHO. 
The regular sentinel surveillance of severe 
acute respiratory infections started since 2009, 
national Influenza lab included in the WHO 
external QA program. 
Armenia actively participates in WHO global 
influenza surveillance by sending aggregate 
influenza testing data to EURO FLU platform 
weekly, published on www.euroflu.org. 
 
Conclusions:  complementary activities of 
different projects lead to successful introducing 
of sentinel SARI surveillance in Armenia. It has  
a good representation of age groups, gender, 
ethnicity, socio-economic status and risk 
factors/medical conditions and  provides  up-
to-date, routinely collected, standardized   data 
on influenza. This is a sound system for 
monitoring severe disease, risk factors, 61 
 
disease burden and providing timely data on 
priority groups to policy-makers. 
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Background:  an influenza pandemic has 
greater potential than any other naturally 
occurring infectious disease event to cause 
large and rapid global and domestic increases 
in deaths and serious illnesses. 
 
Methods:  clinical, epidemiological and virology 
surveillance of influenza, acute respiratory 
infections (ARI) and severe acute respiratory 
infection (SARI) in the Moldova is made in 
according to criteria recommended by EuroFlu, 
such as: geographical spread, intensity and 
trend of the epidemic process, impact on 
health services, the dominant type/subtype of 
virus.  
 
Results:  during the epidemic season weeks 
40/2011-30/2012 there were sporadic cases of 
influenza, caused mainly by influenza 
A(H3N2), with a low intensity of the epidemic 
process and minimal impact on medical 
services. Totally, during this season were 
registered 227 (6370/0000) influenza cases, 
which show a reduction of 20.0 times in 
morbidity over the same period of the previous 
season. 
ARI morbidity ranged from 50.4 0/0000 (week 
52/2011) to 179.3 0/0000 (week 11/2012), 
falling below the epidemic threshold 
(187.00/0000), peaking (201.9 0/0000) at week 
12/2012. From week 13/2012 morbidity has 
been decreasing. This season were registered 
139 964 (3929.6 0/0000) ARI cases, which 
represents a reduction of 1.2 times in morbidity 
compared with the previous season. 
SARI morbidity ranged from 10.8 0/0000 
(week 40/2011) to 48.30/0000 (week 3/2012) 
subsequently decreases successively and 
continuously until the end of the season. 
During this time had been recorded 36,932 
(1036.9 0/0000) cases of SARI, that represent 
an increasing of 1.7 times in morbidity in 
comparison to the previous season.  
 
Conclusions:  improvement of the information 
system for influenza, ARI and SARI 
surveillance connected to the WHO, ECDC 
requirements has allowed us to monitor the 
epidemiological situation in these infections, 
appreciation of the epidemic process trend and 
the spread forecast with developing control 
and response measures according to the 
situation. SARI morbidity served as an 
argument for extending the range of population 
on increased risk quotas for influenza 
immunization for the season 2012-2013 with 
vaccine recommended by WHO.  
 
Acknowledgement:  CDC Cooperative 
Agreement Number: 1U51IP000329. 
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Acute respiratory infections during pregnancy 
are an issue of Public Health concern, due to 
the higher chance of clinical progression to 
severe disease/death and neonatal 
complications.  In this study, we investigated 
the epidemiological and virological features of 
fatal cases among pregnant and non-pregnant 
women from Rio de Janeiro (June/2009-
june/2011), information still scarce in Brazil. 
The study population was composed of 741 
women at reproductive age (15-44 years) from 
which, 38 progressed to death. 
Demographic/clinical/epidemiological 
information was assessed by the 
Epidemiological Surveillance team, using a 
nationally standardized questionnaire. After 
nucleic acid extraction, influenza and other 
respiratory pathogens were detected by real 
time RT-PCR (FTD Respiratory Pathogens 
21plus, Fast-Track Diagnostics). Descriptive 62 
 
and bivariate analyses (chi-square/Fisher’s 
exact test and t-test for means) and multiple 
logistic regressions (taking into account 
variables of epidemiological 
relevance/plausibility) were carried out and 
considered significant when p<0.05. Influenza 
A(H1N1)pdm09 was detected in 23 (60.5%) 
and 300 (42.7%) from fatal and non-fatal 
cases, respectively (p=.024). From these 23 
fatal cases, 13 women were pregnant. Among 
confirmed Influenza A(H1N1)pdm09 cases, 
those who died presented lower per capita 
income (p<.001), higher frequencies of 
dyspnea (p=.003), hospitalization (p<.001), co-
morbidities (p=.025) and a higher interval 
between the 1st. symptoms and hospitalization 
(p<.001). The last, a risk determinant for 
deceases among infected pregnant women 
(n=5.1±3.9 vs. 2.5±3.2 days, p=.012). Among 
the infected non-pregnant women, the 
presence of any co-morbidity was identified as 
an independent risk factor for death 
(AOR=18.5). From 38 fatal cases, 6 samples 
remained negative for all pathogens. Influenza 
A(H1N1)pdm09(n=5), influenza A(n=2); 
H.influenzae(n=4); S.aureus(n=2), 
M.pneumoniae(n=1) and S.pneumoniae(n=1) 
were the solely pathogen detected in 15 
women. Multiple infections were detected in 17 
cases, mostly associated with detection of 
virus+bacteria (n=12). These preliminary 
findings reinforce the lethal role of Flu 
infections - especially among those with 
underlying disease - and highlight the 
usefulness of a syndromic approach for 
elucidation of SARI/fatal cases. 
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Influenza infections are a major public health 
issue, due to their relevant morbimortality and 
economical impact. Although pregnant women 
are under a higher risk for severe outcomes 
and death, this scenario is still poorly explored 
in Brazil. In this investigation, we assessed the 
clinical and epidemiological features of 
Influenza A(H1N1)pdm09 infections among 
845 women of reproductive age (15-44 years) 
from Rio de Janeiro municipality, from 
June/2009-June/2011. 
 
Demographic/clinical/epidemiological 
information was assessed by the 
Epidemiological Surveillance team, using a 
nationally standardized questionnaire.  After 
RNA extraction, Influenza A detection was 
carried out using CDC real time RT-PCR 
protocol. Descriptive/bivariate analyses (chi-
square/Fisher’s exact test and t-test for 
means) and multiple logistic regressions 
(taking into account variables of 
epidemiological relevance/plausibility) were 
performed and considered significant when 
p<0.05. Influenza A(H1N1)pdm09 was 
detected in 43.1% (n=326; 185 pregnant and 
141 non-pregnant women), with a total of 41 
deceases (4.4% vs. 5.7%, in each group, 
respectively). The epidemic peak occurred at 
epidemiological week 30/2009, with a 
substantial decline after that - only 1 
suspected case was confirmed in 2010 (in a 
non-pregnant women). Infected pregnant 
women were significantly younger (25.6±6.3 
vs. 29.3±8.8; p<.001) and presented 
significantly higher frequencies of dyspnea 
(65.9% vs. 51.4%, p=.006), SARI (56.9% vs. 
45.7%, p=.030) and hospitalization (82.7% vs. 
47.4%, p<.001), suggesting a more severe 
clinical presentation and a higher demand for 
health services (OR=5.3; 95%CI 3.1-8.8), 
when compared to their counterparts. After 
multiple logistic regressions, Influenza 
A(H1N1)pdm09 infection among pregnant was 
independently associated with the progression 
to a fatal outcome (AdjOR=3.7; 1.1-12.3); 
tabagism (AdjOR=3.1; 1.2-7.6) and presence 
of fever (AdjOR=2.2;1.1-4.4). Moreover, the 
chance of viral infection inversely decreased 
with age (AdjOR=0.96; 0.93-0.99). Our 
findings reinforce the impact of Influenza 
infections during pregnancy and highlight the 
benefits of vaccination for this exposure 
category. This information is pivotal to tailor 
health policies directed to prevention/control of 
Influenza infections, in the scope of the 
National Program for Influenza Surveillance. 
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In March of 2009, fatal Influenza human cases 
had alarmed in Mexico. Within a short period, 
the 2009 pandemic influenza A (H1N1) virus 
[pdmH1N1] spread in many countries 
worldwide. Since the pdmH1N1 flu virus is a 
re-assortment influenza virus, most people 
have no pre-existing antibodies against it. 
Therefore, it offers the best opportunity to 
investigate the factor related to the infection, 
transmission and severity of the epidemic due 
to the clear antibody background titer. 
Moreover, many studies indicated that school 
children played an important role in spreading 
the pdmH1N1 virus with higher titers of virus 
and longer period of shedding virus during 
infection. In addition, school as a high 
population density place might also facilitate 
transmission of the virus. However, there were 
few studies supported whether different 
population density might lead to the different 
severity of epidemic. Accordingly, we would 
like to address this issue by sero-epidemiology 
studies among schoolchildren. 
 
To explore the relationship between the 
population density and severity of the flu 
epidemic, we conducted a sero-epidemiology 
study by choosing schools in Taipei and 
Kaohsiung City to take blood from 765 and 
901 schoolchildren, respectively and testing for 
their serotiters of anti-influenza 
hemaggultination inhibition (HI) antibody. To 
investigate the other potential confounding 
factors, we obtained the students’ 
demographic characteristics, activity at 
schools and health related information through 
questionnaires. Student’s t and chi-square 
tests were used to analyze the data. 
Furthermore, we compared the data between 
two flu season (2009-2010 and 2011-2012 ) to 
investigate possible changes in the anti-
influenza HI antibody prevalence.  
 
The results showed that the schoolchildren in 
Taipei had significantly higher seroprotection 
rate of anti-pdmH1N1 HI antibody (serotiters 
>1:40) than those in Kaohsiung [ 42.61% ( 
326/765 ) vs. 23.16% ( 104/449 ) ,p<0.05 ], 
and Taipei a capital city in Taiwan has more 
than seven folds of population density 
comparing to Kaohsiung. Besides, our 
preliminary results of seroprotection rate in 
2011-2012 in Taipei was higher than those in 
2009-2010 flu season. [ 69.40% ( 161/232 ) vs. 
42.61% ( 326/765 ) ]. 
 
These results provide scientific evidence of the 
relationship between population density and 
the severity of flu epidemic and an overview of 
the prevalence of seroprotection against 
pdmH1N1 virus among schoolchildren. This 
would help government make more effective 
policies in vaccine allocation and disease 
prevention for next pandemic with emerging 
novel influenza viruses.   
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Meteorological factors are very important to 
facilitate efficient transmission of influenza 
viruses. In general, outbreaks of seasonal 
influenza in Taiwan start from autumn and 
peak in winter season of every year. And it is 
interested to understand whether the emerging 
2009 H1N1 influenza virus (pdm H1N1/09) 
would behave the same as seasonal influenza 
viruses. The specific aims of this study were: 
(1) to investigate whether different daily 64 
 
meteorological factors would be associated 
with different patterns of ILI cases in two 
metropolitans with various climate zones 
(subtropical vs tropical); (2) to evaluate clinical 
and epidemiological characteristics of the 
laboratory-confirmed pdm H1N1/09 influenza 
cases in Taipei and Kaohsiung Cities, and (3) 
to examine the survival of the pdm H1N1/09 
virus at different temperatures. 
Epidemic curve of the pdm H1N1/09 showed 
two waves occurred in both Taipei and 
Kaohsiung in 2009. The ILI patients who 
showed positive results on the Quidel 
OuickVue Influenza A+B rapid test were 
further confirmed by RT-PCR. Using daily 
laboratory-confirmed influenza cases, we 
found these cases had strong correlation with 
mean temperature, maximum temperature, 
water pressure and relative humidity with 1-2 
lag days.  
However, the influenza transmission would be 
affected the existence of live virus particles. 
Therefore, we chose the human seasonal 
H1N1 influenza virus and the pdm H1N1/09 
virus to observe the survival curve. the pdm 
H1N1/09 virus may keep  more live virus 
particles at room temperature and can spread 
fast in the summer season in areas of tropical 
zones. 
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Background:  influenza epidemic is repeated 
annually with variation in size and severity. For 
the early detection and management of 
influenza outbreak, effective surveillance 
system is essentially required. 
 
Methods:  hospital-based Influenza Morbidity & 
Mortality (HIMM), a hospital-based influenza 
surveillance system was established to 
monitor the trend of influenza epidemic and its 
severity, which was composed of two 
surveillance system: emergency room (ER)-
based and inpatients-based surveillance. ER 
influenza-like illness (ILI) index was defined as 
ILI cases per 1,000 ER-visiting subjects, and 
its change was monitored weekly. Number of 
laboratory-confirmed cases and distribution of 
influenza types were also estimated serially. 
Inpatient-based surveillance included 
monitoring for the hospitalization, complication 
and mortality. 
 
Results:  ER ILI index correlated well with the 
number of laboratory-confirmed influenza, and 
it showed bimodal peak at week 4 
(179.2/1,000 ER visits) and weeks13-14 
(169.6/1,000 ER visits). Influenza A was 
predominant during first epidemic peak, while 
influenza B was exclusively isolated during 
second peak after week 10 of 2012. In 2011-
2012 influenza season, mean admission rate 
of ER-ILI patients was 16.3% (weeks 52-20) 
without any increase over the epidemic 
periods. Among the hospitalized patients with 
influenza, 33.6%(41 among 122 patients) were 
accompanied by complications, and 
pneumonia (28.7%, 35 among 122 patients) 
was the most common. Most fatal cases were 
caused by influenza A (96.2%) later than first 
epidemic peak. 
 
Conclusions:  HIMM was effective to monitor 
the trend of circulating influenza activity and its 
severity at the same time. In 2011-2012 
season, influenza epidemic persisted over ≥5 
month periods with bimodal peak of influenza 
A and B in sequence. Overall, 2011-2012 
seasonal influenza was mild, particularly 
regarding influenza B. 
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Background:  established in 2011, the 
Hospital-based Influenza Morbidity and 
Mortality (HIMM) surveillance system, which 
consists of seven tertiary-care teaching 
hospitals, initiated an emergency-room-(ER) 
based influenza surveillance system in Korea. 
During the 2011–2012 influenza season, this 
study assessed the correlation between data 
generated from HIMM surveillance and the 
Korean national influenza surveillance system, 
an integrated clinical and laboratory 
surveillance network involving public health 
centers and private clinics called the Korean 
Influenza Surveillance Scheme (KISS). 
 
Methods:  this study was conducted over a 37-
week period (from the fourth week of 
September 2011 through the fourth week of 
June 2012). We collected influenza-like illness 
(ILI) indices on a weekly basis from the HIMM 
surveillance system, for which an index was 
defined as ILI cases per 1,000 ER visits. The 
index for the KISS was defined as ILI cases 
per 1,000 visits at public and private health 
facilities located in the nation. We compared 
the correlation of data collected through the 
HIMM surveillance system and the KISS using 
cross-correlation analysis. 
 
Results:  the ER-ILI index generated from the 
HIMM surveillance system was correlated with 
the national ILI index from the KISS 
(correlation coefficient = 0.887, p-
value<0.001). A cross-correlation analysis 
showed the highest correlation that resulted in 
a 0-week lag, demonstrating that no 
substantial lag existed in the HIMM 
surveillance system. Further, when compared 
by region, a high data correlation was found in 
the regions in which the HIMM hospitals were 
located—Seoul, Gyeonggi, Gangwon, 
Incheon, and Chungbuk. 
 
Conclusions:  the ER-based influenza 
surveillance system operated by the seven 
tertiary-care teaching hospitals in Korea shows 
a strong correlation with the national influenza 
surveillance system. This high correlation 
validates its use as a complementary tool. 
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Objectives:  identification and characterization 
of influenza strains and determination of 
influenza seasonality in different geographical 
areas of India.  
 
Methods:  epidemiologic data and throat 
swabs were collected from patients with 
influenza like illness. Virus isolation was 
carried out in Madin-Darby canine kidney cells 
and strains identified by hemagglutination 
inhibition assay. After June 2009, real-time 
RT-PCR was used for diagnosis. HA and NA 
genes were sequenced for phlylogenetic 
analyses and determination of markers for 
drug resistance. Meteorological Data were 
collected.  
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Results:  from January 2009 to May 2009, 140 
of 3679 (3.8%) cases yielded isolates. 
Influenza positivity by r RT-PCR from June 
2009 to August 15th 2012 was found to be 
15.9% (2549/16015). In 2009, influenza 
A(H3N2) and p(H1N1), in 2010 p(H1N1) and 
Type B, in year 2011 influenza A(H3N2) and 
Type B,  in 2012 p(H1N1) and Type B 
respectively were predominantly  circulating.  
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Background:  the UK Severe Influenza 
Surveillance System (USISS) is a newly 
established scheme to collect surveillance 
data on hospitalised influenza cases from a 
sentinel network of NHS Acute hospital Trusts 
in England. The system was developed 
following post-2009 pandemic 
recommendations. The system aims to monitor 
the impact of seasonal influenza on the 
population and describe the epidemiology of 
severe disease in time, place and person. 
 
Objectives:  to evaluate this new surveillance 
system.  
 
Methods:  the system was evaluated according 
to the US Centers for Disease Control and 
Prevention Framework for Evaluating Public 
Health Surveillance Systems. Quantitative 
data sources used included data from an 
independent mandatory ICU surveillance 
scheme. Qualitative sources included online 
questionnaires and semi-structured interviews 
with participating trusts and HPA scientists. 
 
Results:  a sentinel group of trusts was 
recruited for the 2011/12 influenza season 
using stratified random sampling. The group 
recruited was largely representative of trusts 
by region, size and trust type. On average 30 
of 36 trusts reported each week. Information 
collected included aggregate numbers of all 
hospitalised confirmed influenza cases and 
detailed epidemiological data including clinical 
risk factors and antiviral use for all ICU/HDU 
admissions. Completion rates for these 
variables were high (80.4% and 76.1% 
respectively).  
The peak number of hospitalisations during the 
2011/12 season corresponded with the peak of 
influenza like illness consultations (per 
100,000) as reported by a GP sentinel 
surveillance system. Most ICU cases were 
reported to both the mandatory and sentinel, 
although a number of additional cases were 
reported to the mandatory scheme only.  
 
75% (n=27) of participating trusts responded 
to the user feedback questionnaire. 63.0% of 
users found the system simple and easy to 
use and 72.0% agreed the level of data 
requested was reasonable. 
  
Reports to trusts were distributed within a 
week of reporting, with a time interval between 
admission and reporting of 3-10 days. 
 
Conclusions:  the USISS sentinel system 
effectively signalled changes in influenza 
activity over the 2011/12 season. The system 
had high acceptability amongst users and 
provided timely and useful information to 
describe the epidemiology of severe influenza 
in England.  
 
This system could be used as a model for 
other countries wishing to establish a system 
for monitoring severe disease. 
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Three waves of activity caused by the 2009 
pandemic A(H1N1) virus occurred in the UK 
over the period April 2009 to March 2011, with  
reports of increased severe disease in 
2010/11. Although the majority of infections 
were mild, more than 400 confirmed deaths 
were reported during the first and second 
wave of the pandemic and more than 500  
confirmed deaths during the winter of 2010/11 
(third wave). 
 
Objectives:  the aims of this study were to 
determine whether viruses from fatal cases 
were genetically different from mild community 
cases and to assess the possible impact of 67 
 
these genetic changes in the increased 
severity observed in the third wave through 
phylogenetic analysis and growth curves. 
 
Methods:  we sequenced whole genomes 
(n=92) of A(H1N1)pdm09 viruses isolated from 
fatal and mild cases in the UK during the three 
waves of A(H1N1)pdm09 activity. The 
concatenated full length coding regions were 
used to construct a time-calibrated phylogeny 
using Bayesian methods. Virus replication was 
evaluated in human airway epithelium cells 
using representative viruses from each wave. 
Results:  whole-genome sequencing and 
phylogenetic analysis showed that viruses 
from fatal cases were not different from mild 
cases, with no statistical correlation between 
phylogenetic clustering and clinical outcome 
and no mutations significantly associated with 
fatal cases. Two main genetic groups 
circulated during the third wave, with several 
signature changes along their genome, mostly 
in polymerase and haemagglutinin genes. 
These findings correlate with a sudden 
increase in the relative genetic diversity of 
pandemic viruses. Despite this, no significant 
antigenic drift was detected. Genome-wide 
changes observed in A(H1N1)pdm09 viruses 
from the third wave might have improved virus 
fitness and consequently have an impact on 
virulence. We compared the in vitro replicative 
ability of representative viruses from the first, 
second and third wave of pandemic in human 
airway epithelium.  
 
Conclusions:  these findings are discussed in 
relation to the evolution of the pandemic virus 
and within the epidemiological context of fatal 
cases during the three waves of 
A(H1N1)pdm09 activity in the UK. 
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Vietnam has been one of the most severely 
infected countries for HPAI viruses A/H5N1 
(CFR of 49.6%). The molecular 
characterization of HPAI viruses A/H5N1 
circulated in Vietnam 2003-2011 is analyzed to 
identify mutations associated with antigenic 
drift and shift, antiviral resistance, receptor 
susceptibility. 
 
Method:  human H5N1 isolates from 2003-
2011 were characterized by high homology to 
contemporary poultry isolates from Vietnam in 
all genes using  Sanger sequencing (ABI 
3130). Phylogenetic trees were analyzed using 
Maximum Likelihood (ML) and Bayesian 
MCMC methods. 
 
Result:  phylogenetic analysis of the 
hemagglutinin (HA) genes of H5N1 viruses 
isolated revealed multiple introductions of 
genetically divergent viruses. However, 
predominant of antigentically are recognized 
with clade 1 from 2003 to 2005, clade 2.3.4 HA 
genes (genotypes V and Z) from 2005 to 2010, 
and  recently named H5N1 clade 2.3.2 has 
become predominant over previously 
circulating clades since 2010.Only viruses 
belonging to two clades (1 and 2.3.4) have 
been recognized as causing human infections 
in this period. Compared to avian genes, the 
PB2 gene from a majority of H5N1 isolates 
from humans had a glutamate to lysine 
substitution that has been previously 
associated with enhanced replication of 
influenza virus in mammalian MDCK cell and 
animal models. Other mutations previously 
correlated with reduced susceptibility to 
antiviral drugs that inhibit neuraminidase or 
block M2 ion channels were detected on NA 
and M genes of clade 1 as well as clade 2.3.4 
H5N1 viruses. Compared to the clade 2.3.4 
H5N1 vaccine candidate virus, 
A/Anhui/1/2005, the recent isolates from 
Vietnam showed 5-7 amino acid substitutions 
in HA1, suggesting the need to monitor the 
antigenic properties of these viruses.  
 
Conclusion:  genotypes of A/H5N1 virus in 
Vietnam were continued predominance of 
genotypes Z and V strains. All of the human 
viruses isolated between 2003 and 2010 
belonged to clade 1 and 2.3.4, whiles animal  
viruses clustered into clade 1, 2.3.2 and 2.3.4. 
PB2 gene from a majority of H5N1 isolates 
from humans had a glutamate (E) to lysine (K) 
substitution that has been previously 
associated with enhanced replication of 
influenza virus in mammalian MDCK cell and 
animal models.  
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Background:  Avian influenza viruses (AIV) 
play a key role in the emergence of pandemic 
strains. H9N2 are currently widespread in 
chickens, quail, and other poultry in Asia and 
have caused cases of influenza in humans. To 
evaluate the potential threat of H9N2 AIV, we 
analyzed the serological HAI antibody and 
prevalence of the H9N2 in human and poultry 
in Shanghai, China during 2008 to 2010.  
Methods: 2798 human serum samples were 
obtained from general and occupationally 
exposure population contacting with avian. 
The serum samples were detected for HAI 
antibodies of H9 subtype by HI assays. 1450 
nasal and throat swabs specimens were 
collected from the influenza-like illnesses in 
sentinel hospital and outbreak, inoculated into 
MDCK cells to isolate influenza viruses and 
identified by RT-PCR. 9297 tracheal and 
cloacal swabs of specimens were collected 
from poultry in the live-poultry markets, 
inoculated into chicken embryo to isolate AIVs 
and identified by RT-PCR; 7 HA segments of 
AIVs H9 were sequenced to analyze the 
genetic variation. 
 
Results:  the average antibody positive rate 
was 4.19% (82/1958) of the general population 
to H9 antigen with HI titers ≥1:20, while 
29.64% (249/840) of the occupationally 
exposure population contacting with avian. 938 
influenza viruses were isolated from nasal and 
throat swabs of the influenza-like illnesses, 
including H3N2, H1N1 and B. 239 AIVs were 
isolated from tracheal and cloacal swabs, 
positive rate is 2.57% (239/9297), all the 
subtype were H9N2. Genetic analysis revealed 
that 7 isolates had an RSSR↓GLF motif at the 
cleavage site of HA, representing low 
pathogenicity in chicken. The mutation at 
position 226 (Q-L) at the receptor-binding site 
was detected. 
 
Conclusion:  the results suggesting that avian-
to-human transmission of H9N2 AIV was 
existed, occupationally exposure population 
contacting with avian had a subclinical 
infection of H9N2 AIV, but human-to-human 
transmission was difficult. The mutation at 
position 226 (Q-L) at the receptor-binding site 
is thought to be one of the amino acid changes 
that must occur before AIV can replicate 
efficiently in humans. But the low pathogenic 
of the virus cleavage site may limit viral 
proliferation in human airway epithelial, so 
H9N2 had not isolated from throat swabs. 
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Interspecies transmission is a crucial feature in 
the ecology and epidemiology of influenza 
virus. Transmission of avian influenza virus to 
a new mammalian species is of great concern, 
because it potentially allows the virus to adapt 
to a new mammalian host, cross new species 
barriers, and acquire pandemic potential. 
Infection of an entire avian influenza virus to 
an unrelated mammalian species is a rare 
event. Recently, avian influenza virus, subtype 
H3N2, was first isolated from serial cases of 
severe respiratory disease in dogs exhibiting 
severe respiratory disease, and transmission 
among dogs was demonstrated by 
experimental reproduction of disease. We also 
demonstrated that dogs have large amount of 
avian influenza virus binding receptor in canine 
tracheal, bronchial, and bronchiolar epithelial 
cells, which suggests potential for direct 
transmission of avian influenza virus (H3N2) 
from poultry to dogs.  
 
In this study, we aimed at presenting a novel 
AI virus causing clinical manifestation in dogs 
and establishing intraspecies transmission, 
and genetic characteristics different from 
equine influenza virus, subtype H3N8 or low 
pathogenic avian influenza virus, subtype 
H3N2.  Especially, during recent canine 
influenza surveillance in South Korea, a novel 
canine influenza virus (CIV) H3N1 which was a 
putative reassortant between pandemic H1N1 
2009 and H3N2 canine influenza viruses was 
isolated. Genetic analysis for 8 genomes of the 
influenza virus revealed that novel H3N1 69 
 
isolate presented high similarities (99.1-99.8%) 
with pandemic influenza H1N1 except for the 
hemagglutinin (HA) gene. The HA gene 
nucleotide sequences of the novel CIV H3N1 
was similar (99%) to that of CIV H3N2 isolated 
in Korea and China. Through the inoculation of 
the novel CIV H3N1 virus, the novel isolate 
could induce the clinical signs including fever, 
cough, and nasal discharges and also 
presented gross lesions in lungs and 
histopathologic changes. And experimental 
infection of seasonal H3N2 influenza virus and 
pandemic 2009 H1N1 virus in dogs were 
performed for the validation of roles of dogs as 
an intermediate vector of influenza viruses.  
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Purpose:  nitric oxide (NO) and reactive 
oxygen species (ROS) have been suggested 
to be involved in the pathogenesis of various 
diseases 3-Nitrotyrosine (3-NT) produced by 
NO/ROS is considered as a biomarker for 
oxidative stress. In fact, we have identified the 
extensive and NO-dependent formation of 3-
NT in the lung of influenza virus-infected mice. 
Acute respiratory distress syndrome (ARDS) is 
characterized as an inflammatory lung 
disease, and associates with enhanced 
formation of NO and ROS.  
 
Immunohistochemical analyses suggested the 
formation of 3-NT in the lungs of patients with 
ARDS. However, biochemical and quantitative 
aspects of 3-NT formation in ARDS patients 
remains poorly understood. In this study, we 
investigated the levels of plasma protein-
bound 3-NT from patient with fulminant ARDS 
by using a reverse phase-HPLC coupled with 
electrochemical detector (ECD). 
Methods:  we analyzed plasma samples from 
40 patients with influenza-negative ARDS (non 
IFV-ARDS group) and from 7 patients with 
influenza-positive ARDS (IFV-ARDS group). 
Two patients with highly pathogenic avian 
influenza A (H5N1)-positive, 4 patients with 
swine pandemic influenza A (AH1pdm)-
positive, and 1 patient with seasonal influenza 
A (H3N2)-positive were enrolled. Plasma 
samples obtained from 25 patients without 
ARDS were used as control (non ARDS 
group). Plasma proteins were precipitated with 
nitrite-free ethanol/acetate buffer followed by 
digestion with pronase. 3-NT separated with 
the HPLC was first reduced at -800 mV to form 
3-aminotyrosine, followed by oxidation with 
second electrode (+200 mV) to detect 3-NT 
electrochemically. Detection limit of this 
system was approximately 1 nM for 3-NT. 3-
NT levels were standardized by tyrosine 
levels, determined by ultraviolet detector, 
connected after ECD. 
 
Results:  patients in the IFV-ARDS group had 
significantly higher 3-NT levels (0.350 
µmol/mol) than did those in the non-ARDS 
group (0.210, p = 0.046). 3-NT levels were 
also significantly higher in the non IFV-ARDS 
group (0.270, p = 0.039) than in the non-ARDS 
group. Interestingly, the difference was not 
significant, however, survived patients had 
higher 3-NT levels than those in non-survivor, 
and also 3-NT levels was higher in patients 
without multiple organ failure (MOF) compared 
with patient with MOF, suggesting a protective 
role of NO and ROS in the pathogenesis of 
ARDS. 
 
Conclusions:  by this method, we could 
successfully detect 3-NT from human plasma 
of ARDS patients. This method is convenient, 
specific and sensitive for 3-NT quantification 
applicable for clinical specimens and hence 
may help further understanding of pathological 
roles of NO/ROS formation in ARDS. 
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Objective:  necropsied or autopsied tissues 
from 5 fatal cases with highly pathogenic avian 
H5N1 influenza virus (H5N1) infection were 
analyzed pathologically to reveal virus 
distribution and the expression levels of 
cytokines and chemokines in lungs. 
 
Method:  formalin-fixed paraffin-embedded 
(FFPE) lung tissues of 5 fatal cases were 
analyzed with several methods as follows: 
Immunohistochemistry for H5N1 NP antigen, 
proinflammatory cytokines and chemokines, in 
situ hybridization for H5N1-genomic RNA and 
mRNA, Double immunofluorescence staining  
with cell marker proteins, Quantitative reverse-
transcription polymerase chain reaction (qRT-
PCR) methods for H5N1-RNA, cytokine and 
chemokine mRNA. 
 
Result:  main histopathological findings 
showed diffuse alveolar damage in the lungs. 
Myeloperoxidase-positive and/or CD68 
(cloneKP-1)-positive neutrophils and 
monocytes/macrophages infiltrated remarkably 
in the alveolar septa and alveolar spaces. 
H5N1 mainly infected alveolar epithelial cells 
and monocytes/macrophages in lungs. H5N1 
mRNA was detected in epithelial cells using in 
situ hybridization.   The expression levels of 
TNF-α, IL-6, IL-8, RANTES and IP-10 
correlated with H5N1 RNA copy numbers 
detected in the same lung region. Double 
immunofluorescence staining revealed that 
TNF-α, IL-6, IL-8 and IP-10 were expressed in 
epithelial cells and/or 
monocytes/macrophages. In particular, IL-6 
was also expressed in endothelial cells. The 
dissemination of H5N1 beyond respiratory 
organs was not confirmed in the cases in this 
study. Further investigation of as many 
autopsied cases as possible is necessary to 
elucidate the pathogenesis of H5N1 infection 
in humans. 
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Background:  Influenza virus infection causes 
both recurrent annual epidemics and more 
serious pandemics that spread rapidly. When 
the influenza A viruses transmit to epithelial 
cells, the viruses replicate in epithelial cells, 
macrophages and leukocytes respond to 
produce chemokines and cytokines. In 
addition, myeloperoxidase (MPO) in 
neutrophils is also associated cellular damage 
with influenza viral infection. H5N1 infection 
with acute respiratory distress syndrome 
(ARDS) starts with high fever, then proceeds 
to serious respiratory failure.  
 71 
 
Methods:  in our study, firstly, we focused on 
the response of cytokines, chemokines and 
MPO activity in ARDS pediatrics patients 
infected with H5N1. Secondly, we examined 
cytokines/chemokines production in A549 
epithelial cells infected with influenza A/H1N1 
virus (PR-8) or nonstructural protein 1 (NS1) 
plasmid in vitro.  
 
Results:  first, in the plasma, levels of IL-12p40 
and TNFR2 in the H5N1-positive group were 
significantly higher than in the H5N1-negative. 
In the NPA, the concentration of sIL-6R in the 
H5N1-positive group was significantly higher 
than in the H5N1-negative group. In addition, 
MPO activity in plasma was significantly higher 
in the H5N1-positive group. These results 
suggest that sIL-6R may be a major 
contributor in the nasal space associated with 
lung injury induced with H5N1 infection. 
Moreover, IL-12p40 and TNFR2 may be 
produced from the pulmonary space or 
endothelial cells to circulate in the blood and 
MPO may be released into the blood from 
activated neutrophils to make the lung injury. 
Second, in vitro study suggests that TNF-α 
and RANTES were predominantly produced 
from the A549 epithelial cells infected with PR-
8 virus. siTNF-α down-regulated RANTES 
expression and secretion of RANTES, IL-8, 
and MCP-1. In addition, siRANTES 
suppressed interferon (IFN)-γ expression and 
the secretion of RANTES, IL-8, and MCP-1. 
Furthermore, administration of TNF-α and 
RANTES promoted elevated secretion of 
RANTES, IL-8, and MCP-1 production without 
the infection, strongly suggesting that TNF-  
may regulate RANTES production followed by 
increase of IL-6, IL-8, and MCP-1 and IFNs 
levels in the initial step. In the next step, the 
cells transfected with viral NS1 plasmid 
showed production of a large amount of IL-8 
and MCP-1 in the presence of the H2O2-MPO 
system, suggesting that NS1 of PR-8 may 
induce a “cytokine storm” from the epithelial 
cells when an H2O2-MPO system exists. These 
findings are similar to the result that MPO 
promotes the development of lung neutrophilia 
and indirectly influences subsequent 
chemokine and cytokine production in the 
lung.  
 
Conclusions:  influenza virus infection induces 
cytokine storm produced in lung epithelial 
cells, which are associated with MPO and NS1 
of influenza virus when the H2O2-MPO system 
acts. 
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The autopsy materials (bronchi, trachea, and 
lungs) from 161 patients who succumbed to 
lethal pneumonia caused by influenza 
A(H1N1)pdm09 virus during 2009-2011 were 
examined. Most of the cases were registrated 
in European part of Russia (87%). The mean 
patient age was 41.2 years (from 3 to 77 
years); 52% of the patients were women; 8% 
were pregnant. Many patients (34.4%) had 
chronic diseases, mainly metabolic (11.5%), 
cardiac (8.2%), and renal (9.4%). The mean 
duration of the illness was 10.5 days (from 2 to 
26 days). We used RT-PCR, virus isolation on 
MDCK and embrionated eggs (EE), 
Hemagglutiniation Inhibition, sequencing, and 
in-cell ELISA to study the properties of 
A(H1N1)pdm09 viruses. 29 strains of 
A(H1N1)pdm09 were isolated: 23 – on EE 
(79%), and 5 – on MDCK (21%). Most isolates 
were characterized as A/California/7/2009-like, 
the virus used as the influenza A(H1N1) 
component of the 2009-11 influenza vaccines 
for the Northern hemisphere. One virus (3.4%) 
showed reduced titers with antiserum 
produced against the reference virus. All 
viruses tested were susceptible to the arbidol 
and neuraminidase inhibitors, oseltamivir and 
zanamivir, respectively, and were rimantadine-
resistant. We detected mutations in HA1 
receptor-binding site in 87 samples [39% of 
total; 29/42 (69%) samples collected in 2009-
2010, and 5/45 (11%) samples collected in 
2010-2011] and in 88.5% of 26 strains isolated 
from these materials. D222G and Q223R were 
the most common mutations found in  69% 
and 30.8% of the strains accordingly. Only in 
11 of the 61 samples (18%) revealed co-
infection of influenza A(H1N1)pdm09 virus and 
other pathogens, including BoV (1 case), 
adenovirus (2 cases), parainfluenza  (1 case), 72 
 
rhinoviruses (6 cases) and Streptococcus (1 
case). Our investigations were supported by 
the Centers for Disease Control and 
Prevention, Atlanta, USA, CoAg: 
U51IPOOO527-02. 
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Objectives:  influenza is a representative acute 
respiratory illness, which causes complications 
in a small portion. The objectives were to 
figure out the clinical manifestations of 
laboratory-confirmed hospitalized adult 
influenza patients using complications as a 
determinant of severity.  
 
Methods:  retrospective case-control study 
was done in adult influenza patients who 
admitted in 7 tertiary care university hospitals 
in Korea from October 2011 to May 2012. A 
complicated case was defined as influenza 
with other organ dysfunction beyond upper 
respiratory tract, which includes pneumonia, 
acute renal failure, acute bronchiolitis, ARDS, 
asthma or COPD aggravation, encephalitis, 
heart failure aggravation and rhabdomyolysis.   
 
Results:  there were 39(31.7%) complicated 
cases among 123 hospitalized adult patients 
with influenza. The most common complication 
was pneumonia (70.6%), followed by acute 
renal failure (9.8%) and acute bronchiolitis 
(5.9%). In univariate analysis, factors 
associated with complications were old age 
(median, 57 vs. 74, P = 0.005), male sex (P = 
0.043), diabetes (P = 0.0003), chronic 
cardiovascular disease (P = 0.0086), 
neuromuscular disease (P = 0.025) and having 
2 or more chronic medical diseases (P < 
0.0001). Complicated patients showed 
tachypnea (P < 0.0001), crackle (P = 0.001), 
increased ESR (P = 0.022) and CRP (P = 
0.0009), lower oxygen saturation (P = 0.004) 
more frequently. Multivariate logistic 
regression analysis revealed that old age (OR 
0.97; 95% CI 0.94-0.99; P = 0.015) and having 
2 or more chronic medical diseases (OR 
11.36; 95% CI 1.87-68.97; P = 0.008) were 
risk factors for complicated influenza. Influenza 
virus type (A vs. B) was not associated with 
risk for complication. Thirty-seven complicated 
patients (90.2%) and 77 uncomplicated 
patients (95%) received antiviral treatment (P 
= 0.441). Complicated patients received 
antibiotics more frequently (P < 0.0001) and 
showed longer hospital stay (P = 0.0178). 
Influenza-related deaths occurred in 4(3.2%) 
of 123 patients.  
 
Conclusions:  the prognosis of hospitalized 
adult patients with influenza during 2011 to 
2012 season in Korea was not serious. Our 
results demonstrate that having 2 or more 
chronic medical diseases is a strong risk factor 
for complicated influenza, therefore early 
intervention and careful observation is 
mandatory for high risk group with multiple 
chronic medical diseases. 
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Background and aims:  the ability of Influenza 
A (infA) viruses to counteract and manipulate 
the host response to infection is well 
acknowledged. In addition, the activation of the 
PI3K/Akt survival pathway by the infA NS1 
protein has been described as one of the 
strategies to delay the apoptotic response of 
the infected cell. As influenza B (infB) viruses 
differ genetically and phenotypically from infA 
viruses, namely at the NS protein level, we 
aimed to compare general apoptosis and 
survival pathways induced by each influenza 
type. 
 
Methods:  MDCK-SIAT1 cells were infected 
with infA(H1N1)pdm09 virus 
A/Portugal/82/2009 (APT82) and infB virus 
B/Lisboa/08/2006 (BLx08). Activities of 
caspase-3 -7 -8 and -9 were measured at 73 
 
several time points post-infection (hpi). Total 
levels of Akt, pAkt, NF- B, I B, p53 and  -
actin were also examined by Western blot.  
 
Results:  our results indicate that the apoptosis 
process induced by BLx08 was associated 
with activation of both intrinsic, caspase-9-
dependent and extrinsic, caspase-8-
dependent pathways as early as at 8hpi. In 
contrast, APT82-induced apoptosis only 
involved the activation of the intrinsic pathway, 
and occurred at 32hpi. 
 
Surprisingly, our data show that the activation 
of the survival pathway PI3K/Akt was 
significantly increased upon BLx08 infection 
when compared with APT82 infection. In fact, 
increased levels of pAkt were observed at the 
same time of caspase activation in the early 
phase of BLx08 infection. This, however, did 
not result in increased downstream NF B 
activation, since its inhibitor I B was also 
markedly upregulated.   
 
Increased p53 levels associated with APT82 
infection may also explain the delayed 
apoptosis response in infA, assessed by 
caspase activity, as it may require 
transcriptional activation that it is deregulated 
and directed to viral replication. 
 
Conclusion:  InfB and infA infection differs in 
time and levels of activation of apoptosis and 
survival signaling pathways.PI3K/Akt activation 
in infB is not sufficient to inhibit apoptosis. 
Further studies will clarify this difference and 
shed light into the use of cellular mechanisms 
as new ways to fight influenza. 
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Influenza virus infection is initiated by virus 
attachment to cell-surface sialoside receptor 
via influenza hemagglutinin (HA). The 
carbohydrate binding specificities have been 
found to be different among avian and human 
influenza A viruses and may affect the tissue 
tropism and transmission. In this study, we 
explored the carbohydrate binding specificity 
of seasonal H3N2, H1N1 influenza and the 
2009 pandemic H1N1 strains that isolated 
from Taiwan during 1999 to 2010 by a high-
throughput carbohydrate solution array. The 
results showed that seasonal H1N1 accepted 
not only a-2,6 sialylated glycans but also a-2,3 
sialylated glycans. However, some of the 2009 
pandemic H1N1 viruses were predominantly 
bound to a-2,3 sialylated glycans and the 
viruses isolated in 2010 had changed the 
binding profiles from 2009, revealing the virus 
adaptation in human population. These results 
indicated a distinct carbohydrate-binding 
repertoire between seasonal H1N1 and the 
2009 pandemic H1N1 viruses. Furthermore, 
thirty-six H3N2 clinical isolates were explored 
successfully and the binding patterns could be 
further classified into three groups. Group 1 
viruses bound predominantly to a-2,6 linked 
glycans and group 2 viruses preferentially 
bound not only to a-2,6 sialylated glycans but 
also other a-2,3 linked sialyl glycans. 
Interestingly, although belong to same H3N2 
genotype, group 2 isolates revealed receptor 
specificity broader than group 1 isolates. There 
were other three virus strains bound 
specifically to a-2,3 linked sialyl glycans, but 
weak or no interaction with a-2,6 linked sialyl 
glycans. These results revealed an 
unexpected diversity in receptor binding 
specificities among recent H3N2 viruses. In 
addition, the data also revealed the 74 
 
occurrences of carbohydrate binding patterns 
of H3N2 every 1-2 years and continuous 
change patterns which were similar to the 
phylogenetic analysis. The viruses isolated 
from 1999 and 2003 bound to dual type 
glycans were more likely to cause severe 
diseases than those isolated from 2001, 2002 
and 2006 which bound only to a-2,6 sialyl 
glycans. This study provided not only 
systematically analysis of receptor binding 
specificities for influenza A clinical isolates, but 
also useful information to monitor the antigenic 
shift and vaccine seeds selection of influenza 
viruses. 
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Background:  hemagglutinin (HA) receptor-
binding plays an important role in the viral life 
cycle. Alterations in the receptor-binding 
domain was proposed to be attributed to the 
salt bridge between the HA1 110-helix and 
HA2 B-loop. However, this was not fully 
elucidated. In this study, we identified HA2 
residues that can affect HA1-HA2 salt bridge 
formation and, likewise, correlated these 
residues to alterations in HA receptor-binding 
properties. 
 
Methods:  throughout this study, H1N1 HA 
amino acid sequences of human, swine and 
avian strains from 1918-2012 were collected 
from the NCBI Web site and a total of 2,830 
amino acid sequences were analyzed. We 
designated subscript 1 and 2 to refer to HA1 
and HA2, respectively. We compared all 
influenza strains obtained from 1918-2012 and 
identified interspecies similar amino acid 
residues that affect the HA1-HA2 salt bridge. 
Similarly, we compared the HA2 B-loops from 
all influenza strains obtained from 1976-2011 
and, likewise, identified interspecies 
differences in the HA2 B-loop that may 
likewise affect the HA1-HA2 salt bridge. We 
used the Phyre 2 server to predict the protein 
conformation and J-mol software for structural 
analyses.  
 
Results:  we found that from 1918-2012, there 
was interspecies similarity in residues 1452 
and 1462 whereas from 1976-2011 there was 
interspecies difference in residue 882 among 
the human, swine and avian strains. In 
establishing interspecies similarity, we found 
that Asn is the preferred amino acid in both 
residues 1452 and 1462 that would favor HA1-
HA2 salt bridge formation. In addition, amino 
acid substitution in either or both residues alter 
the formation of the putative salt bridge which 
consequentially affects HA receptor-binding 
properties. In establishing interspecies 
difference, we found that interspecies amino 
acid residue 882 differs in the HA2 B-loop of 
the human (K882), swine (H882) and avian 
(N882) strains. Moreover, we established that 
variations in the amino acid in residue 882 
could likewise affect the HA receptor-binding 
properties. 
 
Conclusion:  we propose that in the H1N1 
subtype, the amino acid in residue 882 and the 
N1452-N1462 residue influence the HA1-HA2 
salt bridge formation. Furthermore, we 
established that variations in residue 882 and 
the 1452-1462 residue alters HA receptor-
binding properties. 
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Introduction/Objectives:  the H2N2 pandemic 
of 1957-1958 caused significant morbidity and 
mortality worldwide.  Absent from humans 
since 1969, the H2 subtype continues to 
circulate in birds, and recent swine isolates 
possess characteristics of mammalian 
adaptation.  Individuals under the age of 50 
lack immunity to the H2 antigen.  Thus, 
continued H2N2 surveillance and biological 
characterization is critical to mitigate their 
impact should they re-emerge in humans.  
Here we assess the risk of avian, human and 
swine H2 viruses isolated from 1957-2008 by 
evaluating pathogenicity, virulence and 
transmission in multiple mammalian models, 75 
 
as well as susceptibility to current antiviral 
drugs. 
 
Methods:  twenty-seven avian, human and 
swine H2 viruses were assessed for  
replication in differentiated normal human 
bronchial epithelial (NHBE) cells, morbidity 
and mortality in DBA2/J mice and contact 
and/or aerosol transmission in ferrets.  Fifty-
nine H2 viruses were tested for susceptibility 
to adamantanes and neuraminidase inhibitors 
(NAIs).  Susceptibility to adamantanes was 
assessed by sequence analysis of M2 protein, 
and to NAIs (oseltamivir, zanamivir) by 
fluorescence-based neuraminidase enzyme 
inhibition assay. 
 
Results:  in NHBE cells, 17 (73%) avian and all 
human and swine isolates replicated 
productively (>3 log10TCID50/ml).  In mice, 10 
(42%) avian all human and swine viruses 
induced morbidity (>5% weight loss).  
Replication in mouse lungs was observed with 
80% of avian viruses and with all human and 
swine viruses.  Three avian and multiple swine 
and human viruses induced mortality in mice.  
In ferrets, 5 of 9 avian viruses tested replicated 
in the upper respiratory tract (URT) and 3 
exhibited direct contact transmission.  Human 
and swine viruses replicated in the ferret URT, 
but transmission was observed only with swine 
infections.  In all viruses tested, M2 gene 
sequence analysis did not reveal residue 
changes conferring resistance to 
adamantanes.  All viruses tested were highly 
susceptible to NAIs with IC50 values in the 
nanomolar range (0.1-6.0 nM).  
 
Conclusions:  the data presented here are a 
thorough risk analysis of H2 viruses isolated 
from multiple species over 6 decades.  The 
ability of avian and swine viruses to replicate 
and transmit in mammalian models elevates 
their risk to humans.  However, all viruses 
remain highly susceptible to FDA-approved 
antiviral drugs, suggesting their usefulness as 
a control strategy should H2 viruses re-emerge 
in humans. 
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Transmissions of avian influenza viruses (AIV) 
from poultry to humans have raised fears of an 
impending influenza pandemic. Several low 
pathogenic virus strains have been isolated in 
Taiwan. Similarly, migratory bird transfer in 
seasons from Southeastern countries and 
China to Taiwan, which might be dangerous in 
carrying infectious virus. It is important to 
analyze the potential adaptation for the virus to 
infect human. By comparing the sequences of 
HA of the H6N1 viruses, we found that amino 
acid changes on HA1 were higher than those 
on HA2. The antigenic changes have occurred 
on the globular head of HA molecule. By 
hemagglutinination inhibition (HI) assays, 
monoclonal antibodies elicited from one H6N1 
virus showed different HI titers with those 
H6N1 viruses. Amino acid substitutions on the 
HAs of viruses isolated from chicken were 
confined to the HA1 mostly, indicating that 
viruses were circulating in the presence of 
antibody selection pressure in chicken flocks in 
Taiwan. Although the 228
th amino acid of HA 
protein changed from G to S, the 627
th amino 
acid was still E, restriction infection in 
chickens. Both H6N1 2838V and 2838N AIV 
strains contain 167N glycosylation site in the 
HA1 near head region, but it is absence in 
H5N2 3233 AIV. In addition, mAbs recognized 
peptide itself but not carbohydrate. By using 
Qproteome GlycoArray Kit, sialic acid showed 
the highest binding with H6N1 (strain 2838). 
This indicated that the glycan of the H6N1 was 
terminated with sialic acid instead of others. By 
using the DIG Glycan Differentiation Kit, H6N1 
bound Maackia amurensis agglutinin but not 
Sambucus nigra agglutinin. So the virus 
recognized 2-3 linkage instead of 2-6 linkage. 
From the data of gene sequence analysis, 
virus characterization, and glycan binding 
ability, we propose that the present AIVs in 
Taiwan from chickens might not transmit to 
humans. However, it is necessary to detect the 
amino acids of the residue 627
th in PB2 and 
225
th residue in HA to determine the cross-
species ability of further AIVs isolated.  76 
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Objectives:  in Japan, four neuraminidase 
inhibitors (NAIs), oseltamivir, peramivir, 
zanamivir and laninamivir, are approved for 
chemotherapy against influenza and 
prescribed with the highest frequency in the 
world. Therefore, Japan is at high risk for 
emergence of antiviral-resistant influenza 
viruses. We have monitored antiviral-resistant 
viruses since 2008-2009 influenza season by 
both phenotypic and genotypic assays. 
 
Methods:  approximately 5-10% of total 
isolates in Japan were randomly selected and 
subjected to NAI susceptibility assays, NA 
gene sequencing and/or real time RT-PCR 
allelic discrimination to detect H275Y mutation 
in NA gene. The susceptibilities of viruses to 
NAIs were examined by chemiluminescent 
(CL) assay and/or fluorescent (FL) assay and 
expressed as the drug concentrations required 
to inhibit NA activity by 50% (IC50). 
 
Results:  as of July 2012, we detected 157 
(1.3%) oseltamivir- and peramivir-resistant 
A(H1N1)pdm09 viruses possessing H275Y 
mutation and 1 (0.3%) oseltamivir- and 
peramivir-resistant A(H3N2) viruses 
possessing R292K mutation. Out of 157 
H275Y mutant A(H1N1)pdm09 viruses, 28 
(18%) were mixed isolates of 275H and 275Y 
(275H/Y) viruses. By CL assay, 275H/Y 
viruses with a minor composition of the H275Y 
mutation exhibited indistinguishable 
susceptibility to oseltamivir and peramivir from 
the sensitive isolates with 275H, whereas by 
FL assay, they were clearly discriminated 
between 275H/Y and 275H isolates. The 
detection rates of H275Y mutant 
A(H1N1)pdm09 viruses were 0.5% during the 
2008-2009 season, 1.1% during the 2009-
2010 season, and 2.0% during the 2010-2011 
season. Although the H275Y mutant viruses 
did not spread in community, a number of 
person-to-person transmission cases were 
confirmed in hospitals and a facility for the 
handicapped. Furthermore, the percentage of 
H275Y mutant viruses from the cases with no 
known exposure to NAIs increased from 20% 
during the 2008-2009 season to 44% during 
the 2010-2011 season. 
 
Conclusions:  sustained monitoring of antiviral-
resistant viruses in national level is important 
and a combination of CL and FL assay 
systems is useful to precisely evaluate 
susceptibility of viruses to NAIs. 
 
This study was carried out by collaboration 
with the influenza virus surveillance group of 
Japan. 
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Objectives:  the NA-Fluor™, NA-XTD™ and 
NA-Star® Influenza Neuraminidase Assays 
are functional, phenotypic enzyme assays for 
direct quantitation of neuraminidase inhibitor 
(NI) sensitivity of influenza virus isolates, 
enabling detection of any resistance mutation.  
These assays were designed to provide 
researchers with reliable and consistent results 
through standardized reagents and protocols, 
choice of detection technology, compatibility 
with simple instrumentation, flexible assay 
format and high sensitivity.  Additional 
applications include discovery of new NI 
compounds, and for cell-based assays as an 
easier alternative to microneutralization 
assays. 
 
Results:  the fluorescent NA-Fluor™ assay 
uses MUNANA substrate that is quality 
controlled for purity and low background 
signal.  Assay reagents and protocol were 
optimized to provide an economical, 
standardized and easy-to-use assay kit that 
generates IC50 data directly comparable to 
data obtained with NISN MUNANA protocols.  
The NA-Fluor™ assay signal is extremely 
stable, enabling read-time flexibility and high-
throughput capability, or is performed with a 
real-time kinetic read-out. 
 77 
 
The chemiluminescent NA-XTD™ assay 
provides the next-generation NA-XTD™ 
substrate, with assay reagents and 
microplates.  Like the chemiluminescent NA-
Star® assay, the NA-XTD™ assay provides 
highly sensitive neuraminidase quantitation 
with a wide assay dynamic range, providing 
similar IC50 values over a broad range of virus 
concentration.  The NA-XTD™ assay provides 
extended-glow light emission that enables 
accurate IC50 determination up to several 
hours. 
 
IC50 determination has been performed with 
A/H1N1, A/H3N2, B and NI-sensitive/resistant 
(H275Y) influenzas.  NA-XTD™ and NA-Star® 
assay IC50 values are nearly identical and are 
typically slightly lower than NA-Fluor and other 
MUNANA-based assay values.  The NA-
Fluor™ and NA-XTD™ assays are also used 
to quantitate influenza NA activity directly in 
cell-based virus cultures to monitor viral 
growth or inhibition in the presence of 
inhibitory compounds or antibodies.  
 
Conclusions:  phenotypic neuraminidase 
assays are important in conjunction with 
sequence-based screening for global NI 
resistance monitoring.  These assays provide 
convenient, flexible and reliable influenza 
neuraminidase activity quantitation for NI-
sensitivity and cell-based virus quantitation 
assays. 
 
For Research Use Only.  Not intended for any 
human or animal therapeutic or diagnostic use. 
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The H275Y substitution in A(H1N1)pdm09 
virus, causing oseltamivir resistance, has been 
detected sporadically since June 2009. 
Oseltamivir treated immunocompromised 
patients are at higher risk of developing 
resistance and require close monitoring. 
Furthermore, an increasing number of 
detections of the H275Y substitution in 
specimens are from untreated cases from 
hospital and community sources. Rapid, 
sensitive screening methodologies are critical 
for effective surveillance and clinical 
management, particularly in high risk patients.  
 
We developed a real-time PCR assay to detect 
the H275Y substitution in A(H1N1)pdm2009 
viruses, which includes 2 allelic discriminating 
probes and the additional benefit of a third 
control probe binding to a non-influenza 
sequence. Two positive run controls were 
designed to facilitate assay standardization 
and quality assurance. These CE marked 
synthetic RNA transcripts include the PCR 
primer sequence, control non-influenza 
sequence and specific probe sequence for 
either the H275 or Y275 variant.   These 
transcripts are positive controls for RNA 
extraction, reverse transcription and PCR, but 
also eliminate the need to include 275Y 
containing samples as controls in the PCR, 
removing a potential contamination risk with 
false detection of resistance in a test clinical 
specimen. Discrimination of true H275 or Y275 
in specimens from contamination with the 
positive control is given by signal from the third 
probe in the PCR.  
 
All primers and probes were screened to 
provide absolute discrimination between the 
single nucleotide variants encoding the H275Y 
polymorphism. The assay was established in 
one step and two step formats to comply with 
the workflow of diagnostic laboratories in the 
HPA Microbiology Services network. Validation 
was achieved using a blinded panel of 
specimens containing oseltamivir sensitive, 
resistant and mixed genotype viruses, and 
comparison with the ‘gold-standard’ results of 
pyrosequencing.  
 
The assay and controls have been in use for 
two influenza seasons (2010-2012) by seven 
laboratories across England, with more than 
2000 specimens tested. All Y275 detections 
were confirmed by pyrosequencing indicating 
specificity and sensitivity of the real-time PCR. 
Dissemination of the assay and controls to 
regional laboratories increased national 
capacity for surveillance, and allowed effective 
monitoring of treated patients, with delivery of 
results in a clinically relevant time frame. 
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Nasopharyngeal specimens which were 
collected from patients in South Korea during 
the 2009-2011 influenza seasons are 
passaged in Madin-Darby canine kidney 
(MDCK) cells to isolate influenza viruses. The 
total of 380 influenza viruses were identified by 
immunofluorescence assay and by sequence 
analysis. Of the total 380 viruses, most viruses 
were subtyped as 2009 pandemic H1N1 
strains, and only one (0.26%) was categorized 
as an influenza B virus. The remaining 39 
(10.26%) viruses were identified as H3N2 
strains. Whereas the IC50 values of H3N2 
viruses were ranged within those of 
oseltamivir-sensitive strains, some of H3N2 
viruses exhibited unusual sensitivity in a 
plaque reduction assay. These H3N2 viruses 
were found to have novel mutations in the 
neuraminidase gene. 
 
In addition, one of these H3N2 viruses 
retained an additional mutation and resulted in 
the unique property to oseltamivir when 
characterized by plaque reduction assay in 
MDCK cells. Considered together, these novel 
mutations might account for the exclusive 
characteristics of selected H3N2 viruses 
observed in a plaque reduction assay. 
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In 2007 started to be carried out for the first 
time in Portugal a study focused on influenza 
antiviral drug resistance. Three main 
objectives were established:(1)to determine 
the antiviral profile of influenza viruses to 
oseltamivir, zanamivir and amantadine;(2)to 
determine and monitor the baseline level of 
susceptibility along winter seasons and for 
each influenza sub(type);(3)to analyse and 
characterize the whole genome of viruses that 
showed phenotypic levels of inhibition to 
neuraminidase inhibitors(NAIs).  
 
NAIs profile was determined phenotypically, 
using a fluorescence MUNUNA assay, and 
genotypically by NA and HA sequencing. A 
total of 340 seasonal viruses(117 A(H3N2),93 
A(H1N1),130 B) were tested for oseltamivir 
and of 297(112 A(H3N2),68 A(H1N1),117B) 
for zanamivir. Additionally, 142 
A(H1N1)pdm09 viruses were evaluated for 
both NAIs. Whole genome sequencing was 
performed in 27 of the A(H1N1)pdm09 viruses. 
Amantadine profile was determined through 
M2 pyrosequencing or conventional 
sequencing in a total of 205 seasonal A 
viruses (138 A (H3N2),84 A(H1N1)) and of 117 
A(H1N1)pdm09 viruses. 
 
Main results are: 
 
- Resistance to oseltamivir in 27 A(H1N1) 
seasonal viruses(29%,N=93) from 2007/2008 
and 2008/2009 and in one A(H1N1)pdm09 
virus(0.7%,N=142) from 2010/2011. These 
viruses exhibited a highly reduced level of 
inhibition to oseltamivir by phenotypic analysis 
(170-650 IC50 fold-change) and NA H275Y 
mutation; 
 
- One suspected case of clinical resistance to 
oseltamivir with a mixed population of H275Y 
viruses (73,8%H275,26.2%Y275);  
- No resistance to zanamivir; 79 
 
- Dual reduced susceptibility to oseltamivir and 
zanamivir in one B virus (0,85%,N=117) and in 
two A(H1N1)pdm09 viruses(1,41%,N=142). 
These viruses exhibited a 2-4 IC50 fold-change 
level of inhibition to both NAIs. A mixed 
population of D197N viruses was found in the 
B virus (56%D197,44%N197) and  the two 
A(H1N1)pdm09 viruses shared NA I223V and 
PB2 V480I mutations;  
 
- Resistance to amantadine in 49 A(H3N2) 
viruses(35,5%,N=138) from 2005/2006 to 
2008/2009(46  S31N,3 S31N+V27A), and in all 
A(H1N1)pdm09 viruses(S31N). 
 
This 5-year study allowed to establish a 
technical platform for influenza antiviral drug 
resistance evaluation, to timely detect the 
emergence of resistant viruses, to acquire 
know-how on the natural variation of virus 
susceptibility, and to contribute for the 
management of cases suspected of clinical 
resistance. Additionally, it allowed the 
gathering of a large amount of data that will be 
used in more advanced studies, focused on 
evolutionary analysis and on detailed 
characterization of specific mutations. 
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Background:  recent influenza antiviral 
resistance studies in South East Asia, Europe 
and the United States reveal  alarming 
increases in both adamantane and 
neuraminidase inhibitor (NAIs) resistance.  
 
Objective:  to evaluate antiviral resistance of 
Influenza viruses isolated from various parts of 
India.  
Methods:  influenza viruses, isolated from 
2004to 2011 were analyzed. Matrix gene (M2) 
of 206 influenza A/H1N1 and 371 A/H3N2 
viruses for amantadine resistance and 
Neuraminidase gene of 206 A/H1N1, 272 
A/H3N2 and 326 Type B for oseltamivir 
resistance were sequenced. Pandemic (H1N1) 
(n= 493) isolates were tested for H274Y 
mutation by allelic discrimination real time RT-
PCR. Randomly selected resistant and 
sensitive influenza A/ H1N1 and A/H3N2 
viruses were confirmed by phenotypic assay. 
  
Results:  serine to asparagine (S3IN) mutation 
was detected in six isolates of 2007-2008. One 
dual-resistant A/H1N1 was detected for the 
first time in India with leucine to phenylalanine 
(L26F) mutation in M2 gene and H274Y 
mutation in NA gene. A/H3N2 viruses showed 
an incremental trend in resistance to 
amantadine from 22.5% in 2005 to 100% in 
2008 onwards with S3IN mutation. 50 /61 
A/H1N1 viruses tested in 2008-2009 were 
oseltamivir resistant with H274Y mutation, 
while all A/H3N2, pandemic A/H1N1 and Type 
B isolates remained sensitive. Genetic results 
were also confirmed by phenotypic analysis of 
randomly selected 53 resistant A/ H1N1 and 
40 sensitive A/H3N2 isolates.   
 
Conclusions:  emergence of influenza strains 
resistant to amantadine and oseltamivir in 
spite of negligible usage of antivirals 
emphasizes the need for monitoring antiviral 
resistance as part of National Influenza 
Program. 
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Since 2003, highly pathogenic avian influenza 
A (H5N1) viruses have spread in bird 
populations in several countries worldwide 
resulting in sporadic human infection and 
occasionally death. H5N1 viruses continue to 80 
 
evolve in poultry, thus presenting challenges 
for the development of effective vaccines and 
antiviral medications. Oseltamivir, an oral 
neuraminidase (NA) inhibitor (NAI), is the most 
commonly used medication for treatment and 
chemoprophylaxis of influenza infections. 
Resistance to oseltamivir, natural or acquired, 
is one of major public health concerns. As part 
of enhanced surveillance efforts, viruses 
collected from wild birds and poultry in 
Vietnam from 2009-2011, have been 
sequenced and analyzed for established 
molecular markers of resistance. Moreover, 
the susceptibility profiles of these viruses to 
approved and investigational NAIs were 
determined in fluorescent NA inhibition assay. 
Susceptibilities to other anti-influenza drugs 
were assessed using the virus yield reduction 
assay in MDCK cells. Overall, the H5N1 
viruses (n=102) from this study were classified 
into three HA clades: 1.1, 2.3.2, and 2.3.4. 
Oseltamivir susceptible viruses belonging to 
the two latter clades exhibited a mean IC50 
greater than that of the former by ~44 and ~6 
times, respectively. The increased oseltamivir 
susceptibility of clade 1 viruses was previously 
linked to the presence of the Y253H mutation. 
In accord with these findings, a clade 1.1 virus 
with a revertant mutation, H253Y, showed 10-
fold reduction in oseltamivir susceptibility 
compared to other viruses of the same clade. 
One virus from clade 1.1 contained multiple 
unique substitutions outside of the NA active 
site and exhibited a ~95- and ~37-fold 
reduction in susceptibility to zanamivir and 
laninamivir, respectively, yet had only a 
moderate decrease in susceptibility to 
oseltamivir (~14-fold).Three viruses from clade 
2.3.4.2 possessed the I223T change in the NA 
active site and showed a 6-8-fold reduction in 
oseltamivir susceptibility compared to the 
closest matching susceptible virus. 
Susceptibility of these three viruses to 
peramivir was not affected (≤3-fold). Of note, a 
single virus, A/duck/Vietnam/NCVD-664/2010, 
carrying the H275Y mutation, a known 
oseltamivir resistance marker, was detected 
among the recently emergent 2.3.2.1 viruses. 
In laboratory tests, this virus was resistant to 
two NAIs, oseltamivir and peramivir, but 
susceptible to zanamivir and laninamivir, as 
well as M2 blockers and the investigational 
drugs, DAS181 and favipiravir. The H275Y 
substitution did not appear to impair the NA 
functionality of this virus or its replication in cell 
culture. The naturally occurring oseltamivir-
resistant H275Y virus will be tested in a ferret 
model to assess its replicative potential and 
drug susceptibility in vivo. In conclusion, the 
results of this study highlight the importance of 
monitoring viruses for naturally occurring 
substitutions that may alter H5N1 drug 
susceptibility and in vitro drug susceptibility 
profiles. This is especially important in 
countries like Vietnam, where zoonotic H5N1 
viruses are genetically divergent and 
continuously evolving. The identification of 
both known and novel molecular markers, 
particularly for newer NAIs, for which 
resistance markers are not well established, is 
critical in order to understand how virus 
evolution may lead to resistance. 
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Objectives:  accurate and rapid diagnosis is 
very important for appropriate use of antivirals 
and infection control.   We evaluated Clealine 
Influenza A/B/(H1N1)2009(Alere Medical Co., 
Ltd. Tokyo, Japan), a new multi-line 
immunochromatographic assay for rapid 
detection of antigens of influenza A(FluA), 
B(FluB), and A(H1N1)2009 viruses.  
 
Methods:  vaccine strains and clinical isolates 
were used for evaluation of detection limit of 
Clealine.  Nasopharyngeal aspirate 
specimens, nasopharyngeal swab specimens 
and self-blown nasal discharge specimens 
were collected from children and adults with 
influenza like illness for clinical evaluation. The 
performances of Clealine were compared with 
multiplex RT-PCR and other rapid antigen test 
(Espline Influenza A&B-N), and the sensitivity 
and specificity of RAT using multiplex RT-PCR 
as a reference standard were determined. 
 
Results:  clealine detected FluA, FluB, and 
A(H1N1)2009 viruses with detection limit of 
4.6×103 to 7.5×104 pfu/assay.  The sensitivity 
and specificity of Clealine in nasopharyngeal 
aspirate specimens was as follows:  
FluA=94.5% and 100%, FluB=96.8% and 
100%, and A(H1N1)2009=97.3% and 99.1%, 
respectively. Self-blown nasal discharge 81 
 
specimens were easy to collect but the 
sensitivities were lower in self-blown discharge 
specimens than in nasopharyngeal specimens.  
 
Conclusions:  these finding suggest that 
Clealine may have high sensitivity and 
specificity, so may be useful in early diagnosis 
and treatment of influenza in the clinical 
setting. 
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Our 2008 review concluded that the risk of 
neuropsychiatric adverse events (NPAEs) in 
influenza patients was not increased by 
oseltamivir exposure, and did not identify any 
mechanism by which oseltamivir or its 
metabolites could cause or worsen such 
events. We have reviewed more recent 
information on this topic. Between 16 
September 2007 and 15 May 2010, 1,805 
spontaneously-reported NPAEs were identified 
in 1,330 patients receiving oseltamivir: 767 
(42.5%) from Japan, 296 (16.4%) from the 
USA, and 742 (41.1%) from other countries. 
NPAEs were more common in children: 1,072 
(59.4%) events were in those aged  16 years. 
The majority of NPAEs occurred within 48 
hours of treatment initiation (953 events; 
52.8%). Nearly half of the events were serious 
in nature (838; 46.4%). The three largest 
categories of events were abnormal behavior 
(457 events; 25.3%), miscellaneous 
psychiatric events (370; 20.5%) and 
delusions/perceptual disturbances (316 
events; 17.5%). A total of 1,545 events 
(85.6%) in eight different categories were 
considered to be delirium or delirium-like. 
Twenty-eight suicide-related events were 
reported. A US healthcare claims database 
analysis showed that the risk of NPAEs in 
7,798 oseltamivir-treated patients was no 
higher than in 10,411 patients not on antivirals. 
A study on oseltamivir and abnormal behavior 
in Japan was less conclusive. NPAE frequency 
in oseltamivir-exposed Japanese and 
Taiwanese children with influenza was the 
same as in unexposed children with influenza. 
New analysis of the UK General Practice 
Research Database (GPRD) showed that the 
relative adjusted risk of NPAEs in influenza 
patients was 2.18 times higher than in the 
general population. Other epidemiology 
studies reported occurrence of encephalitis 
and similar disorders in influenza patients 
independently of oseltamivir exposure. These 
new data support the findings of the original 
assessment. There is evidence that influenza-
related encephalopathies are caused by 
influenza-induced inflammatory responses, but 
more work is needed to confirm the underlying 
mechanisms. 
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has  revealed  that  activation  of  the  type  I  interferon  pathway  during 
influenza  and  other  viral  infections  suppresses  antibacterial  immune  responses  in  the  lung.  The 
underlying  mechanisms  by  which  viral  infections  results  in  enhanced  susceptibility  to  bacterial 
infections remains a major focus of her laboratory. 
 
 
Jeremy Farrar 
The Hospital for Tropical Diseases, Ho Chi Minh City, Viet Nam 
 
Jeremy trained in medicine in London, Edinburgh, Melbourne and Oxford 
with a PHD from Oxford University and UCSF.  Since 1996 he has been 
the  Director  of  the  Clinical  Research  Unit  Vietnam,  a  Professor  of 
Medicine  at  Oxford  University,  Hon  Professor  of  International  Health 
LSHTM, Global Scholar Princeton University and Adjunct Professor NUS. 
His  interests  are  in  integrated  health  research  across  a  range  of 
infectious diseases.  He was awarded the Ho Chi Minh Medal from the 
Government of Vietnam and the OBE for Tropical Medicine.  He is also 
the Director of the SEAICRN a multilateral partnership involving Indonesia, Thailand, Vietnam, NIAID, 
Wellcome Trust, and led the setting up of ISARIC (www.wellcome.ac.uk/News/Media-office/Press-
releases/2011/WTVM053638).  The Hospital where he is based is involved in the direct management 
of several thousand patients each year with a catchment population of 40 million people. He has 
almost 400 publications. 
 
Elena Govorkova 
St Jude Children's Research Hospital, Memphis, USA 
 
Dr. Govorkova is currently a Laboratory Director in the Department of 
Infectious Diseases at St. Jude Children’s Research Hospital, Memphis 
TN, USA and is a leading scientist in the NIAID Center of Excellence for 
Influenza  Research  and  Surveillance.  She  received a  Medical  degree 
from the Medical Academy in Moscow, Russia, and a PhD from the D.I. 
Ivanovsky  Institute  of  Virology  in  Moscow,  Russia.  Dr.  Govorkova’s 
research interests are primarily focused on evaluation of antiviral drugs 
against highly pathogenic influenza viruses on enzymatic and cellular  
levels, as well as in animal models.  
 
Her work has involved investigation of advantages/disadvantages of combinations of antiviral drugs 
that  target  different  viral  proteins  and  have  different  mechanisms  of  action  on  the  reduction  of 
influenza  virus  replication  in  vitro,  protection  in  animals,  and  emergence  and  fitness  of  resistant 
variants.  She  is  the  author  of  over  80  original  research  publications  and  review  papers  in  peer-
reviewed journals, in addition to patents and awards. Dr. Govorkova is a member of a number of 
professional societies and is a member of the Editorial Board of the Journal of Antiviral Research. She 
is actively sharing her expertise to mentor and train graduate students and postdoctoral fellows. 
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Larisa Gubareva 
Centers for Disease Control and Prevention, Atlanta, USA 
 
Dr. Larisa Gubareva is the Lead of the Molecular Epidemiology Team in 
the Virus Surveillance and Diagnosis Branch, Influenza Division, at the 
Centers for Disease Control and Prevention in Atlanta, GA, USA. The 
Team actively participates in influenza virus surveillance and assessment 
of  influenza  virus  susceptibility  to  FDA-approved  and  investigational 
antiviral  agents.  The  Team  also  monitors  influenza  drug  resistance 
among community isolates/specimens, offers antiviral testing for clinical 
care  use  in  the  US,  and  provides  training  and  technical  expertise  to 
partners in global influenza virus surveillance.  
 
Dr. Gubareva has been an influenza virologist for over 20 years. In 2006, she joined the Influenza 
Division  at  the  CDC.  Her  research  and  public  health  activities  focus  on  understanding  the 
mechanisms  of  drug  resistance,  methods  for  drug  resistance  detection  and  assessment  of  drug 
resistant viruses’ replicative fitness.  In recent years, she has served as a technical advisor for the 
WHO on the Influenza Antiviral Resistance.  
 
Dr. Gubareva is an author/co-author of over 100 peer-reviewed papers and textbook chapters. She 
also serves on the editorial boards of the journals, Antimicrobial Agents and Chemotherapy, Antiviral 
Research, and Antiviral Chemistry & Chemotherapy. Dr. Gubareva is internationally recognized for 
her expertise in influenza antiviral research, as reflected by her various collaborative partners. 
 
Alan Hay 
National Institute for Medical Research, London, UK. 
 
Alan Hay studied Biochemistry at the University of Aberdeen, where he 
first became involved in the study of viruses during his PhD research.  
Following two years of post-doctoral research at Duke University, North 
Carolina, he became a member of MRC scientific staff at the National 
Institute  for  Medical  research  (NIMR)  in  London,  till  his  retirement  in 
2009.  
 
His  research  interests  have  been  principally  concerned  with  various 
aspects of the biochemistry of influenza viruses and their replication, in particular: the mechanisms of 
transcription  and  replication  of  the  virus  genome;  the  antiviral  action  of  the  anti-influenza  drug 
amantadine and the proton channel function of the target M2 protein; and the molecular bases of 
resistance to antiviral drugs against the M2 and NA proteins.  
 
As Director of the WHO Collaborating Centre for Reference and Research on Influenza at NIMR from 
1993, his interests also encompassed the epidemiology and evolution of human and animal influenza 
viruses, in particular in relation to current changes in human viruses and the compositions of influenza 
vaccines, and the emergence of novel human viruses with the potential to cause a pandemic.  
   87 
 
Frederick Hayden 
University of Virginia School of Medicine, Charlottesville, USA 
 
Dr. Hayden is Stuart S. Richardson Professor of Clinical Virology and 
Professor of Medicine and Pathology at the University of Virginia School 
of Medicine in Charlottesville, Virginia, USA. During 2006-2008 he served 
as  a  medical  officer  in  the  Global  Influenza  Programme  at  the  World 
Health Organization, Geneva, Switzerland, and since September 2008, 
has  been  serving  as  influenza  research  coordinator  at  the  Wellcome 
Trust, London.  
 
Dr. Hayden received his medical degree from Stanford University School of Medicine in 1973 and 
completed  his  clinical  training  in  internal  medicine  and  infectious  diseases  at  Strong  Memorial 
Hospital, University of Rochester, New York, USA.  He joined the faculty of the University Of Virginia 
School  Of  Medicine  in  1978  and  became  Richardson  Professor  in  1990.  His  principal  research 
interests have been on the respiratory viral infections with a particular focus on the development and 
application of antiviral agents for influenza and rhinovirus infections. 
 
Dr.  Hayden  is  a  Fellow  of  the  Infectious  Diseases  Society  of  America,  American  Academy  of 
Microbiology, American Society for Clinical Investigation, and Association of American Physicians. 
 
Nguyen Tran Hien 
National Institute of Hygiene and Epidemiology, Hanoi, Vietnam 
    
Assoc.  Prof.  is  Director  of  the  National  Institute  of  Hygiene  and 
Epidemiology (NIHE), a leading scientific research institute in Vietnam in 
the  area  of  epidemiology,  medical  microbiology,  immunology  and 
molecular biology, vaccine and biological product development.  
 
He graduated from Hanoi Medical College, Vietnam in 1978. He had two 
years  (1986-1988)  Postgraduate  training  on  Epidemiology  and  Clinical 
Immunology at the National Institute for Lung Diseases and Tuberculosis, 
Berlin, Germany. He finished the Master Course on Health Development (Master of Public Health), at 
the Royal Tropical Institute, Amsterdam, The Netherlands (1992-1993). Then in 1996, he finished a 
Postdoctoral Course on HIV/AIDS Epidemiology, at University of California, Los Angeles, USA. In 
2002, he got PhD Degree at Freedom University, Amsterdam, The Netherlands. Since 2004 he is the 
Chairman  of  the  National  Sub-Committee  of  HIV  Surveillance  Vietnam;  Vice-Chairman,  National 
Committee of Prevention and Control of Human Avian Influenza and Pandemic (since 2006).  He is 
also the Chairman, Department of Epidemiology, and Director of Center for HIV/AIDS Research and 
Training of Hanoi Medical University; and President, Vietnam Association of Preventive Medicine 
 
By  working  in  HIV/AIDS  area  for  over  24  years,  he  has  much  experience  in  the  HIV/AIDS 
surveillance, prevention and control in Vietnam. In the last 7 years,  he devotes a lot of time for 
research, control and prevention of emerging and re-emerging infectious diseases  such as avian 
influenza H5N1, Pandemic influenza A/H1N1/09, Cholera, Dengue, Foot-Hand-Mouth and Rabies in 
Vietnam. 
 
Over 20 students have successfully completed their master or doctorate courses with the supervision 
of Assoc. Prof. Nguyen Tran Hien. He published more than 100 articles in Vietnam and International 
scientific journals. He is also author or co-author of over 44 text books. 
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Tran Tinh Hien 
Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam 
 
Prof. Tran Tinh Hien is the director of Oxford University Clinical Research 
Unit (OUCRU) in Viet Nam. He received his medical degree from the 
University  of Medicine in  Saigon, Vietnam in  1978, and  his  PhD from 
Oxford University Clinical Research Unit and the Open University UK in 
2004.  He  was  appointed  Professor  of  Tropical  Diseases  at  Oxford 
University,  in  2010  and  has  been  a  Fellow  of  the  Royal  College  of 
Physicians  (Edinburgh)  since  2004.  He  was  a  member  of  several 
committees and advisory groups, including the Clinical Committee on the 
National Programme for the Control of Avian Influenza Virus Infection in 
Humans in Vietnam. He has worked as Principal Investigator for various projects on malaria, typhoid 
fever, Dengue haemorrhagic fever and has involved in dealing with SARS, H5N1 outbreaks and the 
pandemic H1N1/2009 at the Hospital for Tropical Diseases in Ho Chi Minh City in Viet Nam. Prof. 
Hien was also awarded McKay Medal from The Royal Society of Tropical Medicine & Hygiene in 2010 
and Honorary Membership of The American Society of Tropical Medicine in 2011. 
 
 
Peter Horby 
Oxford University Clinical Research Unit, Hanoi, Viet Nam 
 
Peter trained in adult medicine, infectious diseases and public health in 
the UK and Australia. He has previously held positions as International 
Research Fellow at the National Centre for Immunisation Research in 
Sydney; Consultant Epidemiologist with the UK Health Protection 
Agency; head of Communicable Disease Surveillance and Response in 
the Vietnam WHO Country Office; and Director of the Oxford University 
Clinical Research Unit at the National Hospital for Tropical Diseases, 
Hanoi, Vietnam. Peter is currently Senior Clinical Research Fellow at the 
Oxford University Clinical Research Unit in Vietnam, and Adjunct Associate Professor in the 
Department of Infectious Diseases, Yong Loo Lin School of Medicine, National University of 
Singapore. His interests are in the emergence and control of infectious diseases, including avian and 
seasonal influenza, community acquired pneumonia, and dengue. 
 
David Hui 
The Chinese University of Hong Kong, SAR China 
 
Prof Hui is the Stanley Ho Professor of Respiratory Medicine and a Chair 
Professor  at  the  Dept  of  Medicine  &  Therapeutics,  The  Chinese 
University of Hong Kong. He is also the Director of the Stanley Ho Centre 
for Emerging Infectious Diseases, CUHK. 
 
He  graduated  from  the  University  of  New  South Wales  in  Australia in 
1985 and undertook postgraduate training in Respiratory Medicine and 
Sleep Medicine in Sydney. During the major outbreak of SARS in 2003 
and the H1N1 influenza pandemic in 2009, he was heavily involved in the clinical management of 
severe cases. In Feb 2004, he attended the early human cases of H5N1 in Vietnam as a WHO 
advisor.  
 
Dr Hui has published over 200 peer-reviewed journal articles and 21 book chapters since joining the 
CUHK in 1998. His research interests include clinical management of emerging respiratory infections, 
the safety of respiratory therapy in the post SARS era, and medical ward environmental airflow in 
preventing nosocomial infections. 
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Michael Ison 
Northwestern University, Chicago, USA 
 
Dr. Michael Ison obtained is medical degree at the University of South 
Florida College of Medicine.  He then completed his Internal Medicine 
Residency and General Internal Medicine Fellowship at Oregon Health 
Sciences University in Portland, Oregon.  He then obtained his Master of 
Science in Health Evaluation Sciences and did his Infectious Diseases 
Fellowship at the University of Virginia.  During his fellowship, he was 
mentored by Drs. Fredrick Hayden, Larisa Gubareva, and Tom Brachiale.  
His research focused on the immunopathogenesis of influenza and its 
treatment in immunosuppressed and hospitalized patients.  He developed a immunocompromised 
mouse model of influenza to study the development of antiviral resistance.  In addition, he did studies 
of the pharmacokinetics and outcomes of treatment with oseltamivir, zanamivir, and rimantidine in 
hospitalized  patients.    After  leaving  the  University  of  Virginia,  he  undertook  additional  training in 
Transplant Infectious Diseases at the Massachusetts General Hospital and Harvard Medical School 
under the mentorship of Dr. Jay A. Fishman.  He then joined the faculty of the Divisions of Infectious 
Diseases and Organ Transplantation at Northwestern University Feinberg School of Medicine in 2005. 
He  is  currently  the  Medical  Director  of  the  Transplant  &  Immunocompromised  Host  Infectious 
Diseases Service, Northwestern University Comprehensive Transplant Center. 
 
He has continued to be a leader in the respiratory viruses research arena.  He has been the first 
author of the only two prospective interventional studies in hospitalized patients as well as a lead 
investigator  for  studies  to  determine  how  to  prevent  and  treat  influenza  in  immunocompromised 
patients.  He has recently provided advice to the President’s H1N1 Subcommittee, NIH, and BARDA 
on issues related to influenza in hospitalized and immunocompromised patients.  Additionally, he is 
considered an expert in adenovirus infections in immunosuppressed patients. 
 
He, too, is heavily involved in other research and leadership positions in the Transplant Infectious 
Diseases arena. He has been a member and is the current chair of the Advisory Committee on Blood 
Safety  and  Availability  in  addition  to  chairing  the  United  Network  for  Organ  Sharing’s  Disease 
Transmission Advisory Committee from 2006 – 2010.  He was recently elected as one of the At Large 
representatives  on  the OPTN/UNOS  Board  of  Directors  and  member  of the  American  Society  of 
Transplantation Board of Directors.  He, too, has been involved globally as the chair of the Infectious 
Diseases Editorial Group for the CNT/WHO Project NOTIFY Library and the leader of the Infectious 
Diseases  group  of  the  World  Health  Organization  Bologna  Initiative  on  Global  Vigilance  and 
Surveillance. 
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Lance Jennings 
Canterbury District Health Board, Christchurch, New Zealand 
 
Lance  Jennings  is  Clinical  Virologist  to  the  Canterbury  District  Health 
Board,  Director  of  New  Zealand’s  WHO  National  Measles  Laboratory, 
Clinical Associate Professor in the Pathology Department, University of 
Otago, New Zealand, Fellow of the Royal College of Pathologists, London 
and  a  Founding  Fellow  of  the  Science  Faculty,  Royal  Australasian 
College  of  Pathologists.  His  principal  research  interests  include  the 
epidemiology, diagnosis, prevention and treatment of influenza and other 
respiratory viral infections. 
 
Dr  Jennings  has  been  instrumental  in  the  development  of  influenza  control  strategies  for  New 
Zealand, including the introduction of free influenza vaccine, establishment of influenza awareness 
education  (NISG)  and  pandemic  planning.  He  is  co-founder  and  current  chairperson  of  the  Asia 
Pacific  Alliance  for  the  Control  of  Influenza  (APACI).    Dr  Jennings  has  also  been  a  member  of 
WHO/Western Pacific Region Office (WPRO) Avian Influenza Outbreak Response (2004) and Expert 
Influenza (2005) teams in Asia and has held WHO short-term consultancies on measles and influenza 
in Asia and Europe. 
 
He serves on several Ministry of Health and Ministry of Agriculture Advisory Committees, is an expert 
reviewer for research funding agencies, and is on the editorial board of the International Society for 
Influenza  and  other  Respiratory  Virus  Disease  (ISIRV)  journal  Influenza  and  other  Respiratory 
Viruses. His service to virology in New Zealand and internationally was recognised in 2006 with the 
award of the Queens Service Order. 
 
Yoshihiro Kawaoka 
University of Wisconsin-Madison and Institute of Medical Science, 
University of Tokyo, Japan  
 
Dr. Yoshihiro Kawaoka obtained his education in Japan, receiving his 
DVM in 1978 and his Ph.D. in 1983 from Hokkaido University.  Early in 
his career, he identified the critical determinant for high pathogenicity of 
avian influenza viruses; this information is now used by the USDA and 
the  Office  International  des  Epizooties  (World Organisation for  Animal 
Health,  OIE)  as  a  criterion for  rapidly identifying  lethal  and  non-lethal 
avian influenza viruses.  Dr. Kawaoka also established reverse genetics, 
which  allows  the  generation  of  ‘designer’  influenza  viruses.    This  technology  –  coupled  with  his 
findings regarding the attenuation of deadly influenza viruses – has been used to develop candidate 
H5N1 influenza virus vaccines, which have proven efficacious in clinical trials.  Dr. Kawaoka has also 
undertaken the study of the 1918 Spanish influenza virus, which killed over 40 million people.  He 
determined  that  infection  by  the  1918  virus  caused  an  abnormal  immune  response.  Information 
uncovered  by  Dr.  Kawaoka  is  used  globally  by  public  health  agencies  as  they  undertake  the 
enormous task of influenza pandemic planning.  
 
In addition to his work with influenza virus, Dr. Kawaoka also studies Ebola virus. Because of its 
extreme virulence,  Ebola virus  had  to  be  studied  in  laboratories  designated  as  biosafety  level  4 
(BSL4), the highest containment environment possible.  This requirement severely hampered the 
progress of Ebola virus research, as few such facilities exist worldwide.  Dr. Kawaoka was the first to 
establish a pseudotype virus system that allows the analysis of Ebola virus glycoprotein under BSL2 
conditions.  Recently, Dr. Kawaoka developed another system that allows the study of the entire 
Ebola virus replication cycle under non-BSL4 conditions.  
 
In recognition of his work, in 2006, Dr. Kawaoka was awarded the prestigious Robert Koch Award for 
innovative research in the field of influenza virology.   
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Nelson Lee 
The Chinese University of Hong Kong, SAR, China 
 
Dr.  Nelson  Lee  is  currently  the  Professor  and  Head  of  Division  of 
Infectious  Diseases  in  the  Department  of  Medicine  and  Therapeutics, 
Faculty of Medicine, The Chinese University of Hong Kong (CUHK). He is 
also the consultant and chief of the clinical infectious disease services at 
the university hospital, the Prince of Wales Hospital; and clinical faculty 
associate, Stanley Ho Centre for Emerging Infectious Diseases, School of 
Public  Health,  CUHK.  Dr.  Lee  is  the  Chairman  of  the  specialty  of 
Infectious Diseases in The Hong Kong College of Physicians, and serves 
in several advisory boards in Hong Kong’s health authority and professional organizations, leading 
research, professional training, and inform clinical practices related to infectious diseases. 
  
Dr. Lee’s major research interests include severe Influenza and other emerging infections such as 
Severe  Acute  Respiratory  Syndrome,  focusing  on  the  clinical  aspects:  disease  manifestations, 
diagnosis, antiviral treatment, outbreak control, viral kinetics, and immunopathogenesis, particularly 
among  the  hospitalized  adults.  He  has  published  over  120  articles  in  international  peer-reviewed 
journals, and received multiple academic awards, both locally and overseas, on his contributions in 
improving the understanding and management of these emerging infections. He has served as an 
associate editor or referee for more than 20 local and international medical journals. 
 
May Li Lim 
KK Women's & Children's Hospital, Singapore 
 
Dr LIM May Li is Consultant Obstetrician & Gynaecologist and Head of 
Peripartum  Unit  at  the  KK Women's  &  Children's  Hospital,  Singapore. 
She obtained MBBS from University of Queensland, Australia in 1993. 
She  then  pursued  postgraduate  training  in  United  Kingdom  with 
attainment of MRCOG in 2000 and Certificate of Completion of Specialist 
Training in Obstetrics & Gynaecology in 2007. She joined KK Women's & 
Children's  Hospital  in  2008.  She  is  actively involved  in  undergraduate 
teaching and is faculty for OBGYN clerkship for the Duke-NUS Graduate 
Medical  School,  Singapore.  She  leads  in  the  obstetric  emergency  training  workshops  for  junior 
doctors and nursing staff at her institution. Her interests are in intrapartum care, high risk pregnancy 
and maternal medicine. When influenza A H1N1 (2009) struck, Dr Lim was part of the team who 
looked at the emergency planning of O&G services and who led in the management of pregnant 
mothers  with the infection. This led to two publications  sharing her institution's experience in the 
BJOG and Annals Academy of Medicine, Singapore respectively.   
 
Andrew Luks 
Harborview Medical Centre, Seattle, USA 
 
Andrew Luks is an Associate Professor in the Division of Pulmonary and 
Critical Care Medicine and a member of the International Respiratory and 
Severe Illness Center (INTERSECT) at the University of Washington. Dr. 
Luks' practices critical care medicine across a wide range of disciplines 
including the medical, trauma and neurosurgical critical care and has a 
strong interest in care for the patient with severe respiratory failure and 
refractory  hypoxemia.  In  addition  to  writing  the  American  Thoracic 
Society document on Salvage Therapies for Acute Respiratory Distress 
Syndrome Caused by H1N1 Infection and creating numerous teaching resources in pulmonary and 
critical care medicine, he has written extensively on the topic of medicine in austere environments 
and, in particular, on high altitude medicine and physiology. A leading educator at his institution, Dr. 
Luks directs a large program of medical student education in respiratory and critical care medicine at 
the University of Washington for which he has received multiple teaching awards and leads annual 
post-graduate seminars on respiratory physiology and hemodynamic management at the American 
Thoracic Society International Conference. 92 
 
Jenny McKimm-Breschkin 
CSIRO Material Science and Engineering, Melbourne, Australia 
 
Dr. McKimm-Breschkin is a Chief Research Scientist and Project Leader in 
Virology  at  the  Commonwealth  Scientific  and  Industrial  Research 
Organisation  (CSIRO)  in Victoria,  Australia.  After  completing  a first  class 
honours  degree  at  Monash  University,  Melbourne,  Victoria,  in  1974  Dr. 
McKimm-Breschkin won a Fulbright postgraduate award to the Microbiology 
department  at  Pennsylvania  State  University,  Hershey  Medical  Centre, 
where she obtained her PhD in virology in 1978. 
 
She returned to Melbourne University Microbiology department as a Queen Elizabeth II Post-doctoral 
fellow with research focussed on the recently discovered rotaviruses. A second postdoctoral position 
followed at the Walter and Eliza Hall Institute of Medical Research, as a Colin Syme Junior Fellow 
under the supervision of Jacques F. A. Miller working in the field of cellular immunology.  
She then  worked for the Australian Commonwealth Health Department for two years  working on 
animal viruses, before joining CSIRO in 1987. She was part of the team involved in the development 
of Relenza, providing neuraminidase proteins for X-ray crystallography studies, as well as carrying out 
pre-clinical resistance studies as part of the drug registration. 
 
She has continued to work in the evolving field of drug resistance, integrating both structural and 
functional approaches to understanding the mechanisms of resistance. Dr McKimm-Breschkin is a 
member of the Australian and American Societies for Microbiology. 
 
Le Quynh Mai 
National Institute of Hygiene and Epidemiology, Hanoi, Viet Nam 
 
Dr Mai has been beginning in basis research of Arbor viruses, with 13 
years  experience  of  virology  surveillance  of  Dengue  viruses  at  NIHE- 
Hanoi,  Vietnam.  She  was  involved  to  National  Dengue  Surveillance 
project  in  Vietnam  to  improve  Dengue  viruses  surveillance  system, 
development controllability and prevention program. 
 
Since  2003,  when  SARS  outbreak  in  Vietnam,  Dr  Mai  has  extensive 
experience to SARS, identification SARS infection, isolation SARS virus, 
study on ecology of SARS. 
  
More  recently,  Dr  Mai  expanded  her  study  on  influenza  viruses,  early  detection  human  A/H5N1 
infection, identification natural links between poultry outbreak and human endemic.  She is the Head 
of Virology department as well as Director of NIC-NIHE, Hanoi, Vietnam.  NIHE's group was the first 
to confirm that the pathogenic avian influenza A (H5N1) caused human infections in Viet Nam and 
has played a key role in characterizing this influenza virus and the immunopathology association with 
it.  Monitoring  National  Influenza  Program  activities,  upgrade  laboratory  abilities,  improving 
relationships to animal researchers are her work now. 
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Adam Meijer 
National Institute for Public Health and the Environment, Bilthoven, 
The Netherlands 
 
Adam  Meijer  graduated  in  1999  at  the  Faculty  of  Medicine  of  the 
University  of  Utrecht,  the  Netherlands,  on  the  thesis:  Chlamydia 
pneumoniae infection  and  atherosclerosis,  a  molecular  analysis.  Since 
2001 he has worked in the field of influenza.  During 2001 he studied the 
effect  of  antiviral  prophylaxis  and  treatment  on  transmission  of  avian 
influenza between chickens at the Central Institute for Animal Disease 
Control,  Lelystad,  the  Netherlands.  In  2002  he  continued  his  work  on 
influenza at the National Institute of Public Health and the Environment, Bilthoven, the Netherlands; 
since 2003 heading the Section Respiratory Viruses of the Virology department of the Laboratory for 
Infectious Diseases. Research focuses on virological surveillance of acute respiratory infections, with 
a special focus on antiviral susceptibility and determination of molecular determinants for virulence 
and  transmission  networks  at  the  animal-human  interface.  From  2003-2008  he  coordinated  the 
virology  activities  of  the  European  Influenza  Surveillance  Scheme  and  was  instrumental  in  the 
establishment  and  coordination  of the  Community  Network  of  Reference  Laboratories for  Human 
Influenza  in  Europe  (CNRL).  Since  2008  he  is  one  of  the  coordinators  of  the  CNRL  under  the 
auspices of the European Centre of Disease Control and Prevention, with a special focus on influenza 
antivirals. He is advisor for the influenza external quality assessment programme of QCMD, Glasgow, 
Scotland, has been involved in several influenza consultation meetings of the WHO (e.g. on rapid 
tests for influenza and on susceptibility of influenza viruses for antivirals) and recently joined the WHO 
GISRS working group on antiviral susceptibility. 
 
Arnold Monto 
University of Michigan, Ann Arbor, USA  
 
Arnold  S.  Monto  is  the  Thomas  Francis  Jr.  Collegiate  Professor  of 
Epidemiology at the University of Michigan School of Public Health in Ann 
Arbor.    The  major  focus  of  his  work  has  been  the  epidemiology, 
prevention  and  treatment  of  acute  infections  in  the  individual  and  the 
community.  Respiratory infections, in particular influenza, have been a 
major  interest,  with  special  reference  to  the  evaluation  of vaccines  in 
various populations and the assessment of the value of antivirals. He has 
worked on these issues in tropical as well as temperate regions. He led 
the studies of respiratory infection in Tecumseh, MI, a landmark study of infection in the community.  
He has studied various approaches to influenza vaccine use, particularly to control transmission of the 
virus in the community and in nursing homes. 
 
Dr. Monto is involved in assessing the efficacy of various types of influenza vaccine in prophylaxis 
and neuraminidase inhibitors and other compounds in prophylaxis and therapy of influenza, including 
implications of antiviral resistance.  He now heads an observational study of effectiveness of influenza 
vaccines in various settings. His recent activities have included evaluation of face masks and hand 
hygiene  in  the  control  of  influenza  transmission  and  determination  of  efficacy  of  the  traditional 
inactivated  and  live  attenuated  influenza  vaccines.  He  works  extensively  with  national  and 
international organizations on issues related to pandemic preparedness. He has been a member of 
the  Pulmonary  Diseases  Advisory  Committee  and  the  National  Allergy  and  Infectious  Disease 
Advisory Council of the US National Institutes of Health.  He is a past president of the American 
Epidemiological Society and the 2009 recipient of the Alexander Fleming Award of the Infectious 
Diseases  Society  of  America  for  lifetime  achievement.    He  was  a  member  of  the  Emergency 
Committee  making  recommendations  to  the World  Health  Organization  during  the  past  influenza 
pandemic. 
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Masashi Mizuguchi 
University of Tokyo, Tokyo, Japan 
 
Professor  Masashi  Mizuguchi  is  a  pediatric  neurologist  and 
neuropathologist. He graduated from the Faculty of Medicine, University 
of Tokyo, Tokyo, Japan and obtained M.D. in 1980, and since then has 
been  engaged  in  clinical  practice  and  research  at  Tokyo  Metropolitan 
Fuchu/Neurological  Hospital,  Fuchu,  Japan  (1981-1986),  University  of 
British  Columbia,  Vancouver,  Canada  (1989-1991),  National  Center  of 
Neurology  and  Psychiatry,  Kodaira,  Japan  (1993-1996)  Jichi  Medical 
University, Shimotsuke, Japan (1996-2004), and the University of Tokyo 
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